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LIST OF ABBREVIATIONS 
---------------    General     --------- 
3D 3-dimensional 
125I   Iodine-125  
-----------------   C     --------------- 
CF Correction factor 
Ci curie 
CT Computed tomography 
---------------     D     --------------- 
d Diameter 
D  Accumulated dose 
D&  Dose-rate 
Dchamber  Midline ionization chamber dose values  
Dentrance  Dose recalculated to zmax and corrected for non-reference conditions  
DGRT Dose guided radiation therapy 
Dmax Dose at the depth of dose maximum 
Dmidline Midline dose value 
Dnew Dose-rate after the implantation of a new train of seeds 
Dplan   Prescribed dose 
DRa  Dose-rate before the implantation of the last needle  
DRact Actual dose-rate 
DRb Dose-rate after the implantation of the last needle 
DRmax Maximum tolerable dose-rate for the urethra  
 
DRmin Minimum dose-rate  
DRrec Dose-rate measured in the recovery, directly after the implantation 
DRrt Dose-rate real-time  
---------------     E     --------------- 
E Energy 
EPID Electronic Portal Imaging Device 
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---------------     F     --------------- 
Fcal Calibration factor 
Fconversion Conversion factor 
FFTC  Fast-Fourier Transform Convolution 
---------------     G     --------------- 
Gy gray 
----------------     H     --------------- 
HDR High Dose Rate 
---------------     I     --------------- 
Ids Current between the source and the drain 
IDR  Initial Dose Rate 
IMRT Intensity-Modulated Radiation Therapy 
---------------     L     --------------- 
LDR Low Dose Rate 
Linac Linear electron accelerator 
---------------     M     --------------- 
MBRT Opleiding Medisch Beeldvormende en Radiotherapeutische 
Technieken 
MGS  Multi-Grid Superposition  
MLC Multileaf collimator 
MOSFET Metal-Oxide Semiconductor Field Effect Transistor 
MU Monitor unit 
---------------     O     --------------- 
OAR Organ at risk 
---------------     P     --------------- 
PDD  Percentage Depth Dose 
PMMA Polymethylmethacrylaat 
---------------     Q     --------------- 
QA Quality assurance 
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---------------     R     --------------- 
R MOSFET reading in mV 
Rentr Entrance reading 
Rexit  Exit reading 
RTIL Radiotherapeutisch Instituut Limburg 
---------------     S     --------------- 
SD Standard deviation 
Si Silicon 
SiO2 Silicon dioxide 
SSD Source-skin-distance 
---------------     T     --------------- 
t Time interval 
t1/2 Half-life 
TBI Total Body Irradiation 
TIPPB Transperineal Interstitial Permanent Prostate Brachytherapy 
TLD Thermoluminescence detector 
TPS Treatment planning system 
---------------     V     --------------- 
V volt 
VTH  Threshold voltage 
---------------     Z     --------------- 
zmax Depth of dose maximum  
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1.1 INTRODUCTION 
The incidence of cancer in Europe is growing over the last decades. With an estimated 
3.2 million new cases (53% occurring in men, 47% in women) and 1.7 million deaths 
(56% in men, 44% in women) each year, cancer generates an important public health 
problem in Europe and the ageing of the European population will cause these 
numbers to continue to increase even if age-specific rates remain constant1.  
Radiotherapy is an important treatment option for a large range of cancer sites. It uses 
ionizing radiation to damage the cancer cells, and stop them from growing and dividing. 
The radiation can be administered by external beam radiotherapy, where an external 
source of radiation is pointed at a particular part of the body, or by brachytherapy, 
where a radioactive source is placed inside or next to the volume requiring treatment. 
Sometimes a combination of these two techniques is applied. 
External beam radiotherapy is delivered by an external source of radiation, for which 
generally high energy photon or electron beams are used, generated by a linear 
electron accelerator (linac). Photon beams are produced by the rapid deceleration of 
electrons in a target material. Before exiting the treatment head, the generated photons 
pass through several components, which influence the production, shaping, 
localization, and monitoring of the clinical photon beams. These clinical high energy 
photon beams penetrate within the patient’s body and are used to treat deep-seated 
target volumes. The energy deposition of a megavoltage photon beam in tissue is 
characterized by a relatively low surface (skin) dose, in the range of 10%-25% of the 
maximum dose. When the radiation further passes into tissue, dose values increase up 
to a maximum value and then gradually decrease at increasing distance beneath this 
point, because of the beam attenuation in tissue and the inverse square law. Typical 
central axis depth dose curves in water for 6 and 10 MV photon beams, are illustrated 
in figure 1a.   
A large number of techniques using photon beams have been developed for the 
treatment of tumors. Most techniques use multiple beams, all directed towards the 
tumor generally applying a fixed distance from the target (source) in the linac to the 
centre of the tumor. Field sizes range from very small fields used in radiosurgery and 
during Intensity-Modulated Radiation Therapy (IMRT) techniques, standard rectangular 
and irregular fields and very large fields used for special indications where the 
treatment volume is large. For some indications, however, the volume to be irradiated 
is too large for the field size that can be created by a linac at the standard treatment 
distance. To increase the maximum field size for these kinds of treatments, normally 
the source-skin-distance (SSD) is extended. An example of such an extended field 
technique is Total Body Irradiation (TBI). TBI involves radiation of the whole body and 
is used for a large variety of clinical situations, such as hematological malignancies and 
aplastic anemia. The dose distribution during a TBI treatment is generally assumed to 
be homogeneous and within 10% of the prescribed dose value2. Most treatment 
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planning systems (TPS) do not allow the setup of patients at a very large SSD and 
dose calculations are performed by a point-dose determination at the dose prescription 
point. As a result the dose distribution in the other parts of the body is not evaluated 
and rather large uncertainties in the relative dose distribution in the patient’s body may 
occur. To achieve dose uniformity throughout the body, the use of bolus, partial 
attenuators or compensators is necessary. For the design of these compensators, 
detailed information of dose delivery to the whole body is required and a detailed 
calculation of the absorbed dose in the whole body, obtained by a Computed 
Tomography (CT)- based treatment planning, is essential. A comprehensive quality 
assurance (QA) programme is therefore necessary to test a TPS for dose calculations 
of these special treatment techniques. 
Situations where the patient’s contour and normal tissue constraints require more than 
one beam configuration also require a special treatment technique. In these 
treatments, a junction of fields is sometimes unavoidable. A number of techniques 
have been developed to achieve dose uniformity in the area of the field junction, such 
as using split beams. This is achieved by placing a half-beam block along a plane 
through the central axis, thus removing the geometric divergence of the beams at the 
split line. In theory this technique results in an optimal dose distribution in the junction 
area. In practice however, several uncertainties affect the accuracy of this technique, 
originating from factors related to mechanical properties in combination with the QC 
procedures and the adjustments of the linear accelerator’s jaws and the variations in 
the treatment set-up. Consequently there is a risk for tumor recurrence if the target 
volume is underdosed, or for complications if healthy tissues are overdosed. Additional 
studies are therefore necessary to assess the effect of these factors on the dose 
distribution in the junction region and to validate the technique in clinical practice.  
The use of electron beams in radiotherapy treatments is less widespread compared to 
photon beam treatments. In medical linear accelerators, the primary particles used are 
electrons. If the target used to generate the X-rays by bombarding the material with 
electrons and the accompanying flattening filter are removed, a high energy electron 
beam is obtained. A scattering foil is inserted into the beam to scatter the pencil beam 
and to cover the field size required for electron treatment. The electron beam dose 
distribution in tissue is however quite different from that of a photon beam. It is 
characterized by a relatively high surface dose of about 80%-90% of the maximum 
dose, a flat region around the maximum dose followed by a rapid dose fall of beyond 
the depth of dose maximum and a low dose tail which actually represents the X-ray 
contamination of the electron beam, as illustrated in figure 1b. Because of the higher 
skin dose and rapid dose fall off at depth, electron beams are often used to treat 
superficially located tumours. In contrast to photon beams, where generally a multiple 
beam technique is used, electron beams are mostly delivered by using a single field 
technique. 
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In many radiotherapy centers, electron beam treatments are frequently administered 
based on clinical setup, without formal treatment planning. The dose distribution in an 
electron beam treatment is, however, frequently very inhomogeneous due to irregular 
outer surface of a patient, air cavities in or surrounding the treatment volume, or due to 
oblique incidence of the beam. The dose distribution is, as a result of these factors, 
difficult to determine without a proper dose calculation algorithm. Even when a TPS is 
used, dose calculations may not be very accurate in areas having tissue 
inhomogeneities. To overcome random and systematic errors, additional QA during 
treatment is important, to prevent the patient from unacceptable high doses in the 
treatment area or for areas that are under-dosed with the risk for tumor recurrence.  
Of all patients treated with radiotherapy, about 5% to 10% are candidates for 
brachytherapy. Brachytherapy is a very local irradiation. The dose is delivered by one 
or several sealed radioactive sources placed in or adjacent to tumor tissue, having the 
advantage of highly conforming the dose to the tumor volume and better sparing of the 
surrounding tissues. As a consequence, higher tumor doses can be achieved. 
Permanent seed implantation and temporary source loading are important treatment 
Figure 1: Central axis depth dose curves in water for a 10x10 cm2 field size (a) 6 and 10 MV 
photon beams for an SSD of 90 cm and (b) electron beams with energies of 6, 12, 15, 18 and 21 
MeV for an SSD of 90 cm.  
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options used in brachytherapy. In permanent brachytherapy seeds with low energy 
photon emitting radionuclides, such as iodine-125 (125I) or palladium-103 (103Pd), are 
implanted in tissue using needles that are loaded with the radioactive seeds. The 
needle or implant device is then removed, leaving the radioactive seeds behind. The 
seeds remain in the patient’s body for the lifetime of the patient, and give off low doses 
of radiation for weeks or months. Radiation from the seeds travels a very short 
distance, so the seeds can deliver a very large amount of radiation to a very small 
area. This decreases the amount of damage produced in healthy tissues that are close 
to the prostate. The dose is delivered over the lifetime of the sources and the sources 
undergo complete decay. In temporary brachytherapy, sources are implanted for a 
specific time duration. The majority of temporary implants are performed with iridium-
192 (192Ir) and cesium-137 (137Cs). The sources are placed in catheters, needles, or 
other applicators for a brief period of time and then removed when the prescribed dose 
is delivered. Generally, several treatments are given, and the radioactive substance is 
removed each time. The treatments are given over a couple of days or weeks. After the 
last treatment the catheters are removed. To reduce treatment time, high dose rate 
(HDR) sources are used. The effective transmission in water of both LDR and HDR 
point sources is presented in figure 2. At points at a distance from the source, the dose 
fall off is determined by the inverse square law and attenuation, i.e. the combined 
effect of scattering and absorption of the emitted radiation. For 125I the attenuation 
plays a significant role. For 60Co, 226Ra, 137Cs, 198Au and 192Ir the scatter largely 
compensates for the absorption within the clinical range of a few cm from the source.     
Permanent seed placement is commonly used for early stage prostate cancer, where 
in addition to radical prostatectomy, Transperineal Interstitial Permanent Prostate 
Brachytherapy (TIPPB) is an important treatment option. In this treatment the urethra is 
the organ at risk (OAR). The D10 (the dose that covers 10% volume of the urethra) 
should be less than 150% of the prescription dose, the D30 less than 130% and the 
generally accepted maximum tolerable dose level of the urethra should be restricted to 
a maximum of 200 gray (Gy)3. Uncertainties in definition of the urthra on the ultrasound 
images or in seed positioning during the implantation procedure, errors in needle 
positioning or deviations in seed activity will influence the dose deposition in this organ, 
with the risk of too high doses in this organ at risk, resulting in urinary complications4. 
Additional QA, to maximize the probability that each individual treatment is 
administered consistently, accurately and safely and to evaluate the dose in the OAR, 
is therefore highly recommended. 
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1.2 IN VIVO DOSIMETRY IN RADIOTHERAPY  
Radiotherapy is a complex process involving many steps before the actual treatment 
begins. The process starts with the diagnosis and the decision to treat the patient with 
ionizing radiation. Next a complex simulation and dose calculation procedure starts to 
arrive at the optimal treatment plan for a particular patient to be given in one or an 
extended set of fractions (figure 3). Each step in this treatment chain has one or more 
sources of error and it is therefore important that each single step is executed with the 
greatest accuracy possible. The uncertainty in each step may influence the accuracy of 
subsequent steps and, therefore impact the overall treatment result. 
Patient dose verification, in vivo dosimetry, serves as an important part of a QA 
programme in radiotherapy and has been recommended for quality improvement of 
patient care in radiation therapy by several organizations such as the American 
Figure 2: Percent dose variation with distance in water for point sources of 60Co, 226Ra, 137Cs, 
198Au, 192Ir and 125I. Function (1/r2) represents inverse square fall off. 
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Association of Physicists in Medicine5, and the European Society of Therapeutic 
Radiology and Oncology6. In vivo dosimetry is a tool to measure the radiation dose 
delivered to patients during radiotherapy. The aim of in vivo dosimetry is to compare 
these dose measurements with the dose values specified by the radiation oncologist 
and the dose values calculated by the TPS, to ensure that the accuracy of the 
prescribed dose to the target volume is within acceptable limits. In addition to the use 
of in vivo dosimetry for assessing the dose delivered to an individual patient for the 
detection of various types of errors in the dose delivery process, it can also serve as a 
tool to verify new treatment techniques in the clinic, after the initial validation of the 
procedure using phantoms, or as an indicator to assess the dose in organs at risk. 
         
 
Figure 3: Treatment chain of a radiotherapy treatment. 
 
1.2.1 In vivo dosimetry as part of a routine QA programme 
There are a lot of control mechanisms to evaluate the accuracy of the single steps in 
the treatment procedure. These checks are based on QA of the treatment equipment, 
including the linac and treatment planning system, and on the data transfer among the 
various types of equipment, such as transfer of data from a CT-scanner to the TPS and 
from the TPS to the linear accelerator. However, also human procedures are subject to 
error and determine the accuracy of the actual patient treatment. In practice, despite 
these control mechanisms random or systematic errors still may occur7, 8. The 
dosimetric impact of these errors is unique for each case and depends on the 
Diagnosis and staging 
Choice of treatment 
Treatment prescription 
Treatment preparation 
Treatment 
Result 
     
In vivo dosimetry  
measurement 
 
Thesis_Bloemen_v07.pdf   20 23-7-2009   16:22:59
Introduction 
 
21 
proportion of fields in error and volume mistreated7. An additional check during the 
actual treatment delivery provides information about the actual dose delivery and gives 
the ability to correct the dose before the next treatment fraction, when dose errors 
occur. 
1.2.2 In vivo dosimetry as a tool to validate a treatment technique 
Techniques in radiotherapy are improving very fast. The development of a new 
treatment technique or an improvement of the actual treatment procedure is a complex 
procedure. Several steps are required performed by a variety of staff, varying from the 
radiation therapy technologist and the physicist to the medical doctor. When 
implementing a new technique, generally phantom measurements are performed. 
Depending on the extent of the alteration, the accuracy of each single step of the new 
treatment procedure should be as high as possible and the uncertainty within 
prescribed limits. Furthermore, the uncertainty of the final dose delivery should be 
within a pre-defined level. Finally, the new procedure has to be described in a practical 
guideline in order to ensure that each worker uses the same and correct treatment 
steps in the entire treatment procedure, and to ensure that the actual treatment of each 
patient is conform predefined guideliness. Supplementary to a well-defined validation 
of the new treatment procedure, a final check in clinical practice is essential to 
determine the accuracy of the new treatment technique during the actual patient 
treatment and to link the delivered 3D dose distribution to patient related factors.  
1.2.3 In vivo dosimetry to check the dose in organs at risk 
The primary objective of radiation oncology is to make the quality of life for the patient 
during and after the radiotherapy treatment as high as reasonably achievable. For 
curative radiotherapy, it is important to deliver a high radiation dose to the tumor, to 
destroy all cancer cells, thereby limiting the dose to normal tissue, to avoid serious 
complications during and after the treatment. A high accuracy of the actual treatment is 
important to provide the desired tumor control rates and the limited dose values at the 
OARs. In practice, several uncertainties may influence the accuracy of the radiation 
dose to the target and the OAR, such as uncertainties in the delineation of the regions 
of interest, in treatment planning related factors, in accelerator performance or seed 
activity related factors, and errors in the treatment procedure. In vivo dosimetry gives 
the ability to check the dose in or close to OARs to reduce side effects of a treatment 
originating from too high doses in a specific organ. The obtained dose information 
gives the opportunity to adapt the dose or improve the treatment technique. 
Furthermore, knowing the in vivo dose in OARs is essential to link clinical side effects 
to absorbed dose values in these organs.  
Thesis_Bloemen_v07.pdf   21 23-7-2009   16:22:59
Chapter 1 
 
22 
1.3 OBJECTIVES AND OUTLINE OF THE THESIS 
In 1994 the first publications concerning a new type of dosimeter, the Metal-Oxide 
Semiconductor Field Effect Transistor (MOSFET) were published, demonstrating that a 
MOSFET is a promising new detector in the area of in vivo dosimetry 9, 10. After these 
initial publications, other publications followed, mostly concerning the properties of the 
detector in radiotherapy applications11-14.  
In January 2001, MAASTRO CLINIC defined their wishes to extend the QA programme 
in treatment delivery with the goal to set-up a broad dose verification programme 
including a dosimetry check in all patient treatments. Our long term perception for 
photon beam in vivo dosimetry was based on using Electronic Portal Imaging Devices 
(EPIDs). EPIDs measure transit dose values, this 2D dose information, can be used for 
in vivo dosimetry. The use of the EPID for in vivo dosimetry was, however, very new at 
that time and the clinical use of the system could not be obtained within our defined 
deadline. To achieve our short time in vivo dosimetry goals in photon beams, combined 
with our aim to perform in vivo dose measurements at extended distance, in the 
surface region, in electron beams and for brachytherapy purposes, a point detector 
was selected. The MOSFET dosimeter, a relatively new dosimeter in the range of 
detectors suitable for in vivo dosimetry in radiotherapy, seemed a suitable detector for 
our range of applications. The selection was primarily based on the broad spectrum of 
applications where the MOSFET detector was supposed to be useful as a clinical 
dosimeter. A secondary advantage of the MOSFET system was the simple dose read-
out method and the lack of correction factors. Furthermore, the portability of the system 
with the opportunity to perform dose measurements at several linacs using one dose 
verification system, if necessary combined with an additional set of dosimeters with 
accompanying bias supply, was a major advantage in order to reduce costs. The 
simplicity of the system to implement the dose measurement and to integrate the 
measurement protocol into the work processes were other important factors.  
The MOSFET dosimeter is a miniature non-intrusive semiconductor radiation detector. 
The basic MOSFET structure is depicted in figure 4a. The MOSFET is a sandwich type 
device with a positively doped (P-type) silicon semiconductor substrate in addition to 
an insulating oxide layer separating it from the negatively doped (N-type) silicon. Prior 
to radiation a sufficiently large negative voltage is applied to the poly-silicon gate, with 
the result that a significant number of minority carriers (holes) will be attracted to the 
oxide-silicon surface from both the bulk silicon substrate and the source and drain 
regions9. Once a sufficient concentration of holes has accumulated there, a conduction 
channel is formed, allowing current to flow between the source and drain. The voltage 
necessary to initiate current flow is known as the device threshold voltage. When a 
MOSFET device is irradiated, three things happen within the silicon dioxide layer 
(sensitive region): a build-up of trapped charge in the oxide; the increase in the number 
of interface traps; and the increase in the number of bulk oxide traps. Electron-hole 
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pairs are generated within the silicon dioxide by the incident radiation. Electrons move 
out of the gate electrode while holes move in a stochastic fashion towards the Si/SiO2 
interface where they become trapped in long term sites, causing a negative threshold 
voltage shift, which can persist for years. The difference in voltage shift before and 
after exposure can be measured, and is proportional to dose (figure 4b)9.  
The aim of the studies described in this thesis is to investigate the use of MOSFET 
dosimeters in various areas of radiotherapy. The validation of the detector, the 
phantom measurements to test the measurement procedure, the results of patient 
measurements, and methods for the implementation of in vivo dosimetry in daily 
practice for both internal and external beam radiotherapy are described, with the goal 
to: (1) detect various types of errors in the dose delivery process, (2) to validate new 
treatment techniques in the clinic and (3) to assess the dose to organs at risk.  
 
In chapters 2 and 4 results are presented of in vivo dose measurements performed to 
validate new treatment techniques in clinical practice, whereas in chapter 3 the use of 
MOSFETs for verifying the existing practice of applying electron beams is elucidated.  
In chapter 2 the first goal was to describe the accuracy of the MOSFET detector for 
dose measurements in a junction field technique, using half beams. The second goal 
was to evaluate the dose across the split line. The accuracy of the detector was 
determined by an extended set of phantom measurements and the results of this 
phantom study were used for patient measurements, performed on 5 patients receiving 
loco-regional treatment for breast cancer, during 10 sequential treatment fractions. The 
influence of factors related to mechanical properties and QC procedures of the linear 
accelerator are also discussed.  
In chapter 3, we describe the use of MOSFET dosimeters for entrance in vivo dose 
verification during electron beam treatment, performed without build-up material on the 
detector to prevent the target volume from shadowing effects by the detector. A 
Figure 4a: The basic MOSFET structure, showing the oxide, SiO2, the substrate, Si, the source 
and the drain and b: gate voltage before and after exposure as a function of source/ drain 
current. 
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comprehensive set of phantom measurements was performed to determine factors to 
convert the surface readings to absolute dose values at depth of dose maximum. 
Patient measurements were performed to evaluate the detectors under clinical 
conditions and to test the in vivo procedure in daily practice. 
The first aim of the study, described in chapter 4, was to verify a new dose calculation 
technique, a 3-dimensional (3D)-dose calculation for TBI, with the goal to optimize this 
treatment by using 3D treatment planning for individual patients. A set of phantom 
measurements was performed, to check the accuracy of a commercial TPS under TBI 
conditions. The second aim of this study was to use MOSFET detectors for in vivo 
dose verification of the actual delivered dose and to compare these values with the 3D-
dose distribution calculated for our TBI technique by a commercial TPS, and with 
measured TLD results.    
In chapters 5 and 6, the application of MOSFET dosimetry for dose verification in 
organs at risk during brachytherapy is described. In chapter 5, a new linear 5-
MOSFET-array dosimeter was validated for in vivo dose verification after permanent 
prostate implantation using 125I. Patient measurements were performed in order to 
provide information about the actual dose in the urethra. The results were used to 
evaluate the implantation technique, including the accuracy of the TPS and will be 
used in the future to link dose distributions to OARs and clinical side effects.  
The goal of the study described in chapter 6 was to investigate the feasibility of a 
linear-MOSFET-array for real-time dosimetry during permanent prostate brachytherapy 
with the opportunity to adapt the treatment plan if the dose in the urethra would be too 
high. The results were used to check the treatment chain and prevent patients from 
getting urinary complications as a consequence of too high doses in this organ at risk.  
Chapter 7 discusses the results of the studies described in this thesis, their clinical 
relevance and their implementation in clinical practice. Furthermore future 
developments are presented in this chapter. 
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ABSTRACT 
Background and purpose: We report on the accuracy of MOSFET detectors to 
measure dose distributions in the region of a field junction in a split beam technique, 
compared to ionisation chamber and photographic film. We present a study on 5 
patients receiving loco-regional treatment for breast cancer.  
Materials and methods: The dose variation at the junction was measured with the 
Patient Dose Verification System Model TN-RD-50 (MOSFET system). Phantom 
measurements were performed to investigate the MOSFET accuracy in a half field 
matching method and the influence of factors related to the accelerator. The aim of the 
patient measurements was to determine the effect of patient related factors on the 
dose at the junction over a period of 10 irradiation fractions. 
Results: The MOSFET detector overestimates the dose in the junction area, therefore 
a correction factor was determined to correct the MOSFET results. Phantom 
measurements showed overdosages as well as underdosages, depending on the 
matching field direction (X or Y). Patient measurements showed dose values that 
deviated up to 133 % ± 3 % (2SD). The average values of 10 irradiation sessions 
showed a continuous, almost linear, variation of dose value across the junction.  
Conclusions: (1) Significant dose deviations in the junction area average out over 
repeated treatments; (2) One individual measurement in the junction area should not 
lead to any action; (3) A linac QA procedure to check the dose at the junction line 
should simulate the clinical situation sufficiently; (4) MOSFET dosimeters overestimate 
dose values in the penumbra region. 
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2.1 INTRODUCTION 
Adjacent treatment fields are commonly employed in external beam therapy. There are 
several reasons why a treatment volume is treated with adjacent fields; an important 
one is the extension of the treatment volume. If the treatment volume is longer than the 
maximum field size, more than one beam has to be used (e.g. irradiation of the entire 
muscle compartment in soft-tissue sarcoma). Another reason may be the anatomy of 
the patient: the patient’s contour and normal tissue constraints may require more than 
one beam configuration (e.g. irradiation of head and neck tumours when lateral neck 
fields are placed adjacent to an anterior supraclavicular field). 
A number of techniques have been developed to achieve dose uniformity in the area of 
the field junction. One technique uses split beams. With this method, the beam is split 
along the plane containing the central axis by using a half-beam block, thus removing 
the geometric divergence of the beams at the split line. The split beam technique, 
using asymmetric collimator jaws, is easy to perform and reduces the treatment time 
significantly. In theory, the split beams should match perfectly. In the clinical situation 
however, there is a possibility of introducing dose deviations across the junction. These 
can originate from factors related to mechanical properties and quality assurance (QA) 
procedures of the linear accelerator’s jaws and to the treatment set-up, e.g. patient 
movements. Consequently, this region is at risk for tumour recurrence if it is 
underdosed or for complications if it is overdosed. 
To determine the dose across the split line, in vivo dosimetry may be used. Various 
techniques have been employed, e.g. TLD10, 17, standard film1, 2, 9, 13, gafchromic film14 
and semiconductors2, 3, 5, 13. Recently there has been an increasing interest in the use 
of Metal Oxide-silicon Semiconductor Field Effect Transistors (MOSFETs) as a device 
for in vivo dosimetry7, 8. Since January 2001, our institute has applied MOSFET 
dosimetry as part of a quality assurance programme for treatment delivery. In the 
present study we investigated the use of such detectors to measure dose distributions 
in the region of a field junction in a split beam technique.  
In this paper we report on the accuracy of the MOSFET detector in such an application, 
compared to ionisation chamber and photographic film and we present a study on 5 
patients receiving loco-regional treatment for breast cancer. This loco-regional 
technique consists of three half-fields, using split beams. A dose of 50 Gy in 25 
fractions is delivered. The beams are split along the plane containing the central axis 
by closing the diaphragms or leaves, thus removing the geometric divergence (fig. 1). 
Measurements were performed at the centre of the junction between the upper 
supraclavicular and the lower breast fields. The influence of factors related to the 
mechanical properties and QA procedures of the linear accelerator, are also dicussed. 
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2.2 METHODS AND MATERIALS 
2.2.1 Linear accelerator 
Measurements were performed using an Elekta SLi15 linear accelerator with a 
multileaf collimator (MLC). The MLC consists of 40 pairs of leaves, each projecting to a 
width of 1 cm at the isocenter (100 cm source-axis- distance). The leaves are made of 
tungsten and are 7 cm thick. The leaves replace the Y- blocks, while the X- blocks are 
standard. Each leaf can travel 12.5 cm across the central beam axis (collimator rotation 
axis) and has a positional accuracy of 1 mm. The end of each leaf is rounded which 
causes a broader penumbra than with focussed collimator blocks. The entire MLC 
assembly fits inside the standard treatment head, providing shaping for the full 40 x 40 
cm2  treatment field6,11.  
2.2.2 Dosimeter system 
To determine the dose across the junction, the patient Dose Verification model TN-RD-
50 (MOSFET system), produced by Thompson and Nielsen Electronics Ltd. (Ottawa, 
Canada), was used. The MOSFET dosimeter is an electronic device, which integrates 
the radiation dose. A silicon chip of 1 mm x 1 mm (active area 0.2 mm x 0.2 mm) is 
Figure 1: Loco regional radiation technique. Three matching fields are employed in the breast 
cancer treatment technique; a: anterior view of the treatment technique; b: lateral view of the 
treatment technique. 
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attached to a 1 mm layer of black epoxy at the end of a flexible cable. For high-energy 
photon beams (above 1 MV) the flat side of the dosimeter is facing the beam. The 
water equivalent depth of the MOSFET is about 0.8 mm or 1.8 mm, depending on 
which sensor side faces the beam15. In this study the detectors were placed with the 
round side of the bulb in contact with the surface of the patient, so measurements were 
performed at an equivalent depth of 0.8 mm. The MOSFET dosimeter is sensitive to 
radiation damage and one of its electrical properties (“threshold voltage”) changes 
continuously with the absorption of radiation. This voltage is a function of absorbed 
dose. The signal can be permanently stored. Variation in signal with temperature 
changes is within the detector’s reproducibility15, 16. A negligible variation of the 
dosimeter response was determined for gantry angles up to 25 degrees. For angles 
between 25 to 90 degrees, the response decreased up to 2.5%15. Dose- rate 
independency, as stated in literature7, was checked. To simulate variation in dose per 
pulse, measurements were performed with MOSFETs and an ionisation chamber at 
80, 100 and 140 cm from the focus using 6 MV photon beams. This resulted in relative 
dose per pulse values of 1.6, 1.0 and 0.5. The standard deviation for the measured 
ratios of the two signals was within 1.5 %. 
A standard bias supply (TN-RD-20), equipped with a 9V battery, provided a regulated 
bias voltage of 7.4 V to the standard dosimeters (TN502), with a sensitivity of 1 
mV/cGy. It also provided the interface from dosimeter to reader; this connection is 
necessary during “zero-ing” and “reading” the dosimeters. The total threshold voltage 
was read out in mV and converted to the corresponding dose in cGy. 
Calibration was performed under full build-up, with the 6 MV photon beam and a 
cylindrical ionisation chamber (PTW type 31002, Physikalisch Technische 
Werkstaetten, Freiburg) as a reference. The calibration factors for the individual 
dosimeters ranged from 1.05 to 1.10. The reproducibility of these factors is about ± 3 
% (2 SD) at about 100 mV voltage shift15, 16.  
The measurements were divided into two parts: phantom measurements and patient 
measurements. 
2.2.3 Phantom measurements 
All phantom measurements described below, were performed with 6 MV photon 
beams, using a rectangular polystyrene phantom (30 cm x 30 cm x 15 cm) at 100 cm 
SSD and 0º gantry angle. Five dosimeters were placed over a length of 1.4 cm, with 1 
mm distance between them. Two half-blocked, 10 cm x 10 cm, adjacent fields using 
collimator angles of 0, 90 and 270 degrees were delivered. Dosimeters 1 and 2 were 
placed at the superior border of the inferior fields, dosimeter 3 exactly on the match line 
and dosimeters 4 and 5 at the inferior border of the superior field. The detectors were 
covered with 1.5 cm of a water-equivalent build-up material. The fields were set-up 
using laser lines. The central beam axis was positioned at the centre of the phantom 
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and the automated field set-up system was used; i.e. collimator angle and jaws were 
set without moving the treatment table.  
The dose variation in the match region was evaluated in the following way; a straight 
line was fitted through a plot of the readings of dosimeter 1, 2, 4 and 5. In case of an 
ideal match the plot of the reading of dosimeter 3 was expected to coincide with this 
line (within 1 SD). Over- and underdosage were defined as the ratio of the dosimeter 3 
reading and the mean value of dosimeter 1, 2, 4 and 5 readings.  
The aim of the phantom measurements was to investigate the MOSFET accuracy in a 
half field matching method (2.3.1), the influence of factors related to the accelerator 
(2.3.2) and the effect of contaminant electrons on the patient measurements (2.3.3). 
The results of these phantom measurements were used to determine the matching 
characteristics under optimal conditions, without deviations caused by patient 
movements.  
2.2.3.1 MOSFET accuracy in a half field matching method 
To determine the accuracy of the MOSFET detector in the junction area, comparisons 
with film and ionisation chamber were made. Kodak-Xomat V films were positioned 
under 1.5 cm of tissue equivalent build-up material on a polystyrene phantom and 
densities were readout with a Multidata model 9710 densitometer (MultiData, St-Louis).  
A PTW type 31002 cylindrical ionisation chamber was scanned across the junction at 
1.5 cm depth in water, with the chamber’s axis positioned parallel to the junction. The 
Semi Flex Tube Chamber has a diameter of 0.7 cm and a volume of 0.125 cm3. Five 
repeated sets of measurements were performed and the results were averaged.  
2.2.3.2 The influence of accelerator related factors  
The measurements to investigate the accelerator related factors were divided in two 
parts; measurements to investigate the accuracy of collimator angle and X- and Y- 
block setting and measurements to determine the reproducibility of block positioning.  
 The accuracy of collimator angle and block settings was investigated for three 
situations. In the first situation the X1- and X2- blocks were matched. The same 
MOSFET set up was then used matching the X2- block with the Y1-leaves (situation 2) 
and matching the X2- block with the Y2- leaves (situation 3). The three situations are 
described in table 1. For each situation, three sets of measurements were performed 
and the results were averaged. 
The reproducibility of block positioning matching the X1- and X2- blocks, was 
determined with the ionisation chamber. Five repeated measurements were performed 
and for each measurement the blocks were positioned using the automated set- up 
system.  
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2.2.3.3 The effect of contaminant electrons on the junction dose 
The MOSFET measurements on the patients were performed without any build-up 
material (see below); therefore the effect of contaminant electrons on the determined 
over- or underdosage values was investigated. The MOSFETs were covered with 0, 
0.5, 1.0 and 1.5 cm build-up material, respectively. For all depths five repeated sets of 
measurements were performed, the results were averaged and the ratios of the 
dosimeter 3 reading and the mean value of dosimeter 1, 2, 4 and 5 readings were 
computed. The same measurements were performed with the ionisation chamber in 
water and the average ratios were compared to those of the MOSFETS.  
2.2.4 Patient measurements 
The aim of the patient measurements was to determine the effect of patient related 
factors, such as patient movement, on the dose at the junction over a period of 10 
irradiation fractions. Measurements were performed on 5 patients. Three of them had 
received a complete mastectomy. Two patients had received breast-conserving 
surgery. Two half-blocked adjacent fields using 6 MV photon beams were delivered. In 
one patient a 10 MV beam for the upper supraclavicular field was used (the correction 
for energy dependence when measuring in a 10 MV beam instead of in a 6 MV beam 
is less than 1%). For all patients, the X2- block of the cranial field matched the Y1- and 
Y2- leaves of the caudal fields. The details of field parameters are described in table 2. 
Five dosimeters were taped on the skin, at the same location during all measurements. 
The fields were set up in an isocentric technique, using laser lines, and the automated 
set-up system, without moving the treatment table. Five MOSFETs were placed as 
described in the first paragraph of 2.3. To determine the precise location of the 
MOSFET dosimeters during the 10 irradiation fractions, the MOSFET location was 
indicated on the patient’s skin. One person performed all measurements. 
Table 1: Field set-up of phantom measurements investigating the influence of collimator, block 
and leaf setting. 
 
Field AP inferior AP superior AP inferior AP superior AP inferior AP superior
Field size
X1 0.0 10.0 5.0 10.0 5.0 10.0
X2 10.0 0.0 5.0 0.0 5.0 0.0
Y1 5.0 5.0 0.0 5.0 10.0 5.0
Y2 5.0 5.0 10.0 5.0 0.0 5.0
Gantry  0 0 0 0 0 0
Collimator 0 0 90 0 270 0
situation 1 situation 2 situation 3
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Build-up material on the patient’s skin during 10 irradiation fractions would significantly 
increase the skin dose under the detector and would reduce the dose at depth. This 
effect is unacceptable over 10 irradiation fractions. Therefore measurements were 
performed without build-up. The purpose was to compare the readings of the five 
dosimeters, in order to assess the dose variation over the junction during 10 radiation 
fractions. Since the conversion to dose is uncertain when no build-up is used, the 
results are stated as relative readings.   
 Table 2: Field set-up of patient measurements. 
 
Field breast breast supraclav . breast breast supraclav . breast breast supraclav .
Fieldsize
X1 8.0 8.0 6.9 0.0 0.0 6.3 0.0 0.0 8.9
X2 15.0 15.0 0.0 12.2 12.2 0.0 12.0 12.0 0.0
Y1 15.6 0.0 8.7 18.0 0.0 9.0 18.7 0.0 10.1
Y2 0.0 19.1 -1.8 0.0 16.7 1.1 0.0 17.6 -2.0
Gantry 32 212 10 56 236 10 47 227 5
Collimator 270 90 0 270 90 0 270 90 0
patient 1 patient 2 patient 3
 
Field breast breast supraclav . breast breast supraclav .
Fieldsize
X1 0.0 0.0 8.0 0.0 0.0 7.7
X2 9.8 9.9 0.0 9.5 9.5 0.0
Y1 0.0 16.1 0.0 0.0 13.7 0.8
Y2 15.9 0.0 6.8 14.9 0.0 7.6
Gantry 309 129 350 308 128 350
Collimator 90 270 0 90 270 0
patient 3 patient 4
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2.3 RESULTS  
2.3.1 Phantom measurements 
2.3.1.1 MOSFET accuracy in a half field matching method 
Matching X1- and X2- blocks, the MOSFET measurements showed an overdosage of 
111 % ± 1.7 % (1 SD). For film measurements this value was 106 % ± 2.0 % (1 SD) 
and for ionisation chamber measurements 105 % ± 0.7 % (1 SD). It appears that the 
MOSFET detector gives higher readings in the penumbra region. Therefore a 
correction factor was determined to correct the MOSFET results. This factor is equal to 
the ratio of the ionisation chamber and MOSFET overdose values and has the value of 
0.95 ± 0.02 (1 SD). Matching X2- blocks and Y1- leaves, the MOSFETs showed a 
relative dose value of 100 % ± 2.0 % at the junction area. Film measurements showed 
an underdose of 95 % ± 1.5 % (1 SD). The correction factor matching X2- blocks and 
Y1- leaves has the value of  0.95 ± 0.02 (1 SD), equal to the factor matching X1- and 
X2- blocks. All measurement results described below are corrected with this factor. 
2.3.1.2 The influence of factors related to the accelerator 
The measurement results of the three test situations, investigating the accuracy of 
collimator angle and block and leaf setting, are shown in table 3. Matching X1- and X2- 
blocks  (situation 1) gives an overdose of 105 % ± 1.7 % (1 SD). Matching X2- block 
and the Y1- leaves (situation 2) gives an underdose of 95 % ± 1.4 % (1 SD) and 
matching the X2- block and the Y2- leaves (situation 3) an underdose of 91 % ± 1.7 % 
(1 SD) at the match line.  
The test to investigate the reproducibility of block positioning showed for the X1- and 
X2- blocks a mean overdose value of 106.7 %. The standard deviation was  0.53 % (1 
SD). The overdose value ranges between  106.1 % and  107.4 %. 
 
Table 3: Results of phantom measurements. For all situations three measurements were 
performed and the results were averaged. 
 
dosimeter mean reading S.D. mean reading S.D. mean reading S.D.
1 103.6 2.12 111.2 0.00 103.5 2.12
2 107.0 2.83 107.2 0.71 101.3 0.71
3 117.6 1.41 109.6 1.41 98.0 1.41
4 106.0 0.71 109.2 0.71 99.0 0.00
5 107.4 2.12 109.2 2.12 102.5 3.54
situation 1 situation 2 situation 3
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2.3.1.3 The effect of contaminant electrons on the junction dose 
The ratio of the readings performed at various depths, gives an almost horizontal line 
over the measuring depths for both MOSFET and ionisation chamber. No 
demonstrable influence of contaminating electrons on the MOSFET reading at the 
surface was found. 
2.3.2 Patient measurements 
Fifty measurements were performed, during 10 different irradiation sessions of 5 
patients. For all patients, the X2- block of the cranial field matched the Y1- and Y2- 
leaves of the caudal fields. The phantom measurements in these situations (3.1.1) 
showed that a correction factor of 0.95 has to be applied. The average of the 10 
measurements, corrected for overestimation of the detector, is given in figure 2a-e. A 
point depicts the mean value for each single detector. The error bars indicate the 
standard deviation of the measurements. An ideal field match will show a smooth line 
through the data points.  
For patient 2 build-up was used in the inferior tangential breast fields, required for 
adequate treatment of skin involvement. This caused the relatively high readings of 
dosimeter 1 and 2 in the caudal region. The build-up influenced the reading of 
dosimeter 3 up in this caudal region. As expected, the reading of this dosimeter was 
higher than the reading of dosimeter 3 for the other patients, but was still in a line with 
the reading of dosimeter 2 and 4 for this patient. We can conclude that there is a 
smooth dose variation in the measurement area, in spite of the partial build-up in the 
junction area. Measurements on patient 4 showed low readings of dosimeter 4 and 5 in 
the superior supraclavicular region. In this region, a 10 MV beam was used. Due to this 
higher energy (10 MV instead of 6 MV) there are less contaminating and secondary 
electrons in the surface region. This explains the lower skin dose, measured with the 
MOSFET dosimeters in this superior supraclavicular area. The reading of dosimeter 3 
was influenced by the use of this 10 MV beam, but was still in a line with the reading of 
dosimeter 2 and 4. There was a homogeneous dose in the whole junction area, in spite 
of the use of two different energies.  
The mean results for all patients showed no significant deviations, because of the 
relative high SD of the measurements in the central junction area. The individual 
irradiation session measurements showed, in contrast to the mean results, large dose 
errors across the junction. Errors of up to 133 % ± 3.0 % (2SD) were measured. These 
matching errors, caused by patient movement during radiation, are responsible for the 
high SD. 
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Figure 2a-e: Patient measurements. Average readings of 10 patient measurements for 5 
patients. A point depicts the average value for each single detector. The vertical lines indicate 
the standard deviations of the 10 measurements. 
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The standard deviation for the individual MOSFET-dosimeters, during 50 
measurements, is illustrated in figure 3. The dosimeter on the junction (3) presents the 
highest SD. Movements mostly affects the dose at the junction. The smallest standard 
deviations are seen for dosimeter 1 and 5. 
 
 
2.4 DISCUSSION  
Significant dose variation at the junction can be caused by a minimal positioning 
inaccuracy of the jaws at the position of the central axis (offset). A 10 % deviation of 
the dose value around the 50 % point on a beam profile is related to a misalignment of 
1 mm at a SSD of 100 cm for one block or 0.5 mm per block when the deviation for 
both blocks is in opposite position. Our QA programme is performed using film 
dosimetry and a deviation less then 10 % at the junction line is accepted, even if the 
penumbral shapes are unequal (junction between a collimator and MLC). In practice 
this means that an offset, or disagreement between light field and radiation field edge 
(50 %) at the central axis, of 0.5 mm or less will be accepted.   
Patient measurements showed evident over- and underdosages across the junction, 
up to 133 % ± 3 % (2SD). A 140 % overdose at the junction equates to an overlap of 
approximately 2 mm at the junction line. The region of overdose around the match line 
Figure 3: Patient measurements. Standard deviations of the 5 MOSFET readings during 50 
patient measurements. Dosimeter 1 and 2 were placed at the border of the inferior tangential 
breast fields, dosimeter 3 exactly on the match line and dosimeter 4 and 5 at the border of the 
superior supraclavicular field.  
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is 3-4 mm wide13. The most likely cause of these over- and underdosages across the 
junction is patient movement during treatment. Patient movements can originate from 
muscle tension and breathing during positioning. Relaxing during the treatment affects 
the position of the patient in relation to the irradiation beam. Also variations in head 
position can affect the dose in the junction area.  
 
Using MOSFET dosimeters appears to be a suitable method to measure the dose 
across a junction. The detectors are small; thus many detectors can be placed together 
in a relatively small area. However, the effect of overestimating the dose in the 
penumbra region has to be taken in account.   
2.5 CONCLUSIONS 
Based on the presented results, our recommendations for an adjacent field method, 
using a split beam technique with Multi Leaf Collimators are:  
1. For individual fractions of a treatment significant deviations may be present at the 
junction. These deviations average out over repeated treatments to give relatively 
smooth dose distributions over the junction area; 
2. One individual measurement in the junction area should not lead to any action, 
because random errors greatly affect the measurement; 
3. The QA procedure to check the dose at the junction line should simulate the 
clinical situation as accurately as possible, in order to recognise deviations that 
occur in clinical situations. This means that the field size, collimator- and gantry 
angles used in the QA procedure must be similar to the clinical situation. 
4. If using MOSFET detectors in a match line region, a correction has to be made to 
the measurement results, to correct for the overestimation of the detector in the 
penumbra region. 
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ABSTRACT 
Background and purpose: To determine the factors converting the reading of a 
MOSFET detector placed on the patient’s skin without additional build-up to the dose at 
the depth of dose maximum (Dmax) and investigate their feasibility for in vivo dose 
measurements in electron beams.   
Materials and methods: Factors were determined to relate the reading of a MOSFET 
detector to Dmax for 4 to 15 MeV electron beams in reference conditions. The influence 
of variation in field size, SSD, angle and field shape on the MOSFET reading, obtained 
without additional buid-up, was evaluated using 4, 8 and 15 MeV beams and compared 
to ionization chamber data at the depth of dose maximum (zmax). Patient entrance in 
vivo measurements included 40 patients, mostly treated for breast tumours. The 
MOSFET reading, converted to Dmax, was compared to the dose prescribed at this 
depth.  
Results: The factors to convert MOSFET reading to Dmax vary between 1.33 and 1.20 
for the 4 MeV and 15 MeV beam, respectively. The SSD correction factor is 
approximately 8 % for a change in SSD from 95 cm to 100 cm, and 2 % for each 5-cm 
increment above 100 cm SSD. A correction for fields having sides smaller than 6 cm 
and for irregular field shape is also recommended. For fields up to 20 cm x 20 cm and 
for oblique incidence up to 45º, a correction is not necessary. Patient measurements 
demonstrated deviations from the prescribed dose with a mean difference of -0.7 % 
and a standard deviation of 2.9 %.  
Conclusion:  Performing dose measurements with MOSFET detectors placed on the 
patient’s skin without additional build-up is a well suited technique for routine dose 
verification in electron beams, when applying the appropriate conversion and 
correction factors. 
Thesis_Bloemen_v07.pdf   46 23-7-2009   16:23:01
Electron beams 
 
47 
3.1 INTRODUCTION 
Patient dose verification has been recommended for quality improvement of patient 
care in radiation therapy by several organisations such as the American Association of 
Physics in Medicine11, and the European Society of Therapeutic Radiology and 
Oncology8, 23. In vivo dosimetry has become an important part of a quality assurance 
(QA) programme in a radiotherapy department and has proven to be very useful in 
assessing the dose delivered to an individual patient, as well as in the detection of 
various types of errors in the dose delivery process7,13. Several dosimetry systems are 
available for use in radiotherapy. The most commonly used detector types for patient 
dose verification are diodes7, 12, 17, 23 and thermo-luminescence dosimeters (TLDs)7,15,23. 
Recently there has been an increased interest in the use of the metal oxide-silicon 
semiconductor field effect transistor (MOSFET) for in vivo dosimetry purposes1, 2, 3, 4, 5, 6, 
9, 14, 18, 19, 20, 21, 22. The system uses miniature non-intrusive MOSFET semiconductor 
radiation dosimeters (size less than 4 mm2). Other characteristics of MOSFET devices 
are the direct and simple dose readout, the portability of the system and the recording 
of the accumulated dose of each detector. The output can be converted from mV to 
cGy by entering a calibration factor in the reader for each single dosimeter. MOSFETs 
exhibit in addition a good linearity of their response5, 9, 22. 
Only limited information is available about the use of MOSFET detectors for dosimetric 
verification of radiotherapeutic treatments. After the initial evaluation of Soubra et al.22 
showing that the characteristics of MOSFET detectors make them very promising for 
clinical dosimetry, only a few publications described their actual use in the clinic. 
Ramani et al.18 determined important physical characteristics of the detectors to 
demonstrate the usefulness of MOSFETs as clinical dosimeters. Measurements were 
performed at different sites of the patients’ body, with both photon and electron beams 
of various energies. MOSFET and TLD measured dose values were compared and 
related to the expected dose. However, not many details (number of patients, the use 
of build-up, the presence of an insert or air gap, and the angular dependence during 
the electron beam measurements) are provided. Scalchi and Francescon21 calibrated 
MOSFET detectors to perform in vivo dosimetry during 6-MV treatments, both in 
normal set-up and during total body irradiation conditions. However, these authors did 
not present results of clinical studies. More recently the use of MOSFETs for clinical 
IMRT dosimetric verification has been reported5, but that study also concerned only 
phantom measurements.  
Since January 2001, our department uses MOSFET dosimeters as part of a quality 
assurance programme of treatment delivery1. Since July 2002, in vivo dosimetry has 
been performed to check the entrance dose for all curative and elective treatments 
applying photon beams. In December 2002, we also implemented MOSFET dosimetry 
for QA of electron beams.  
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In this paper we present the results of a systematic study of MOSFETs for 
measurements in electron beams. The goal of the study was to perform entrance in 
vivo measurements without additional build-up on the detector to prevent the target 
volume from shadowing by the build-up material of the detector. However, in most 
cases we are not interested in the dose at the surface. For this reason we converted 
the readings obtained with MOSFET dosimeters, placed on the patient’s skin/ phantom 
without build-up, to absolute dose values of zmax under reference conditions. A 
comprehensive set of phantom measurements was performed to determine these 
conversion factors. Measurements in the surface region are, however, sensitive to 
differences in energy and spatial distribution of electrons in clinical conditions 
compared to reference conditions. Supplementary measurements were performed to 
investigate the influence of these non-reference conditions, such as SSD, gantry angle, 
field size and shape on a MOSFET measurement, yielding an additional set of 
correction factors. Patient measurements were analysed with the aim to evaluate the 
use of MOSFET detectors under clinical conditions. 
3.2 MATERIALS AND METHODS 
3.2.1 MOSFET dosimeters 
All measurements were performed using TN-502RD MOSFET dosimeters, produced 
by Thomson and Nielsen Electronics Ltd (Ottawa, Canada). For phantom 
measurements the MOSFET AutoSense system (TN-RD-60), developed for on-line 
radiotherapy applications, was used. The standard TN-RD-50 patient verification 
system, which does not allow on-line dose reading, was used for patient 
measurements. The two systems are virtually identical; the only difference is that the 
AutoSense system can be used for repetitive measurements as the control box of the 
MOSFET system can be read out without entering the treatment room.  
The sensitivity of the MOSFET detector depends on the oxide thickness and on the 
gate voltage provided by the bias supply. Thomson and Nielsen have two types of 
MOSFET detectors, standard/ high sensitivity and two voltages on the bias supply, 
standard sensitivity (1 mV cGy-1) and high sensitivity (3 mV cGy-1). At lower dose level 
(<1 Gy) the high sensitivity bias and/ or the high sensitivity MOSFETs are 
recommended in order to cover this low dose range with an optimal reproducibility. 
However, the lower sensitivity dosimeters associated with the lower gate bias, enable 
the MOSFETs to be irradiated to a higher accumulated dose.  
The TN502RD MOSFET dosimeter is a dual-bias dual-MOSFET detector. This kind of 
detector consists of two identical MOSFETs, fabricated on the same silicon chip and 
operating at two different gate biases (1V and 15V). During irradiation each sensor will 
produce a threshold voltage shift, the gate voltage necessary to allow charge 
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conduction through the MOSFET. The reader measures and records the threshold 
voltages by passing current through the cable to the MOSFET chips. The difference 
between the two threshold voltage shifts is a function of absorbed dose and will be 
displayed on the reader. The bias supply provides a constant bias voltage on the 
MOSFET during irradiation. Details of the process involved in the use of a MOSFET as 
a dosimeter can be found elsewhere5, 18, 21, 22. The silicon chip (1 mm square, active 
area 0.2 mm x 0.2 mm) is covered with an epoxy bulb on top of the MOSFET gate 
oxide. The water equivalent thickness of the MOSFET is about 0.8 mm (flat side) and 
1.8 mm (epoxy bulb side), under normal beam incidence in a 10 x 10 cm2 field of a 6 
MV X-ray beam at 100 cm SSD21.    
For this study, a set of standard MOSFETs with the bias supply set at standard 
sensitivity was used. The MOSFETs were taped on the surface of the phantom, or skin 
of the patient, with the flat side of the detector facing the beam. After each irradiation 
the dose was read out by connecting the bias supply to the readout device. Before use, 
the MOSFETs were calibrated in a 6 MV photon beam, as will be described below.  
3.2.2 Calibration procedure 
Calibration is performed to convert the dose-induced dosimeter voltage shift to cGy. It 
has to be executed prior to the first measurement with a new dosimeter and after any 
lengthy period of not being used. After applying the appropriate calibration factor (Fcal), 
the system may yield dose values at specific sites18, including organs at risk and in 
junction areas1. Although the goal of the study was to perform entrance in vivo 
measurements in electron beams without build-up material on the detector, Fcal is 
obtained in photon beams under full build-up, to obtain maximum accuracy and 
repeatability. In our hospital the MOSFETs are first calibrated at depth in a photon 
beam, and the same detectors are then used for entrance in vivo dose measurements 
in both photon beams (with build-up) and electron beams (without build-up).  
MOSFET calibration was performed using a 6 MV photon beam, 10 cm x 10 cm field 
size and 100 cm SSD. Five detectors were placed in a circle in a PMMA home-made 
calibration phantom at depth of Dmax, at minimal distance from the central axis of the 
beam. Ten measurements were performed and the results were averaged. We 
compensated for actual accelerator output by measuring this output with a calibrated 
cylindrical ionisation chamber (PTW type 31002, Physikalisch-Technische 
Werkstaetten, Freiburg, Germany), following the Dutch code of practice for the 
dosimetry of high-energy photon beams. Fcal was determined as the ratio of the 
measured output voltage of the dosimeter and the actual Dmax. Fcal was entered into the 
MOSFET reader to obtain a reading in cGy. For entrance in vivo measurements in 
electron beams without build-up, conversion factors were established.  
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3.2.3 Phantom measurements 
Phantom measurements were performed (1) to determine the conversion factor 
(Fconversion) between the readings of the MOSFET performed without additional build-up 
(based on photon calibration), to the Dmax in electron beams (2.3.1.) and (2) to 
determine correction factors (CFs) for varying SSD, beam angle, field size and shape 
on the measurement result (2.3.2.). For all measurements, an Elekta SL-15i linear 
accelerator was used. Square applicators with dimensions ranging from 6 cm to 20 cm 
and a length of 42 cm were combined with inserts yielding field sizes ranging from 4 
cm tot 20 cm square. The applicator is fitted to the surface of the phantom/ patient at 
95 cm SSD. A radiation dose of 100 cGy was delivered for zmax. The detector was 
placed with the round epoxy side of the detector on the surface of a PMMA phantom. 
The measurement results were compared to absolute dose values obtained with a 
Markus ionization chamber placed at the depth of Dmax (PTW type M23343, 
Physikalisch-Technische Werkstaetten, Freiburg, Germany).  
3.2.3.1 Conversion factors 
For an accurate comparison of MOSFET reading with the prescribed dose (i.e. 
corresponding to Dmax), the MOSFET readings at the surface (performed without build-
up) were converted to Dmax. Because the magnitude of Fconversion depends on the energy 
of the beam, measurements were performed using 4, 6, 8, 10, 12 and 15 MeV beams. 
Three MOSFET detectors were taped on a phantom and for each energy 10 
measurements were performed under reference conditions (100 cm SSD and a 10 cm 
x 10 cm applicator and insert size). Because in the clinical situation, the basic 
procedure is to irradiate patients at 95 cm SSD, we converted these factors to values 
at 95 cm, using the correction for SSD (including the inverse square law). Markus 
chamber measurements were performed at zmax. The measurement results were 
averaged and Fconversion was determined as:  
MV) (6 F 95) 10,  x10 surface, (E, R
95) 10,  x10Z(E, dose(E) F
cal
 max,
conversion ∗=                         (1) 
where R is the MOSFET reading in mV, with the MOSFET at the surface of the 
phantom. The dose at the depth of dose maximum for non-reference conditions, which 
is generally called entrance dose during in vivo dosimetry8, is now calculated from the 
reading of the MOSFET (mV) at the surface, according to: 
(E)CF   *(E) F *(6MV) F *R D  iconversioncalentrance ∏=                          (2) 
3.2.3.2 Influence of varying SSD, beam angle, field size and shape 
Additional measurements were performed to determine CFi(E), the variation in the ratio 
between the reading of the MOSFET at the surface and the dose determined with an 
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ionisation chamber placed at zmax, when changing the reference conditions (SSD, 
angle of incidence, field size and field shape).  
To investigate the influence of variation in SSD on the MOSFET reading, 
measurements were performed using an SSD varying from 95 to 110 cm for a 10 cm x 
10 cm insert. Distances of 95, 100, 105 and 110 cm SSD were used in an 8 MeV 
electron beam, while measurements at 95 and 110 cm SSD were performed for 4 and 
15 MeV electron beams. Three MOSFETs were taped at the centre of the field, on the 
surface of the phantom. Ten measurements were performed, and the results were 
averaged and related to the Markus chamber measurements performed at zmax.  
Older studies reported a large angular dependence for MOSFETs in photon beams18, 
21, although a more recent study showed a much smaller angular dependence, within 
2.5 % for gantry angles varying between 0 and 180 degrees5. No information is 
available about the angular dependence of MOSFET detectors in electron beams. The 
angular dependence of the MOSFET detectors was therefore investigated by placing 
three MOSFETs at the centre of a PMMA cylindrical mini-phantom with 1.5 cm radius 
(Fig.1a). The mini-phantom was placed on a small Styrofoam block, which is almost air 
equivalent material, to approach free air geometry. The centre of the phantom was 
positioned in the middle of a 10 cm x 10 cm electron field at 100 cm SDD, with the flat 
side of the detector facing the beam at 0º gantry angle. Gantry angles were varied 
between 0 and 90º in steps of 150 for measurements in the 8 MeV beam, and from 0º, 
45º to 90º degrees using the 4 and 15 MeV beams. Measurements were repeated 10 
times for each gantry angle and the readings were related to the readings at 0º. The 
output variation of the linear accelerator as a function of gantry angle was determined 
to be less than 1 % for the three beam energies.  
Beside the earlier described non-isotropic response of the MOSFET, in the clinical 
situation the effect of gantry angle rotation on the MOSFET reading (performed without 
build-up) is due to two factors: the ratio MOSFET reading at the surface/ ionisation 
chamber at zmax and differences in the contribution of electron scatter from the surface 
of the phantom when changing the angle of incidence of the beam. To approach this 
situation and to investigate the influence of this scatter component, measurements 
were performed with the detector fixed on the flat surface of a rectangular PMMA 
phantom (Fig 1b.). Three MOSFET dosimeters were positioned at the centre of a 10 
cm x 10 cm field at 100 cm SSD. Gantry angles were varied between 0 and 90º in 
steps of 150 for measurements in the 8 MeV beam, and from 0º, 45º to 90º degrees 
using the 4 and 15 MeV beams. Measurements were repeated 10 times for each 
gantry angle and the readings were related to the readings at 0º. 
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The influence of field size was investigated using 4 cm x 4 cm and  6 cm x 6 cm inserts 
(6 cm x 6 cm applicator), 10 cm x 10 cm insert (10 cm x 10 cm applicator) and 20 cm x 
20 cm insert (20 cm x 20 cm applicator) and the detectors were positioned at the 
surface of the phantom placed at 95 cm SSD in a 8 MeV electron beam. For the 4 cm x 
4 cm and 20 cm x 20 cm field sizes with corresponding applicators also the 4 MeV and 
15 MeV electron beams were investigated. Three MOSFET dosimeters were irradiated 
with a dose of 100 cGy and for each situation 10 measurements were performed. 
Ionization chamber measurements were performed at zmax, determined for each field 
size and energy. The MOSFET measurements were averaged and related to the 
ionization chamber results. 
 
 
Figure 2: A shaped insert, made of Cerrobend, used to investifgate the influence of shape, size 
and position of the opening in the insert on the MOSFET reading. Numbers 1, 2 and 3 are the 
cut-outs and A, B, C and D are the measuring locations. 
Figure 1: Experimental set-up for the determination of the angular dependence of the MOSFETs,
using a cylindrical PMMA (a) and a flat phantom (b). 
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To investigate the influence of field position and field shape on the MOSFET response, 
a limited set of measurements was performed using a home-made insert for the 20 cm 
x 20 cm applicator with three openings (Fig. 2). Measurements at the centre of opening 
1 (location A) and 2 (location B) (both 6 cm x 6 cm) were performed to investigate the 
influence of field position in the applicator. Measurements close to the upper (location 
C) and lower edge (location D) of opening 3 (5 cm x 18 cm) were performed to 
investigate the influence of field shape. Three MOSFET dosimeters were placed at the 
surface of the phantom for each location, using beam energies of 4, 8 and 15 MeV. 
Measurements were repeated 10 times, the results were averaged and related to 
ionization chamber measurements performed at zmax at the same distance from the 
field axis. The value of zmax was determined for a 6 cm x 6 cm field size and 4, 8 and 15 
MeV electron beams. Based on data available in the literature, it was assumed that 
zmax for a 6 cm x 6 cm field size is almost identical to that of a 5 cm x 18 cm field size16.  
3.2.4 Patient measurements 
Forty patients were included in the clinical study. The patients were irradiated at 
several locations; 31 on the breast/ thorax wall, 6 on the internal mammary lymph node 
region, 2 on the skull and one at the testis. The radiation dose per fraction ranged 
between 1.8 to 2.0 Gy and 6, 8, 10, 12 and 15 MeV electron beams were used. Field 
sizes varied between 6 cm and 20 cm diameter (round or square). For 9 patient 
treatments a customised insert was used, while for 14 patients an air gap between the 
insert and the skin, ranging between 0.5 and 4 cm, was present (SSD 95.5 up to 99 
cm).  
Patient entrance in vivo measurements were performed during the first fraction of the 
treatment. The detectors were located at the centre of the insert, with the round epoxy 
side of the detector in contact with the skin, for every beam given to the patient. The 
SSD at the centre of the field was measured for each beam. After the application of the 
MOSFET and the measurement of the SSD, the patient was irradiated and after the 
completion of the beam the MOSFET was read out. The MOSFET reading at the 
surface was converted to Dmax, using Fconversion obtained as described earlier. This dose 
obtained from the MOSFET measurement, recalculated to zmax and corrected for non-
reference conditions (Dentrance), was compared to the prescribed dose (Dplan). The 
deviation is presented as (Dentrance - Dplan)/Dplan*100. In 8 patients the electron beam was 
given in combination with one or more photon beams within a fraction and the number 
of monitor units (MUs) was calculated using the FOCUS treatment planning system 
version 3.0 (CMS Inc., Saint Louis, MO, USA). FOCUS applies a modified version of 
the Hogstrom dose calculation algorithm. For the other patient irradiations, where the 
electron beam was given alone, a home-made interpolation program based on 
measurements was used to calculate the radiation dose. A maximum deviation of 
about 3 %, based on experimental verification, can be attributed to these calculations 
due to limitations of this algorithm.  
Thesis_Bloemen_v07.pdf   53 23-7-2009   16:23:02
Chapter 3 
 
54 
3.3 RESULTS 
3.3.1 Phantom measurements 
Fcal for the individual dosimeters ranged from 1.05 to 1.10. The mean reproducibility of 
Fcal and CFs is about 2.0 % (1 SD) in photon beams with full equilibrium, 10 successive 
measurements at about 100 mV and standard sensitivity.  
3.3.1.1 Conversion factors (Fconversion) 
The results of the measurements shown in Fig. 3 demonstrate that the ratio of the 
MOSFET reading at the surface (in cGy) and the ionisation chamber dose at zmax 
increases with increasing beam energy. The result varies between 0.75 ± 0.02 and 
0.83 ± 0.02 (1 SD) for an energy range of 4 - 15 MeV. This means that Fconversion, 
necessary to convert the MOSFET reading to Dmax, decreases with increasing energy 
of the beam. Fconversion is 1.33 for the 4 and 6 MeV beam and 1.30, 1.26, 1.24 and 1.20 
for the 8, 10, 12 and 15 MeV beams, respectively, at 95 cm SSD for a 10 cm x 10 cm 
field size. The reproducibility of the MOSFET detector measurements varied between 
1.1 % and 2.5 % (1 SD). 
3.3.1.2 Influence of varying SSD, beam angle, field size and shape (CFi) 
The ratio of the MOSFET reading at the surface/ ionisation chamber dose (zmax), 
decreases with increasing SSD, which would result in an underestimate of the entrance 
dose by the MOSFET. The results are shown in Fig. 4a. The decrease of the ratio 
MOSFET reading at the surface /ionisation chamber dose (zmax) is 8.3 % for the 8 MeV 
beam, for an SSD variation from 95 cm to 100 cm SSD (ratio 0.92 ± 0.03). Further 
increase to 110 cm SSD gives a smooth underestimation of (1.7 %), up to a ratio of 
0.90 ± 0.03 (1 SD). The 4 MeV beam gives a 10.4 % underestimation in dose for an 
SSD variation from 95 cm to 110 cm SSD (ratio 0.90 ± 0.03). For the 15 MeV beam an 
underestimation of 7.4 % is observed (0.93 ± 0.03). These measurements prove that a 
correction for SSD is necessary, especially for SSD up to 100 cm.  
The results of the measurements performed using a cylindrical mini-phantom, 
demonstrate that the angular dependence of the MOSFET detector in electron beams 
is small. For the 4 MeV beam the reading decreases 3.2 % with increasing gantry 
angle: from 61.6 ± 1.3 cGy at 0º to 60.3 ± 1.4 cGy at 45º, and 59.6 ± 1.1 cGy at 90º. 
For the 8 MeV beam, the variation in detector response with gantry angle is negligible 
(within 1.0 %). Also for the 15 MeV beam, the angular dependence of the detector is 
small, within 2.9 %: from 88.5 ± 1.4 cGy  at 0º to 89.7 ± 1.7 cGy at 45º and 87.1 ± 2.0 
cGy at 90º.   
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The results of the measurements investigating the MOSFET reading at the surface 
/ionisation chamber dose (Dmax) and the contribution of electron scatter during gantry 
rotation are shown in Fig. 4b. The variation in dose caused by a variation in angle 
towards 45º, the range of angles that is clinically most important for electron beams, is 
within 3 % for 4, 8 and 15 MeV beams. The ratio of the readings at 45-degree gantry 
angle and at 0 degrees are for both MOSFET 1 and 3, 1.03 ± 0.03, 0.99 ± 0.02 and 
1.00 ± 0.03 (1 SD), for the 4, 8 and 15 MeV beams, respectively. The ratio of the 
readings for MOSFET 2 is 1.14 ± 0.02, 1.06 ± 0.02, 1.04 ± 0.01 (1 SD), for the same 
energies. For larger angles towards 75º, an increase of reading was detected for all 
MOSFETs. The average ratio of the reading at 750 compared to that at zero degrees is 
for the three MOSFETs at 8 MeV 1.24 ± 0.03 (1 SD). The results of MOSFET 2 were 
kept out of this analysis, because of its abnormal behaviour compared to the other 
detectors. For gantry angles up to 45º, a correction is not necessary. For gantry angles 
larger than 45º, a significant deviation was demonstrated; however these angles are 
not very relevant in clinical situations.  
The ratios of the MOSFET reading at the surface/ ionisation chamber dose (Dmax) for 
changes in field size are shown in Fig. 4c. The value of Fconversion does not depend on 
field size, for field sizes larger than 6 cm x 6 cm. For fields smaller than 6 cm x 6 cm, 
the MOSFET overestimates the entrance dose by about 5% depending on the electron 
beam energy. Using 4 MeV beams, the ratio is almost independent of field size, while 
for a field size of 4 cm x 4 cm for the 8 MeV and 15 MeV beam the ratio is 1.05 and 
1.06, respectively.  
Figure 3: Fconversion , expressed as MOSFET reading in cGy at the surface/ ionisation chamber 
dose at the depth of dose maximum (Dmax) in cGy, for 4, 6, 8, 10, 12 and 15 MeV beams at 95 
cm SSD cm and a 10 cm x 10 cm applicator.  The mean result of 10 measurements using three 
MOSFETs and the standard deviation are given. 
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Figure 4a: MOSFET reading at the surface/ ionisation chamber dose (zmax), as a function of 
SSD and normalized to 95 cm SSD for 8 MeV electron beams. b: Angular dependence of 
MOSFET reading at the surface, normalized to 0 degrees using 8 MeV electron beams. c: 
MOSFET reading at the surface/ ionisation chamber dose (zmax) as a function of field size and 
normalized to a 10 cm x10 cm field size, for 4, 8 and 15 MeV electron beams. The mean result 
of 10 measurements using three MOSFETs and the standard deviation are given in these three 
figures. 
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The shape of the insert and the position of the dosimeter in the radiation field, affect a 
MOSFET measurement without additional build-up. The magnitude of this effect 
depends on the energy of the beam. The influence of field position and field shape on 
the MOSFET response is within 4.0 % for the 4 MeV beam. The ratios of the relative 
readings for locations B, C and D, compared to location A for the 4 MeV beam are: 
0.99 ± 0.01, 1.02 ± 0.02 and 1.04 ± 0.02 (1 SD), respectively. For the 8 MeV beam the 
ratios of the readings are 1.01 ± 0.01, 0.95 ± 0.03 and 1.04 ± 0.02 (1 SD) and for the 
15 MeV beam 0.94 ± 0.04, 0.95 ± 0.03 and 0.95 ± 0.03 (1 SD). These results 
demonstrate that for the lower energies (4 and 8 MeV) there is no significant deviation 
in MOSFET reading during variation in field position (B) and shape (C and D).  For 
higher energies (15 MeV) however, the reading decreases in these situations with 5.9 
%.  
3.3.2 Patient measurements 
MOSFET entrance in vivo measurements were performed during the first treatment 
session of 40 patients. The MOSFET reading at the surface was converted to dose at 
the depth of dose maximum using Fconversion, as determined during the phantom 
measurements. Field sizes varied between 6 cm and 20 cm diameter (round or square) 
and therefore a field size correction was not necessary. For 14 patients a correction for 
SSD was applied for distances between the insert and the skin ranging between 0.5 
and 4 cm. The patient measurements (Dentrance), first converted to Dmax and then 
corrected for SSD, were compared with the prescribed dose (Dplan).  
   
 
Figure 5: The distribution of dose deviations for 40 patients irradiated with electron beams, 
calculated as the MOSFET reading converted to Dmax and corrected for SSD, compared with the 
prescribed Dmax.  
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The deviations between the prescribed dose values and the MOSFET results ranged 
between   -8.1 % and 4.7 %. The mean result of all measurements was -0.7 % with a 
standard deviation of 2.9 %. The data for all 40 patients are presented in Fig. 5.  
3.4 DISCUSSION AND CONCLUSION 
The ratio of the MOSFET reading at the surface and the ionisation chamber dose at 
the depth of Dmax increases with increasing beam energy. This variation may be 
caused, in part, by the lower surface dose in lower energy electron beams. However 
part of it could also be caused by an energy dependence. 
This study shows that the mean MOSFET reproducibility is 2.0 % (1 SD) for readings 
of 100 mV, 10 successive measurements and standard sensitivity of the bias supply. 
This is of the same order of magnitude as observed by other groups. Jornet et al. 
determined an intrinsic precision of MOSFETs working in the standard sensitivity mode 
of 2.5 % (1 SD) for doses of approximately 1 Gy9. At higher doses the precision of the 
detector increases. Ramani et al. performed measurements with a MOSFET at 
standard sensitivity and readings of 2 Gy, measuring a standard deviation of the 
readings of 1 %18.  The overall uncertainty in dose determination using the above 
described calibration methodology is about 4% (1SD). This uncertainty is determined 
as the root-sum-square of the individual errors of CF, Fconversion, Fcal and R, which are all 
estimated  to be about 2%, given as 1 SD.   
By using the MOSFETs without any build-up, less shadowing by the detector of the 
target volume occurs. The price to be paid for this advantage is that the detector 
becomes more sensitive for electrons scattered by the collimating system and the 
insert. This is reflected in a rather strong dependence of the MOSFET response on 
SSD. As a consequence, for each patient measurement, the SSD has to be measured 
to perform a correction. This absence of build-up led also to the insert- shape 
dependence and higher readings for fields smaller than 6 cm x 6 cm, which is probably 
caused by the electrons scattered from the edge of the insert. 
The angular dependence of the MOSFET response as measured inside a mini-
phantom is small. Up to 45 degrees the angular dependence can be ignored, whilst at 
larger angles the effect is about 3 % at maximum and seems to be somewhat energy 
dependent. This small angular dependence was also observed by Chuang et al.5, and 
was explained by these authors as a result of improvement in detector design 
compared to previous detectors18,21. The increment in dose, measured with the 
MOSFET detector at the surface of the phantom without additional build-up, may be 
caused by an increase in the contribution of electrons scattered from the phantom into 
the detector, leading to a reading that increases with the angle of irradiation.  
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The importance of the role of quality assurance in radiotherapy is generally accepted, 
due to the complexity and many steps involved in the radiotherapeutic process. 
However, the workload involved in developing and assessing an in vivo dosimetry 
programme, is often a problem for a radiotherapy department. In our institution we 
developed an in vivo dosimetry protocol, using MOSFETs, for all curative and elective 
photon and electron beam treatments, and for special indications such as the 
determination of the dose in organs at risk, or for junction measurements1. Due to the 
intensive use of MOSFETs for in vivo dosimetry purposes in our institution, special 
attention is therefore paid to making it an easy to use technique with acceptable 
accuracy.  
The use of the detector is simple and in vivo dosimetry using MOSFETs is easy to 
integrate into the work processes. In our institution the radiation technologists perform 
the patient measurements. We developed a user interface in which the radiation 
technologists have to type in some specific treatment data. This program automatically 
converts the reading to Dmax and corrects for the influence of SSD. The deviation of the 
measurement is given as a percentage of the prescribed dose. Action levels of ± 7-10 
%, depending on the treatment site, are applied. These action levels are based on our 
experience with entrance dose measurements in photon beams and defined as the 
level were 85 % of the measurements are within the action level during the first 
measurement. The result of this study demonstrates that the overall uncertainty in dose 
determination for entrance in vivo dosimetry in electron beams is about 4%, 1SD. 
Action levels of 7% for all treatment sites, treated with electron beams using the 
described methodology, are therefore adequate. If deviations exceed the action level, 
all treatment data are checked, a physicist will evaluate the measurement result, and 
the measurement has to be repeated. 
In this study we performed a comprehensive set of phantom measurements to 
determine CFs with a reproducibility of about 2 % (1 SD), using standard bias voltage, 
standard MOSFETs and a radiation dose corresponding to 100 MUs. These CFs can 
be taken the same for all MOSFETs of a certain batch. However, some MOSFET 
detectors may show a deviating behaviour, in non-reference conditions. In our 
situation, one MOSFET responded differently to gantry angle rotation during the 
phantom measurements. For estimating generally applicable CFs, this is a practical 
difficulty. We decided not to take individual CFs into account, which may introduce 
some additional uncertainty. The inaccuracy that is introduced using such a procedure 
is accepted in order to keep the workload adequate and is taken into account in our 
tolerance levels. To evaluate the inter-batch variation and variation in MOSFET design 
we recommend to repeat part of the phantom measurements periodically. 
When performing entrance in vivo measurements without build-up, Fconversion is 
necessary to convert the MOSFET reading at the skin to Dmax, whilst a correction for 
SSD and small fields (< 6 cm) also has to be applied. To estimate accurate conversion 
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and CFs, an extensive set of phantom measurements has to be performed, for which 
an on-line system is recommended10, 19.  
The results of this study demonstrate that the characteristics of MOSFETs in electron 
beams (reproducibility, field size and angular dependence) make them well suited for in 
vivo dosimetry. Under these circumstances, in vivo dosimetry measurements can give 
supplementary information about the actual absorbed dose at a specified point. In 
addition, due to the current lack of electronic data transfer in our department, this 
method has become an essential part of our quality assurance programme. 
As a result of this study, protocols for in vivo entrance dose measurements of electron 
treatments are developed and all patients treated with curative intent will undergo 
these measurements. 
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ABSTRACT 
Background and purpose: Predicting the 3-dimensional (3D)-dose distribution of our 
Total Body Irradiation (TBI) technique, using a commercial Treatment Planning System 
(TPS). In vivo dosimetry, using MOSFETs and thermoluminescence detectors (TLDs), 
was used to verify the calculated dose distributions.  
Materials and methods:  A total body CT scan was performed, loaded into our TPS 
and a 3D-dose distribution was generated. In vivo dosimetry was performed at five 
locations on the patient. Entrance and exit dose values were converted to midline 
doses using conversion factors, previously determined with phantom measurements. 
TPS predicated dose values were compared with MOSFET and TLD in vivo dose 
values.  
Results: MOSFET and TLD dose values agreed within 3.0 %; MOSFET and TPS data 
within 0.5 %. The convolution algorithm of the TPS, which is routinely applied in the 
clinic, overestimated the dose in the lung region. Using a superposition algorithm 
reduced the calculated lung dose with approximately 3 %. The dose inhomogeneity as 
predicted by the TPS, can be reduced by using a simple IMRT technique.  
Conclusions: The use of a TPS for calculating dose distributions in individual patients 
during TBI treatments is strongly recommended. Using a TPS gives good insight in 
over- and under-dosage in the patient and the influence of patient positioning on dose 
homogeneity. MOSFETs are suitable for in vivo dosimetry purposes during TBI, when 
using appropriate conversion factors. MOSFET, TLD and TPS results agree within 
acceptable margins. 
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4.1 INTRODUCTION 
Total Body Irradiation (TBI) is a complex radiotherapeutic technique, used for the 
treatment of certain haematological, oncologic, and immunologic diseases. The role of 
TBI is to destroy the recipient’s bone marrow and tumour cells and to immunosuppress 
the patient sufficiently to avoid rejection of the donor bone marrow transplant. The dose 
in a TBI treatment is often prescribed to a point inside the body in the pelvic region at 
the height of the umbilicus, referred to as the dose prescription point1. It is generally 
assumed that the dose in the rest of the body should be within 10 % of this prescribed 
dose1. Mostly, Monitor Unit (MU) calculation is done by point-dose determination at the 
dose prescription point. Computed Tomography (CT)-based treatment planning, 
however, can provide a much more detailed calculation of dose delivery to the whole 
body of the patient. This is important because of the special irradiation technique, the 
uncertainties in patient positioning and the fact that the quality of life and long term side 
effects become more and more important with the increasing survival rates2, 3. Most 
treatment planning systems do not allow the set up of patients at a very large SSD, 
because the system is not designed for these techniques and has to be validated 
under these circumstances. A set of phantom measurements has therefore to be 
performed, to check the accuracy under TBI conditions. Several authors described the 
use of a TPS for TBI treatments, based on home-made CT-aided PC-based planning 
systems4 and conventional CT-based treatment planning systems5-9. These groups 
demonstrated that a commercially available TPS is in principle suitable for predicting 
the dose distribution in a patient under TBI conditions. However, the use of a TPS for 
the calculation of a 3D-dose distribution in the patient’s total body, correlated to 
individual patient treatment data and patient positioning procedures, has not been 
described. Abraham et al.9 evaluated the positioning of the arms related to the lung 
dose, however, the influence of position on other structures was not investigated.  
It was the first aim of this study to investigate whether TBI treatments could be 
optimized by using 3D treatment planning of individual patients. 
In vivo dosimetry during TBI gives the opportunity to check the dose in the patient and 
to verify whether predicted and measured dose values correspond within certain levels, 
but is difficult to perform due to the complexity of the irradiation technique. To obtain 
meaningful results, a TBI in vivo dosimetry method must first be validated with 
phantom experiments before it can be implemented clinically. TLDs have been proven 
to be useful detectors for measurements under TBI circumstances due to their small 
dependence on direction, dose rate, temperature, and energy in the therapeutic range, 
and their wide applicable dose range6, 10-14. Accuracies within 3-4 % (1SD) can be 
reached10-14. Compared to TLDs, the Metal Oxide Field Effect Transistor (MOSFET), a 
relatively new kind of detector, has the advantage of direct dose readout. Earlier 
publications described important physical characteristics of these detectors to 
demonstrate the usefulness of MOSFETs as a clinical dosimeter of radiotherapeutic 
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treatments with photon15-24, electron25 and proton26 beams, junction of fields27, IMRT 
fields19, 28, 29 brachytherapy30-32 and intra-operative irradiation33, 34. The system uses 
miniature non-intrusive MOSFET semiconductor radiation dosimeters (size less than 
4mm2) and shows a good linearity of the response with no sensitivity variation with 
temperature and accumulated dose in the therapeutic high-energy range15, 28, 35, 36. 
Reports about the clinical use of MOSFET dosimeters for in vivo measurements during 
TBI treatments are, to the best of our knowledge, not available. Scalchi and 
Francescon37 calibrated MOSFET detectors to perform in vivo dosimetry during 6-MV 
treatments, both in normal set-up and during TBI conditions. However, these authors 
did not present results of clinical studies.  
The second aim of this paper was to use both MOSFETs and TLDs for the in vivo 
verification of the actual delivered dose and to compare these values with the 3D-dose 
distribution calculated for our TBI technique by a commercial TPS.    
4.2 MATERIALS AND METHODS 
4.2.1 Treatment planning system 
For this study, our clinically applied TPS was used (XiO 4.3.0, CMS Inc., Saint Louis, 
MO, USA), to evaluate the dose distribution in the full patient’s body. In our institution 
we apply routinely the so-called Fast-Fourier Transform Convolution (FFTC) dose 
calculation algorithm present in the TPS, a relatively simple algorithm that does not 
account for electron transport. XiO has another algorithm available, the Multi-Grid 
Superposition (MGS) algorithm, which takes electron transport into account and is 
therefore more accurate in areas with large inhomogeneities such as the lung region38, 
39, but is more time consuming. For this study we used the FFTC algorithm for 3D-dose 
prediction, as routinely applied in our clinic. The MGS algorithm was also used for a 
better prediction of the dose in the lung region. CT slices were loaded into the TPS, the 
dose was calculated using inhomogeneity corrections and a 3D-dose view was 
generated to evaluate the dose distribution over the patient’s body.  
4.2.2 MOSFET detector 
MOSFET dosimeters, semiconductor transistors with dimensions of 0.2 mm by 0.2 mm 
by 1 mm produced by Thomson and Nielsen Electronics Ltd (Ottawa, Canada), were 
used. For all measurements standard MOSFETs (TN-502RD) were applied, with the 
bias supply set at standard sensitivity (1 mVcGy-1). The TN-RD-50 patient verification 
system was used for patient measurements. For phantom measurements, which 
required a lot of repetitive measurements, the MOSFET AutoSense system (TN-RD-
60) developed for on-line radiotherapy was applied in order to shorten measurement 
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times, as the control box of the MOSFET system can be read out without entering the 
treatment room.  
Calibration was performed to convert the radiation-induced dosimeter voltage shift to 
cGy and the calibration coefficient was defined as the ratio of the measured voltage 
shift of the dosimeter and the actual dose measured with the ionization chamber at the 
depth of dose maximum (Dmax). A homemade polystyrene phantom, full build-up and 
reference conditions (6-MV photon beam, 10 x 10 cm2 field size and 100 cm SSD) 
were used, to obtain maximum accuracy and repeatability. The accelerator output was 
measured with a calibrated cylindrical ionization chamber (PTW type 31002, 
Physikalisch-Technische Werkstaetten, Freiburg, Germany), following the Dutch code 
of practice for the dosimetry of high-energy photon beams40. Once calibrated, the 
dosimeter may be used with or without build-up material when applying appropriate 
conversion factors.  
4.2.3 Tl detector  
For this study, LiF chips type TLD-100 (Harshaw, Solon, USA) were used. Each 
detector consists of three TLD rods (1 mm x 1 mm x 6 mm) packaged together in a 
plastic pouch. For all measurements, the readings of the three detectors were 
averaged.  
Before irradiation, the standard annealing procedure was carried out using a Victoreen 
oven (Model 2600-62, Victoreen Inc., Cleveland, USA). During this process the TLDs 
were positioned on an aluminum planchet and heated at a temperature of 400 ºC for 1 
hour, followed by a lower temperature phase of 105 ºC for 1.5 hours. After annealing, 
the TLDs were packaged and for each patient twelve packages from the same batch 
were used, seven for calibration and five for patient measurements. 
In order to establish the dose as a function of TLD reading, a calibration was performed 
using reference conditions. The relationship between TLD response and absorbed 
dose was expressed by a linear fit for a dose range between 0.2 and 3.0 Gy. One TLD 
package was read out without receiving radiation to determine the background signal. 
The detectors were read out with a commercial semiautomatic TLD reader (Harshaw 
4000, Solon, USA).  The heating cycle of this oven has two parts, a 5-second pre-heat 
zone heating the tray to a temperature of 150ºC and a reading-phase of 10-seconds 
using a linear heating rate of 25ºC/s followed by a constant temperature plateau of 
235ºC. One person performed both the annealing and heating, following strict 
procedures.   
4.2.4 Phantom measurements  
The accuracy of the central axis Percentage Depth Dose (PDD) data, beam profiles 
and absolute dose values calculated by the TPS were checked under TBI 
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circumstances. The actual dose values were measured under TBI circumstances using 
an ionization chamber at the center of a polystyrene phantom (40 cm x 40 cm x 30 
cm). For the PDD measurements the depth varied between 2 and 28 cm. The off-axis 
dose values were measured at a depth of 10 cm with an interval of 2 cm up to off- axis 
positions of 20 cm, and intervals of 4 cm for further positions, by shifting the position of 
the phantom. The actual dose values were compared to the dose values calculated by 
the TPS for these positions, inside a rectangular phantom of 40 cm x 40 cm x 30 cm.  
A conversion factor under TBI conditions was determined to convert entrance and exit 
in vivo readings, obtained without build up material and using the calibration factor, 
Fcal(10x10,100), determined under reference conditions (100 cm SSD, 10 x 10 cm2 field 
size), to midline dose data under TBI circumstances. To obtain this factor, three 
calibrated MOSFET detectors were irradiated under TBI conditions, positioned at the 
entrance and exit point of a full scatter phantom close to the isocentre of the beam. 
The diameter of the phantom was 10 cm, 20 cm or 30 cm. An ionization chamber 
(PTW type 31002, Physikalisch Technische Werkstaetten, Freiburg, Germany) was 
placed at the center of this phantom. A 1.5 cm thick PMMA screen was positioned 
between the source and the phantom to bring the position of dose maximum to the 
surface. An Elekta SL-15i linear accelerator with a 10-MV photon beam was used. 
MOSFET entrance and exit readings for a field size of 40 x 40 cm2 at 400 cm SSD 
(Rentr(40*40,400)  and Rexit(40*40,400)) were compared to midline ionization chamber dose 
values (Dchamber). The factor to convert entrance and exit MOSFET readings to 
midline dose is called Fconversion. The value of Fconversion was determined for 
diameters (d) of 10, 20 and 30 cm and dose rates ( D& ) of 100 and 400 MU/min.  
Fconversion was then calculated as:  
( )/2F*RF*rR DF )(10x10,10000)(d,40x40,4)(10x10,10000)(d,40x40,4 midline)(d,)D(d, calexitcalent
chamber
conversion +=&      (1)    
Fconversion values were determined in the same way for TLD entrance and exit 
measurements. Once Fconversion is known, midline dose values (Dmidline) can be 
obtained from measured entrance and exit MOSFET readings using:      
         
( )[ ] conversioncalexitcalentr
midline
F*/2F*RF*R
D
)(10x10,10000)(d,40x40,4)(10x10,10000)(d,40x40,4
)D(d,
+
=&   (2) 
In the clinical situation the patient-to-screen distance varies for each part of the body, 
depending on the position and thickness of the patient. The build up effect of the 
screen and the influence of varying phantom-screen distance on the entrance and exit 
dose values was therefore also investigated under TBI conditions. The build up effect 
was tested by relating the dose values measured with the screen positioned directly in 
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contact with the phantom, to the dose values performed without the screen. The 
influence of the screen-phantom distance on the dose values was investigated by 
varying the position of the PMMA screen between 0 and 40 cm distance from the 
phantom. Both entrance and exit measurements were performed using three MOSFET 
dosimeters placed at the entrance point and two detectors at the exit point of the beam. 
For each situation, ten measurements were performed. 
4.2.5 Patient measurements 
Patient measurements were performed to investigate dose homogeneity and the 
influence of patient position in each individual patient and to compare TPS predicted 
data with MOSFET and TLD in vivo dose data. Before treatment a total body CT scan 
was made with the patient in treatment position, i.e. lying in a vaccuum mattress on the 
right side of the body. Rice bags were positioned around the extremities, to reduce the 
dose at these positions during irradiation. By performing the CT scan with these rice 
bags, the dose calculated using the CT data should be equal to that during the clinical 
situation and the calculated and measured dose data can then directly be compared. A 
set of 1 cm CT slices was made, from the ankle to the patient’s head. The CT images 
were loaded into our clinical TPS. Dose distributions were normalised to the dose at 
the prescription point, midline at the position of the umbilicus. Midline dose values were 
determined at five locations in the patient’s body, i.e. (1) jugulum; (2) right lung; (3) 
umbilicus; (4) upper leg and (5) ankle.  
For the treatment, an Elekta SL-15i linear accelerator and a 10-MV photon beam were 
used, applying the maximum field size of 40 x 40 cm2, whilst the collimator was rotated 
over 45 degrees. By positioning the gantry at 274º and the couch alongside the 
treatment room wall, an extended source mid-line distance of 400 cm could be 
achieved, in order to cover the patient’s entire body with the radiation field. Parallel 
opposed beams were used by delivering each fractional dose in two equal set-ups and 
switching the patient’s position between the two fields. Because the TBI protocol does 
not require skin sparing, a 1.5 cm thick PMMA screen was positioned between the 
source and the patient to raise the surface dose to at least 90 % of the prescribed TBI 
dose. The number of MUs was calculated using: 
 100] / 20)-(PDU [1  *  
OF
TTD MUs # +=                                                                  (3) 
where TTD is the Total Target Dose, OF is the Output Factor of the linear accelerator 
in cGy per MU at a distance of 400 cm at a depth of 10 cm in water, and PDU is the 
Patient Diameter at the position of the Umbilicus in cm. The number of MUs is 
prescribed at the patient’s midline. The second part of equation 3 accounts for the 
difference in position between the dose prescription point and OF depth. An increase in 
depth of 1.0 cm, which corresponds to an increase in patient diameter of 2.0 cm, 
results in an increase in # MUs of 2.0 %. This equation is similar to using a tissue-
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phantom ratio varying linearly with depth, which is a valid assumption at this extended 
SSD and relevant depths of 10 to 15 cm. In this equation, 20 is the diameter of the OF 
phantom in cm. MOSFET and TLD detectors were taped to the patient, with the round 
epoxy side of the detector towards the skin, at the entrance and exit point at five 
locations on the patient’s body, previously determined during CT scanning. The 
measured entrance and exit MOSFET and TLD readings were converted to midline 
dose, using Fconversion, as described earlier. MOSFET and TLD midline dose values 
were compared to midline dose values calculated by the XiO treatment planning 
system, at these five locations.  
For a sub-group of patients an additional CT scan was made to investigate the 
influence of patient positioning on the 3D-dose prediction.  Two sets of CT scans were 
made, one with the patient having the arms crossed before the thorax and the other 
with one or two arms along the body, depending on the ability of the patient to lay 
comfortably in such a position. The CT scans were loaded in the TPS and a 3D-dose 
calculation was made for both positions.  
4.3 RESULTS 
4.3.1 Phantom measurements 
The accuracy of the TPS along the central axis of the beam at a depth of 10 cm using 
TBI conditions was excellent. The output of the accelerator and the absolute dose 
calculated by the TPS under these circumstances agreed within 1.7 %, the calculated 
value being lower. The PDD calculated by the TPS up to a depth of 28 cm, was within 
2.0 % of the actual dose measured with the ionization chamber. The dose profile of the 
linear accelerator is almost flat; the off-axis dose values were within 2.0 % of the dose 
on the central axis. These measured dose values, compared to the dose values 
calculated by the TPS for these positions, agreed within 1.2 %, as can be seen in 
figure 1.   
Fconversion, as determined for the MOSFET dosimeters, is 1.12 ±0.01, 1.08 ±0.01 
and 1.06 ±0.01, for phantom diameters of 10 cm, 20 cm and 30 cm, respectively. We 
interpolated this data using the equation 0.000069x2 - 0.00565x + 1.1675 (R2=1) to 
determine the factor for other diameters. The conversion factors to convert TLD 
entrance and exit values to midline dose values are 1.15 ±0.02, 1.10 ±0.01 and 1.07 
±0.01, using the equation 0.000112x2 - 0.00858x + 1.2248 (R2=1) to interpolate the 
data. Fconversion is independent of dose rate. The results are shown in figure 2. 
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The ratio of the entrance dose values measured with a MOSFET dosimeter in the 
surface region (water-equivalent thickness of the MOSFET is 0.8 mm, flat sided), with 
and without the PMMA screen, was 1.51. The dose in the surface region decreases 
with increasing phantom-to-screen distance. For distances of 5, 10, 20 and 40 cm the 
ratios, normalized to the dose value with the screen at 0 cm distance, are 0.97, 0.94, 
0.92 and 0.83 respectively (figure 3). 
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Figure 2: Fconversion, determined in a 10-MV photon beam using a dose rate of 100 MU/min. 
Phantom diameters ranged between 10 cm and 30 cm.  
 
Figure 1: Dose profile of the TBI beam of the linear accelerator at a depth of 10 cm, 40 x 40 
cm field size and 400 cm SSD, measured with an ionization chamber and calculated by the 
Treatment Planning System (TPS). 
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4.3.2 Patient measurements   
Ten patients were included in the clinical study and fifty entrance- and exit- 
measurements were performed. A radiation dose of 200 cGy prescribed at the dose 
prescription point, was given in one single fraction. The PDU, used to calculate the 
number of MUs, ranged from 24 cm to 36 cm. MOSFET and TLD measured entrance 
and exit readings were converted to midline dose using Fconversion and the relevant 
radiological diameters of the patient taken from the CT-data. The mean difference 
between the MOSFET and TLD results was -3.0± 0.2 % (1SD), where the mean 
MOSFET reading was lower compared to the TLD reading. The maximum deviation 
was found in the upper leg and the ankles, where a deviation of -4.2 % and -4.0 %, 
respectively, was found. The reason might be that the MOSFET and TL detector were 
taped next to each other at these smaller parts of the body where relatively large dose 
gradients exist. The mean MOSFET dose values were 0.5 ±0.1 % (1SD) lower 
compared to the TPS dose values, while the TLD results were 2.4 ±0.1 % (1SD) higher 
compared to the TPS data. Part of the observed differences may be due to the 
somewhat lower dose calculated by the TPS, as observed during the phantom 
measurements. Mean MOSFET, TLD and TPS results for the five measurement 
locations are given in table 1.  
Figure 3:  Entrance and exit dose measurements as a function of phantom-screen distance, 
normalized to 0 cm. Average results of ten measurements are shown for each distance.  
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Several authors have shown that the rather simple tissue inhomogeneity correction in 
the FFTC dose calculation algorithm overestimates the dose in lung dose regions. To 
quantify the influence of the FFTC algorithm, which is applied routinely in our clinic, on 
the 3D dose distribution, calculations were also performed using the MGS algorithm 
present in the TPS38, 39. Using this algorithm reduced the calculated lung dose by 
approximately 3 %, yielding better agreement between the measured and TPS 
calculated dose values. For the other, relative homogeneous areas, using the MGS 
algorithm has no significant advantage, however extends the calculation times 
significantly. The data, using the MGS algorithm for the lung dose points and the FFTC 
algorithm for the other locations, are presented in figure 4.  
 
Table 1: Mean MOSFET, TLD and TPS dose values for the five measurement locations. The 
TPS data were calculated using the MGS algorithm at the position of the lung and the FFTC 
algorithm for the other locations. 
 
Method
dose S.D. dose S.D. dose S.D. dose S.D. dose S.D.
MOSFET 223.6 16.7 209.9 13.6 199.6 15.2 213.8 16.9 220.5 19.4
TLD 230.4 11.1 216.9 13.3 203.5 14.6 223.4 17.0 229.7 23.7
TPS 212.7 11.2 220.0 12.1 199.8 0.7 212.4 20.4 218.2 16.2
Jugular Ankle Upper leg Umbiculus Lung 
(cGy)(cGy) (cGy) (cGy) (cGy)
Figure 4: Midline patient dose values measured with MOSFET and thermoluminescence 
detectors (TLD), and calculated with theTreatment Planning System (TPS). The mean result of 8 
patients and the standard deviation are given. The locations 1 to 5 are positioned at the jugulum, 
right lung, umbilicus, upper leg and ankle, respectively.  
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Individual patient measurements demonstrated high dose values, particularly in the 
extremities, where deviations of 24 %, compared to the prescribed dose, were found. 
The 3D-dose distributions, calculated by the TPS, showed even higher local dose 
values.  To get an impression of the high dose regions in one patient during a TBI 
treatment, a 3D view is presented in figure 5a, illustrating the areas having 110 % or 
higher dose values and a local dose of 246.3 cGy. Figure 5b shows isodoselines in a 
transversal plane in the pelvic region and figure 5c isodoselines in a transversal plane 
in the thoracic region. 
 
 
Figure 5a: 3-dimensional (3D)-dose distribution of an individual patient, indicating areas having 
a dose higher than 110 % (grey area). b: 110% (white line), 100% (black line) and 90% (white 
line) isodoselines in a transverse plane, in the pelvic region. c: 110% (white line), 100% (black 
line) and 90% (white line) isodoselines in the thoracic region. 
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The influence of patient positioning, investigated by the dose calculation with the 
patient in two positions, demonstrated that the arms crossed before the thorax gives 
the opportunity to reduce the higher dose values in the lungs. Such a procedure is, 
however, not sufficient for high-dose TBI, where the dose in the lung should be 
reduced by lung blocks. By crossing the arms, in some patients the upper arm is facing 
the beam and reducing the dose in the areas underneath, while the patient is not 
capable to bend the arm in front of the thorax. Crossing the arms at a lower place, e.g. 
in the stomach area, can reduce this inconvenience, nevertheless has the 
disadvantage of shadowing the belly region. By positioning the arms along the body 
there is no shadowing of the arms, however the dose in the upper arm will receive 
higher doses values caused by the smaller diameter. Thereby, most patients indicated 
that it was not pleasant to lie upon their arm, so in several cases the arm underneath 
was bend before the patient’s body. 
4.4 DISCUSSION AND CONCLUSIONS 
A commercially available TPS is in principle suitable for predicting the dose distribution 
in a patient under TBI conditions6-9, 41. In earlier publications, these CT-based plans 
were mainly used for deriving better dose values in some parts of the body, e.g. by 
having more accurate information of the patient thickness8. CT-based treatment 
planning for TBI may provide, however, precise and accurate dose calculations for the 
whole body and allows for the correlation of clinical outcomes with the dose values 
actually delivered. Dose distributions can in addition be used for evaluating the 
positioning of the patient. This study demonstrated a large variation in dose. Part of the 
high-dose values observed for the lungs could be explained by the dose calculation 
algorithm. Depending on its presence in the TPS, a MGS or comparable advanced 
dose calculation algorithm is recommended to calculate the dose in the lung region.  
Most TBI protocols require a dose homogeneity along the body axis within ±10 %1. 
Due to the large variation in body thickness and internal tissue heterogeneities, it is 
difficult to meet this requirement and the use of compensators is necessary. As applied 
in many centers, we used rice bags as a bolus to reduce the dose in the extremities. In 
vivo dosimetry and planning system results demonstrated that this rice bags 
significantly reduced the higher dose regions, however were not sufficient to reduce the 
dose within the required 10 % dose variation. Preliminary measurements to investigate 
the use of a Multi Leaf Collimator (MLC) as a compensator, are promising. Figure 6 
illustrates an MLC compensator, for the same patient shown in figure 5. Figure 6a 
shows the leaf position and figure 6b the 3D-dose distribution in the patient, treated 
with both open and MLC beams using beam weights of 1.00 and 0.12, respectively. 
The high dose regions are significantly reduced. Further optimization can be obtained 
when more MLC segments are used. Simple intensity-modulated radiation therapy 
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(IMRT) treatment techniques of TBI may therefore be a good alternative to treat these 
patients with an optimal dose distribution, as described by Hui et al42. Patient data 
resulting from the use of IMRT in TBI treatments using conventional linear 
accelerators, however, has not been described and is subject of further study in our 
department. 
 
The influence of patient positioning on the dose values in the patient was also 
investigated by CT-based treatment planning. The position of the patient, resulting in 
the most homogeneous dose distribution, depends on the treatment technique that is 
used (lung blocks, compensators) and on the performance status of the patient. 
Caution must be used when crossing the arms before the lower thorax/belly, because 
the dose in the areas underneath decreases and an under-dosage is introduced. The 
arms along the body resulted in higher dose areas in the arms caused by the smaller 
diameter, however, this problem can be solved when using an MLC as a compensator 
to reduce the dose in this area.  
To receive an acceptable dose in the surface region of the patient, it is important that 
there is a short patient-to-screen distance. Increasing the screen-to-phantom distance 
from 0 cm to 40 cm, which is the clinical situation for the smaller parts of the body, 
reduces the dose in the surface region by 17 %. This causes an under-dose in the 
superficial areas because patient immobilization makes it almost impossible to position 
the patient in close contact with the screen along the body axis.  
This study demonstrated that both TLDs and MOSFETs are suitable for in vivo 
dosimetry under TBI circumstances. The detectors, calibrated under reference 
conditions, were used for in vivo dose measurements under TBI circumstances and 
their readings were converted to the midline dose, using a conversion factor. In the 
Figure 6: a: A Total Body Irradiation (TBI) beam shaped with a Multi Leaf Collimator (MLC), to 
reduce the high dose regions in the patient, for the same patient as presented in figure 4a. b: 
The high dose regions visible in figure 4a, reduced as a result of using the MLC as compensator.  
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lung region deviations between in vivo dose values and TPS data were observed. The 
rather simple tissue inhomogeneity correction algorithm (FFTC algorithm) in our TPS 
was the main reason for this deviation. The deviation decreased when using a MGS 
algorithm. The use of the same conversion factor for both the homogeneous and 
inhomogeneous situation also influenced the accuracy. The radiological diameter was 
used to convert the measurements and account for the lung inhomogeneity assuming 
the patient is homogeneous. However, if the dose specification point lies inside the 
lung, our simple conversion method using equation 2, is no longer valid and may 
underestimate the dose by about 3 %43.  
The overall uncertainty in dose determination using MOSFETs and the calibration 
methodology as applied in this study, is about 3.5 % (1SD). This uncertainty is 
determined as the root-sum-square of the individual errors of Fconversion, Fcal and R, 
which are all estimated to be about 2.0 %, given as 1 SD.  The mean MOSFET 
reproducibility is 1.8 % (1SD) for readings of 200 mV, 10 successive measurements 
and standard sensitivity of the bias supply. The mean reproducibility of our TLD dose 
determinations was 3.7 % (1SD) under the same circumstances. In this study we 
placed three TLDs together and averaged the results, to improve the accuracy.  
This study demonstrated that CT-based 3D treatment planning of TBI is not only 
mandatory for evaluating the complete total body dose distribution, but could also 
indicate areas to position dosimeters for in vivo dose verification. Points along the 
central part of the beam are not representative of the high or low dose regions in a 
patient. For the evaluation of new TBI techniques such as the use of IMRT, in vivo 
dosimetry, for instance by using MOSFETs, is strongly recommended. 
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ABSTRACT 
Purpose: In vivo dosimetry during brachytherapy of the prostate applying 125I seeds is 
quite challenging, due to the high dose gradients and low photon energies involved. 
We present the results of a study using MOSFET-dosimeters to evaluate the dose in 
the urethra after a permanent prostate implantation procedure.  
Methods and materials: Phantom measurements were carried out to validate the 
measurement technique, to determine the measurement accuracy and to define action 
levels for clinical measurements. Patient measurements were performed with a 
MOSFET-array in the urinary catheter directly after the implantation procedure. A CT-
scan was made and dose values, calculated by the treatment planning system, were 
compared to in vivo dose values measured with MOSFET-dosimeters. 
Results: Corrections for temperature dependence of the MOSFET-array response and 
photon attenuation in the catheter on the in vivo dose values are necessary. The 
overall uncertainty in the measurement procedure, determined in a simulation 
experiment, is 8.0 % (1SD). In vivo dose values were obtained for 17 patients. In the 
high dose region (>100 Gy) calculated and measured dose values agreed within 1.7 % 
±10.7 % (1SD). In the low dose region outside the prostate (<100 Gy) larger deviations 
occurred.  
Conclusions: MOSFET-detectors are suitable for in vivo dosimetry during 125I 
brachytherapy of prostate cancer. An action level of ±16 % (2 SD) for detection of 
errors in the implantation procedure is achievable after validation of the detector 
system and measurement conditions. 
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5.1 INTRODUCTION 
Brachytherapy using transperineal interstitial permanent prostate implants (TIPPB) 
addresses a highly conformal dose to the tumor volume. Uncertainties in seed 
positioning during the implantation procedure, errors in needle positioning, migration of 
seeds or deviations in seed activity, however, may cause deviations from the 
prescribed dose. Several studies evaluated the dose in the prostate and organs at risk 
(OARs) after TIPPB, using a post-implant CT-scan and the treatment planning system 
(TPS) to calculate the absorbed dose1. Using this method, errors in dose calculation, 
such as inter-seed attenuation, compensation for tissue inhomogeneities and errors in 
seed activity are not easy to detect2-4. In addition, seeds with a short inter-seed 
distance are difficult to recognize on the CT-image. Inaccuracies in seed registration 
will result in inaccurate dose information. In vivo dosimetry may provide useful 
information about the actual dose in the urethra5. It will be useful to evaluate the 
implantation technique, including the accuracy of the TPS and will give us the ability to 
link dose distributions in OARs to clinical side effects. Nevertheless, in vivo dosimetry 
during brachytherapy is quite a challenge, due to the high dose gradients and the low 
energy of the photons emitted by the seeds.  
The aim of this study is to validate the new linear 5-MOSFET-array dosimeter for dose 
verification after permanent 125I prostate implants, in order to evaluate the dose in the 
urethra.  
5.2 MATERIALS AND METHODS 
125I brachytherapy sources (Intersource125, International Brachytherapy Inc) with a 
mean nominal activity of 0.6 U (0.5 mCi) were used. The activity of each seed in a 
batch is stated to be within ±4 % of the mean nominal activity provided by the 
manufacturer.  
Our clinically applied TPS (PSID 4.1, International Brachytherapy), designed for real-
time dynamic ultrasound-guided radiation therapy of prostate cancer, was used for 
dose calculation. This system complies with the AAPM TG-43 recommendations6. 
Patient planning is based on the criteria that the 145 Gy isodose line covers the 
prostate volume, the urethra dose does not exceed 200 Gy and the medium rectum 
volume exceeding 100 Gy should be less than 8 cc7.  
For dose measurements, a high-sensitivity MOSFET-array (Linear-5ive-array 
TN502LA5, Best Medical, Canada) at high-sensitivity bias setting was used. The array 
contains five MOSFET dosimeters, which are 4 mm long, 1.8 mm wide and 1.3 mm 
thick, all fixated on a 46 cm flexible cable, with 2 cm inter-MOSFET-spacing. The 
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Mobile MOSFET Dose Verification System (TN-RD-70W) of the same company was 
used for on-line dose readout on a remote-PC.  
5.2.1 Phantom measurements 
5.2.1.1 Angular dependence of the MOSFET-array response 
Studies performed with single dosimeters5, 8 and with the linear-array at 60Co energies9, 
demonstrated a small angular dependence. To test the angular response of the linear-
MOSFET array for 125I sources, the detector was placed at the center of an in-house 
made PMMA phantom (figure 1a). Three strengths, each containing of three seeds, 
were placed at 0.5 cm, 1 cm and 1.5 cm distance from the detector, in order to obtain 
higher dose-rates and more accurate measurements. The direction from the MOSFET 
to the top of the black epoxy bulb of the detector was defined as 0 degrees. The angle 
of the detector was varied in steps of 30° from 0° to 330°. For each angle 5 
measurements were obtained and the results were averaged. The result of each angle 
was related to the mean result of all angles. 
5.2.1.2 Calibration of the detector 
A calibration coefficient was determined for each MOSFET of the linear-array as the 
ratio of the measured voltage shift and the actual dose. An in-house made PMMA 
calibration phantom (8cm x 8cm x 15cm) was used, where the MOSFET-array was 
placed at the center and 12 seeds were positioned circularly around the detector 
(figure 1b). Each MOSFET was placed in the plane of the seeds, 5 measurements 
were performed for each MOSFET and the results were averaged and compared to the 
calculated dose values.  
5.2.1.3 Absorption of the catheter material   
The in vivo measurements are performed with the MOSFET-array placed in a catheter. 
The TPS assumes all material surrounding the seeds is water i.e. the influence of 
catheter absorption on the dose distribution is not included. To test the difference in 
absorption between water and the catheter material, we performed a set of phantom 
measurements.  An in-house made PMMA phantom, similar to the calibration phantom 
was used, however with a larger hole in the center of the phantom allowing for catheter 
placement, and a second ring containing 12 holes for seed placement at 2 cm distance 
from the detector in order to approach clinical dose-rates. A Foley-catheter, a silicone 
2-way catheter with an outside diameter of 6 mm (18 french) and a length of 40 cm 
(Ref 170605, Teleflex Medical B.V) was positioned in the center of the phantom. The 
MOSFET-array was placed in the catheter and 24 strands, each containing 3 seeds, 
were placed around the detector. The phantom was placed in a water tank, in order to 
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fill the space between the MOSFET and catheter material with water (figure 1c). The 
position of the array was determined accurately (±0.5 mm), having MOSFET 2 
positioned in the plane of the center of the strands. The MOSFET-position was related 
to the marks on the flexible cable of the array, relative to the top of the phantom, and 
defined as MOSFET-position 1 (MP1). Five measurements were performed. To 
investigate the absorption of the catheter material in case the radiation passes the 
catheter under an oblique angle, the MOSFET-array was pulled down along the 
catheter with a distance of 8.8 mm (MP2), 17.6 mm (MP3), 25.1 mm (MP4), 33.9 mm 
(MP5) and 42.7 mm (MP6), again by using the marks on the flexible cable in relation to 
the top of the phantom. For each position 5 measurements were performed.  
The results were related to an equal set of measurements in the same phantom 
positioned in a water tank, however with water occupying the space where the catheter 
material was previously. The results are presented as the ratio of the MOSFET-reading 
attenuated by catheter material compared to the attenuation of the same layer of water.   
5.2.1.4 Temperature dependence of the MOSFET-array response 
Ramaseshan et al.13 described the temperature response of micro-MOSFETs, 
demonstrating a 0.5 % variation when increasing the temperature from 20° to 40 °C. 
The temperature dependence of the new MOSFET-array was not yet described. To 
test the variation in MOSFET-array sensitivity due to temperature changes, the large-
hole phantom (without the catheter material) and 12 single seeds were used. The 
temperature sensor was placed inside the hole close to the MOSFET-array without 
shielding the detector from the radiation. The phantom was positioned into a water tank 
and the water temperature was varied between 19°C and 40°C. MOSFET 3 was 
positioned in the plane of the seeds. Measurement times of 10 minutes were used. The 
temperature was determined at the start and the end of the measurement, and the 
mean temperature was used for the results. The results were related to initial 
calibration conditions at room temperature (20°C).  
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Figure 1: Phantoms used to investigate the response of the linear-MOSFET array. a: Phantom 
to test the angular response. Seeds were placed at 0.5 cm, 1 cm and 1.5 cm distance from the 
detector. The black epoxy bulb of the detector was defined as 0°, the angle of the detector was 
varied in steps of 30° from 0° to 330°. b: Phantom for calibration of the MOSFET-array to 
convert the radiation induced voltage shift into dose. The linear MOSFET-array is inserted in the 
central hole, in the plane of the seeds. c: Set-up to investigate the absorption by the catheter 
material. The phantom (8 cm x 8 cm x 15 cm) is placed in a water tank, a catheter placed at the 
centre of the phantom. The results of the 5 MOSFETs (M1-M5) and six MOSFET-array positions 
(MP1-MP6) were related to an equivalent set of measurements without the catheter material. 
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5.2.1.5 Total measurement uncertainty 
The reproducibility of the MOSFET-detector depends on the energy of the radiation 
and the integrated dose measured by the MOSFET detector. Lavallee et. al.10 reported 
uncertainties of about 6% (1 SD) using an orthovoltage beam with a mean energy of 30 
keV and dose values of about 55 cGy. During the clinical measurements, the 
uncertainty may be even larger due to the lower signal and positional inaccuracies of 
the detector. To estimate the total uncertainty, a simulation of a complete treatment 
was performed. A tank, containing a urinary catheter, was filled with gelatin. Needles 
were inserted through the holes in the wall of the phantom. We planned a needle 
distribution, mimicking a clinical plan, using 19 needles and 57 seeds. After the 
placement of the seeds the MOSFET-array was placed in the urinary catheter and 
dose values were obtained (position 1). Five measurements of 10 minutes were 
performed and the results were averaged. After the measurements the MOSFET-array 
was pulled out over a distance of 1 cm, in order to obtain more dose information along 
the catheter (position 2). Again 5 measurements were performed. The in vivo dose 
values of both positions were extrapolated to the accumulated dose values, using the 
half-life (t1/2) of 125I: 
tIDRD ∗=   and 2ln/)( 2/1tt =            (1) 
Figure 1 d: Set-up to test the total measurement uncertainty, presented as a frontal view (i) and 
a lateral view (ii) of the phantom. The marks, illustrated in the frontal view, present the holes that 
were used for seed implantation. The lateral view presents the seed distribution, the urinary 
catheter and the MOSFET-array positions in the catheter. 
 
ii
(d) 
i 
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where IDR is the Initial Dose Rate and t1/2 is 59.4 days. The measurement set-up is 
shown in figure 1d. Figure 1di presents a frontal view of the phantom and the template. 
The marks illustrate the holes that were used for seed implantation. Figure 1dii 
presents a lateral view of the phantom, showing the seed distribution, the urinary 
catheter in the gelatin and the MOSFET-positions in the catheter.  
After the in vivo measurements, a dummy MOSFET-array having radio-opaque 
markers at each MOSFET-detector position was placed in the catheter. The phantom 
was placed in a CT-scanner and CT-slices of 1 mm thickness and 1 mm separation 
were acquired for both MOSFET positions 1 and 2. The CT-scans were loaded into the 
TPS and the measured extrapolated dose results were compared to the TPS 
calculated dose values. 
5.2.2 Patient measurements 
In vivo dose measurements were performed in 17 patients. Directly after the 
implantation, the patient was transported to the recovery. A Y-connector was inserted 
between the catheter and the urine bag and a sterilized high-sensitivity linear-array 
was placed into the catheter. The end of the array was positioned at the top of the 
catheter. The position of the array was fixed using a rubber wedge, which also 
prevented urine leakage from the catheter. Measurements were performed for one 
hour, with automatic read-out every 5 minutes. Constant dose-rate was assumed 
during the interval, in light of the half-life of 125I. After the dose measurements, the array 
was removed from the catheter and the patient was transported to a CT-scanner. In the 
scanner room, a sterilized dummy linear-array was positioned to the top of the catheter 
and again fixed with the rubber wedge. A CT-scan was made, using 1 mm slice-
thickness and slice-separation from the bladder dome up to the perineum. The CT-
slices were then loaded into our TPS. In vivo dose data and calculated dose values 
were compared. 
5.3 RESULTS 
5.3.1 Phantom measurements 
5.3.1.1 Angular dependence of the MOSFET-array response  
The results of the measurements of the angular dependence of the detector response, 
related to the mean result of all angles, are given in figure 2. A deviation of 3.1 % 
(±0.51 %, 1SD) at 0° was observed, probably due to the shape of the epoxy layer that 
imbeds the MOSFET. The deviations at other angles were within the observed 
deviation at 0°. The results are comparable to the results of other studies5, 8, 9. 
Thesis_Bloemen_v07.pdf   90 23-7-2009   16:23:05
Brachy prostate 
 
91 
 
 
5.3.1.2 Calibration of the detector 
The sensitivity of the individual MOSFETs of the MOSFET-array, ranged between 15.2 
mV/cGy and 16.5 mV/cGy resulting in an average calibration coefficient of the 
MOSFETs of 0.06 cGy/mV with an uncertainty of ±6 % (1SD). The results are 
consistent with the values provided by the manufacturer for a random batch of 
MOSFET-arrays. The response of the detector was linear within 1 % for dose values 
ranging from 0.4 cGy to 4 cGy. For values below 0.05 cGy, the background noise 
exceeds the MOSFET-reading indicating that dose values below 0.05 cGy are not 
reliable. 
5.3.1.3 Absorption of the catheter material 
The degree of absorption by the catheter material depends on the angle of incidence of 
the radiation on the catheter. If the MOSFET is positioned in or very close to the plane 
of the seeds (MP1, MP2 and MP3), the effect of the absorption of the catheter material 
compared to water is almost constant. When the radiation passes the catheter 
obliquely, the absorption increases. The additional absorption measured by the 
MOSFET positioned in the catheter relative to the measurements in water is for MP1, 
MP2 and MP3 on average 9.1 %. For MP4, MP5 and MP6 the absorption is 21.8 %, 
24.8 % and 37.6 %, respectively. A correction for catheter attenuation is therefore 
Figure 2: Angular dependence of the MOSFET array response for 125I photons. The result of 
each angle was related to the mean value of all angles.  
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required. In practice it is difficult to perform such a correction because the dose will be 
influenced by the number of seeds at different distances from the measuring point. We 
used an approach where we linked the distance between the MOSFET and the seeds, 
and thus the angle of incidence, to the IDR. Figure 3 illustrates the deviation, caused 
by the absorption of the catheter, plotted against IDR. For high dose-rates (>5.2 cGy/h) 
the correction is taken constant (~9 %), while for the lower dose-rates (<5.2 cGy/h), the 
attenuation caused by the catheter was approximated by a logarithmic correction (Y= -
13.835 ln(IDR)+33.1). 
 
5.3.1.4 Temperature dependence of the MOSFET-array response 
The influence of temperature on the sensitivity of the detector is illustrated in figure 4. 
Because the results are based on single measurements, a relatively large fluctuation in 
the data was observed. However, a linear fit through these data points demonstrated 
an evident deviation between MOSFET sensitivity for room temperature compared to 
patient temperature, showing that the MOSFET sensitivity increases with increasing 
temperature. The ratio of the measurements performed at room-temperature compared 
to body-temperature is on average 1.11 and the temperature coefficient is 0.6 %/°C. 
This means that the dose values during patient measurements will be on average 11 % 
higher compared to the values defined during phantom measurements. A correction is 
therefore required. When the MOSFET-temperature is constant, a fixed correction of 
11 % can be applied to the in vivo dose values.  
 
Figure 3: Catheter attenuation, as a function of the initial dose rate. 
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5.3.1.5 Total measurement uncertainty 
The total measurement accuracy, determined during the simulation of the clinical plan 
(at room-temperature), corrected for catheter attenuation, can be derived from figure 5. 
The shapes of the measured and calculated curves correspond reasonably well. The 
observed average deviation between measured and calculated dose values is 4.9 % 
±8.3 % (1SD) for MOSFET-position 1 and. -0.4 % ±7.6 % (1SD) for MOSFET-position 
2. The overall mean of both measurements is 2.3 % ±8.0 % (1SD), the measured dose 
values being higher than the calculated dose values.  
The uncertainty in the measurements is higher in the low-dose-rate regions compared 
to the high-dose-rate region, due to increase of the noise/signal ratio of the dosimeter. 
For dose-rates below 4.8 cGy/h, the measurement uncertainty is 9.5 % (1SD). For 
dose-rates of 4.8 cGy/h and higher, the uncertainty is 4.8 %.  
5.3.2 Patient measurements 
The position of the MOSFET-array, relative to the prostate 200 Gy isodose line in a 
patient, is presented in figures 6a and 6b, showing a sagittal view and an oblique view, 
respectively. Figure b illustrates that the 200 Gy isodose line and MOSFET-position do 
not overlap, demonstrating that the dose in the urethra does not exceed 200 Gy. 
Figure 4: Temperature dependence of the MOSFET array for 125I photons. The dotted vertical 
lines indicate both calibration and patient temperature. The dose readings (▲) are related to 
room temperature.  
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 The measurements demonstrated that the mean IDR in the bladder neck, observed by 
MOSFET 1, was 0.7 cGy/h ±0.3 cGy/h (1SD). With distance from the bladder towards 
the prostate gland the dose-rates increased and reached their maximum inside the 
prostatic urethra where a mean IDR of 5.9 cGy/h ±1.3 cGy/h was observed. The 
highest dose-rates were observed for MOSFETs 3 and 4, depending on the length of 
the prostate. Extrapolated to the accumulated dose (D), the maximum observed dose 
was 197 Gy. Towards the perineum, dose-rates decreased to 1.6 cGy/h, as measured 
by MOSFET 5.  
The mean deviation between measured and calculated dose values corrected for 
temperature dependence of the detector response and catheter absorption is 9.2 % 
±22.3 % (1 SD). This rather large deviation is mainly due to uncertainties in the lower 
dose area (extrapolated dose values <100 Gy or IDR < 4.8 cGy/h), where a mean 
deviation of 12.0 % ±24.7 % (1 SD) was observed. In the high-dose area (accumulated 
dose >100 Gy), in or close to the prostatic gland, the mean deviation was 1.7 % ±10.7 
% (1 SD). The global dose deviation, given as the dose relative to the highest dose 
value measured with a MOSFET in a particular patient, is however a more realistic way 
of expressing the deviations in this low dose region. In this way, the mean deviation of 
all points was 1.6 % ±9.2 % (1 SD) and for the lower dose region (<100 Gy) 1.5 % 
Figure 5: Measured MOSFET dose values for position 1 (pos 1) and position 2 (pos 2), 
corrected for catheter attenuation and dose values calculated with the treatment planning 
system (TPS), plotted against the initial dose rate. Pos 1 and pos 2 are shifted 1 cm relative to 
each other.  
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±7.2 % (1SD). Both corrected and uncorrected global dose deviations, relative to the 
maximum dose value, are presented in figure 7.  
 
Figure 6: Three-dimensional illustration of the MOSFET array position relative to the seeds and 
the 200-Gy isodose surface. The MOSFETs are presented as boxes ( ), the 200-Gy isodose 
surface is presented as a black cloud. A lateral view (a) and an oblique–transversal view (b) are 
presented.  
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5.4 DISCUSSION  
In this study we demonstrate that, in order to perform in vivo dosimetry in 
brachytherapy, a good validation procedure of the detector system under clinical 
conditions is very important. If detectors used for this purpose have well-known 
characteristics, in vivo dosimetry is a good tool for QA of the treatment process and a 
prerequisite to relate dosimetric parameters to clinical outcome. In addition to the use 
of in vivo dosimetry after TIPPB, this approach could also be used for other 
brachytherapy techniques, such as HDR brachytherapy of prostate cancer or of other 
cancer sites.  
The linear MOSFET-array, is suitable for measurements after TIPPB. In this study a 
high-sensitivity array was inserted into the urinary catheter. When fully inserted into the 
catheter, generally one MOSFET is located in the bladder neck, 2 or 3 MOSFETs are 
located in the prostate and 1 or 2 MOSFETs are located beneath the prostate. A mean 
global deviation (related to the maximum dose values) of 1.6 % ±9.2 % (1 SD) 
between in vivo and calculated results was found during our in vivo measurements. 
This result is within the measurement uncertainty and is very promising.  
Figure 7: Uncorrected results of all patient measurements relative to calculated extrapolated 
dose values (▲), and the same extrapolated results corrected for temperature dependence of 
the MOSFET array response and catheter attenuation, presented as the global dose deviation 
(■), that is, deviations in percentages of the maximum dose measured in each experiment.  
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During patient measurements the MOSFET-array is located inside a catheter and the 
catheter material consequently reduces the measured dose values. In order to 
quantitatively compare the calculated and measured dose values, the latter ones have 
to be corrected for the catheter attenuation. The extent of the absorption depends on 
the angle of incidence of the radiation through the catheter material. We used an 
approach where we linked the distance between the MOSFET and the seeds, and thus 
the angle of incidence, to the IDR. For the higher dose-rate areas, in or close to the 
prostatic gland, a correction of about 9 % is applied, while for the lower dose-rate areas 
the correction is a logarithmic function of IDR. This correction is not related to the 
MOSFET response, which is dose rate independent.  
In this study a temperature dependence of the MOSFET-array response of about 11 % 
was observed, when raising the temperature from 20° to 37 °C. Ramaseshan et al.13 
described the temperature response of the micro-MOSFET, demonstrating a 0.5 % 
variation when increasing the temperature from 20° to 40 °C. These different 
observations are due to fundamental design differences between the linear-array and 
the micro-MOSFET-dosimeter. In the MOSFET-array, the 5 MOSFET-dosimeters 
share a distant common MOSFET, located at the array’s connector and always at room 
temperature, leading to less compensation of the threshold voltage variations of the 5 
MOSFETs when they reach body-temperature. In the case of the micro-MOSFET, the 
dual-MOSFET-dosimeter design is implemented on a similar silicon-chip, with both 
sensors following similar temperature variations, leading to their differential response 
independent of temperature14. After the MOSFET-array’s insertion inside the catheter, 
it is advised to allow a short waiting period (~5 minutes), in order to stabilize the 
MOSFET to body temperature before starting the measurements.  
An extended set of phantom measurements was performed, to validate the detector-
system under clinical conditions. For these measurements, seeds with an activity of 
approximately 0.6 U (0.472 mCi) were used. The low dose-rates emitted by the seeds 
resulted in relatively long measurement times and higher noise/signal ratio. Using high-
activity seeds for calibration and phantom measurements will reduce measurement 
times and may result in smaller measurement uncertainties5.  
The total measurement uncertainty involved in this measurement method was 
determined by simulating the procedure in a phantom and comparing the in vivo dose 
measurement results with calculated dose values. The uncertainty of these 
measurements is ±8.0 % (1 SD). Based on these results, action levels for in vivo 
measurements of ±16 % (2 SD) should be achievable. When the dose difference 
exceeds the action level, the cause of the deviation between the planned and 
measured dose distribution will be investigated and that knowledge may be used for 
future implantations.  
Cygler et al.5 described the use of MOSFET-detectors for dosimetric verification after 
TIPPB. In that study the feasibility of micro-MOSFET-detectors for QA and in vivo 
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dosimetry of the urethra was investigated, showing that MOSFET-detectors are 
suitable for clinical dosimetry after TIPPB. In their study the micro-MOSFET was used 
and moved along the urethra in 1 cm steps, because at the time of that study, an array 
of MOSFETs was not yet available. This method is however time consuming and 
introduces an uncertainty in MOSFET-position. Clinical studies describing the use of a 
linear-MOSFET-array are limited9, 15, 16. The results on angular response agree with the 
results in this study, however data about catheter absorption and temperature 
response were not provided.   
Brachytherapy is a good tool for the treatment of prostate cancer. Although this is an 
effective treatment option, significant complications involving the genitourinary tract 
may result. A consequence of exceeding the maximum tolerable urethra dose level is 
acute urinary morbidity17. Other treatment complications involve radiation proctitis and 
the development of a rectal ulcer18. Real-time dosimetry during the implantation 
procedure is a promising tool to check and adjust the treatment conditions and dose 
values in the genitourinary tract during the implantation. Real-time dosimetry gives the 
opportunity to make changes in needle positioning during the procedure and avoid 
unacceptable dose values in organs at risk due to inaccuracies in needle positioning or 
seed activity. Real-time dosimetry has not yet been described and is the subject of 
further study in our department.  
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ABSTRACT 
Purpose: To develop a technique to monitor the dose-rate in the urethra during 
permanent implant brachytherapy using a linear MOSFET-array, with sufficient 
accuracy and without significantly extending the implantation time.  
Methods and materials: Phantom measurements were performed to determine the 
optimal conditions for clinical measurements. In vivo measurements were performed in 
5 patients during the 125I brachytherapy implant procedure. To evaluate if the urethra 
dose obtained in the operation room with the ultrasound transducer in the rectum and 
the patient in treatment position is a reference for the total accumulated dose, 
additional measurements were performed after the implantation procedure, in the 
recovery room.  
Results: In vivo measurements during and after the implantation procedure agree very 
well, illustrating that the ultrasound transducer in the rectum and patient positioning do 
not influence the measured dose in the urethra. In vivo dose values obtained during the 
implantation are therefore representative for the total accumulated dose in the urethra. 
In 5 patients the dose-rates during and after the implantation were below the maximum 
dose-rate of the urethra, using the planned seed distribution.  
Conclusion: In vivo dosimetry during the implantation, using a MOSFET–array, is a 
feasible technique to evaluate the dose in the urethra during the implantation of 125I 
seeds for prostate brachytherapy. 
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6.1 INTRODUCTION 
Transperineal Interstitial Permanent Prostate Brachytherapy (TIPPB) using 125I seeds 
has become a widely practiced treatment for early stage prostate cancer. The risks of 
normal tissue complication in this treatment depend on the dose received by the 
organs at risk (OAR), such as the urethra. The dose in the urethra is based on 
calculations of the treatment planning system (TPS) and a post-implant CT-scan. 
There are, however, various sources of uncertainty that may influence the actual dose 
in the urethra such as uncertainties in: seed activity, seed position, delineation of the 
urethra on the US image, and uncertainties in the dose calculation. Several studies 
described urethral strictures after a permanent prostate implant1, 2.  
In vivo dosimetry is a technique to assess the actual absorbed dose per unit time 
(dose-rate) in the urethra. In our previous study3, in vivo dose values were obtained 
after TIPPB for 17 patients. We demonstrated that a linear-MOSFET-array is suitable 
to evaluate the dose-rate in the urethra3. In vivo dosimetry during the implantation (i.e. 
real time), gives next to the in vivo dose data also the opportunity to constantly monitor 
the actually delivered dose-rate in the urethra during the implantation. As a result, in 
vivo dosimetry may assist in reducing the incidence of early or late urinary side effects.  
The goal of this study is to develop a technique to monitor the dose-rate in the urethra 
during an implantation, with sufficient accuracy and without significantly extending the 
implantation time.  
6.2 MATERIALS AND METHODS 
In vivo dosimetry is a technique to monitor the dose-rate during the seed implantation. 
In this study, a detector was placed in the urethra during TIPPB, with the opportunity to 
measure the dose-rate in this OAR during the implantation. For the measurements we 
used extra high sensitive dual Metal Oxide Semiconductor Field Effect Transistors 
(MOSFETs), model TN1002-LA5 (MOSFET-array, Best Medical Canada, Ontario). The 
array contains five MOSFETs, placed on a flexible wire with 2 cm inter-MOSFET 
distance. It is narrow (1.5 mm wide, 1.3 mm thick, 460 mm long) and waterproof, which 
makes it suitable for measurements inside a patient. The calibration coefficient of the 
detectors, converting the radiation-induced voltage shift into dose, decreases with 
increasing energy in the keV range4. Therefore, calibration was performed with the 
same radiation type as used for the clinical measurements. Other authors 
demonstrated drifts along the entire lifetime of the device for low x-ray energies4. To 
avoid underestimation of dose measurements, a recalibration of the device was 
performed periodically (~2000 mV). The Mobile MOSFET Dose verification system 
(TN-RD-70W, Best Medical Canada, Ontario), using Bluetooth to transfer the data 
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wireless to a computer installed with the MobileMOSFET software, was used for dose-
read out. Because of the wireless readout, galvanic separation is ensured and it is safe 
to perform measurements in the operation room. Automatic dose readout was used 
and each dose measurement (cGy) was added to the stored sum of the previous 
measurements. Such a procedure has the advantage that relatively short integration 
times can be applied because dose values accumulate during the implantation, and 
more accurate dose information is obtained. Dose-rate was obtained by subtracting 2 
sequentially obtained measurements, and the results were extrapolated to an 1 hour 
time period (cG/h).  
For implantation we used a modified peripheral loading technique. Before implantation, 
a treatment plan (pre-plan) was made based on transrectal ultrasound images with the 
patient in treatment position (PSID 4.1 system, Sonotech, Bellingham, UK). Needles 
were loaded with single seeds or strands of seeds, based on the TPS data. The seeds 
were inserted into the prostate under ultrasound guidance. A template was used for 
needle positioning and the template coordinates were derived from the pre-plan data. 
During the implantation, the position of the seeds in the prostate was depicted on the 
longitudinal US images, and the dose-rate provided by the treatment plan was adapted 
subsequently. The final dose distribution after the implantation was defined as post-
plan. The calculations of the TPS were based on the TG-43 protocol of the American 
Association of Physicists in Medicine5.  
A Foley-catheter, a silicone two-way balloon catheter with an outside diameter of 6 mm 
(18 French) and a length of 40 cm (Ref 170605, Teleflex Medical BV) was used to 
visualize the urethra. The MOSFET-array was positioned into the catheter. Correction 
for the influence of the catheter on the dose-rate was necessary for comparison of in 
vivo and calculated dose values, because the TPS does not take inhomogeneities into 
account. A correction of 9.1 % was used for the MOSFETs in or close to the prostate, 
having dose-rates higher than 5.1 cGy/h; for dose-rates lower than 5.1 cGy/h we used 
a dose-rate dependent correction as described in our previous study3. An 11% 
correction for temperature dependence, as a result of changes in MOSFET sensitivity 
between room (calibration) temperature and body temperature, was used3. The 
uncertainties on the phantom and patient measurements are given as one standard 
deviation (1 SD) of the mean. 
6.2.1 Phantom measurements 
In vivo measurements to obtain the dose-rate during the implantation of the seed 
strands were performed in a phantom in order to: (1) determine the dependence of 
dose-rate on time for 3 clinically used implantation techniques and (2) to simulate the 
clinical procedure in a phantom. For these measurements, an in-house made phantom 
filled with gelatin was used. The phantom consisted of a PMMA casing (10 cm x 10 cm 
x 10 cm) with 49 holes drilled in its wall, comparable to the template used during the 
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patient measurements. The phantom contained a urine-catheter for the placement of 
the array and was filled with of a solution of gelatin in water. Forty seeds with an 
activity of 0.488 mCi (0.620 U) were used in strands of 2 or 3 seeds, mimicking the 
configuration of a clinical plan. The seeds were implanted through the wall of the 
phantom into the gelatin, using a seed distribution typical for a patient treatment. The 
time between the placements of the seeds in the gelatin was sixty seconds.  
 
Figure 1: Template used for needle placement, positioning the seeds according to; a: sequence 
1, in circles from the outside to the inside; b: sequence 2, zigzag from the outside to the inside 
and c: sequence 3, using the conventional sequence. The black boxes contain a strand of 3 
seeds, the grey boxes a strand of 2 seeds and the shaded dark grey box illustrates the urine-
catheter.  
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6.2.1.1 Phantom test to determine the dose-rate increase during 
implantation 
Measurements were performed during the implantation to determine the dependence 
of dose-rate on time. Besides our in-house used implantation sequence, two other 
sequences were tested with the aim to determine whether our in vivo measurement 
procedure can be extended to implantations performed by physicians using other 
implantation sequences. A constant time interval between the insertions of the strands 
and a fixed seed distribution was used. The integration time used to collect the dose 
was 30 seconds. The results were used; (1) to assess the most steep and critical part 
of the dose-rate for the urethra during the implantation and (2) to determine the 
increase in dose-rate between subsequent needles. Having a nearly linear dose-rate 
increase would facilitate the prediction of the dose-rate after the implantation of a new 
strand. Figure 1a shows sequence 1, where the seeds were implanted in circles into 
the gelatin from the outside to the inside. The numbers in the boxes illustrate the 
needle sequence. The design of sequence 2 (figure 1b) was based on a placement 
zigzag from the outside to the inside. Sequence 3 (figure 1c) illustrates the design of 
needle placement as used in our hospital, starting with the seeds in the left side of the 
prostate, continuing with the seeds in the contra-lateral side and finishing with the 
seeds under the urethra. 
6.2.1.2 Simulation of the clinical procedure in a phantom 
In the patient procedure, the final dose-rate at the end of the implantation should be 
restricted between a minimum dose-rate as obtained from the treatment plan and the 
maximum tolerable dose-rate of the urethra (9.7 cGy/h, or an integrated dose of 200 
Gy6). To mimic this procedure, we performed a simulation of the clinical practice in a 
phantom. In clinical implants the number of seeds depends on the size of the prostate, 
and generally more than 50 seeds are use in our institution. Compared to an average 
prostate implantation procedure, we used in this experiment less seeds. As a 
consequence the dose-rate in the catheter was not as high as during a patient 
treatment and the maximum tolerable dose level of the urethra was not a relevant 
parameter. As a result, we used the highest expected dose-rate in the urethra, 
determined from the TPS, as an indicator for the dose-rate limit during the implantation. 
In addition to the maximum acceptable dose-rate, also a minimum dose-rate value was 
used as an indicator to detect errors that result in an underdose. This value was 
determined as the dose-rate at a distance of 1 cm from the maximum dose-rate in the 
urethra. A distance of 1 cm was used because the MOSFETs were hardly visible in the 
US-scan and the MOSFET location does not necessarily coincide with the highest 
dose point in the prostate. The inter-MOSFET distance is 2 cm and the maximum 
distance from this highest dose point and the closest MOSFET detector is therefore 1 
cm or less. Consequently at least one of the MOSFETs should have a reading higher 
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than the minimal value, thus providing a general dose level check. Based on the 
measurements to determine the dose-rate increase during the implantation, the dose-
rate is most critical in the last part of the implantation procedure. As a consequence, 
during this part the actual dose-rate was checked more accurately. Before implanting 
the last 2 needles, a short waiting period was introduced in order to collect 3 
measurements. The results of these 3 measurements were averaged to obtain the 
dose-rate with a better accuracy and this average was compared to the maximum 
expected dose-rate. When the dose-rate was close to the maximum tolerable dose-
rate, we used a simple approach, based on a nearly linear dose-rate increase (see 
Results) to determine the dose-rate increment after the implantation of the next strand. 
We used the actual dose-rate ( )actD&  and the dose-rate before the implantation of the 
last strand ( )lastD&  to determine the dose-rate after the placement of the next 
strand ( )D&Δ as: ( )lastDactDactDD &&&& −+≅Δ . After implanting all seeds, again 3 
measurements were performed before removing the array from the catheter, in order to 
obtain the final dose-rate more accurately. 
6.2.2 Patient measurements 
In vivo measurements were performed during the implantation of 5 patients. Before 
implantation the array was fixed with a rubber wedge into the urine catheter with the tip 
of the array touching the tip of the catheter. Using this setup results in a positioning of 
MOSFET 1 into the bladder base, MOSFETs 2, 3, and 4 in or close to the prostate and 
MOSFET 5 in the urethra apical of the prostate. The maximum allowable dose-rate 
was set to 9.7 cGy/h, which results in an integrated dose of 200 Gy, being the 
generally accepted maximum tolerable dose of this organ at risk6. The minimum dose-
rate for the MOSFET in the high dose area was determined using the pre-plan, and the 
procedure as explained for the simulation measurement, taking the dose value at a 
distance of 1 cm from this highest dose-rate in the urethra. The integration time was 1 
minute. The dose measurements were started when the physician started the 
implantation. The seed strands were implanted, starting with the seeds in the left side 
of the prostate, continuing with the seeds in the contra-lateral side and finishing with 
the seeds under the urethra, conform sequence 3 (fig 1). During the first part of the 
implantation, the dose-rate was only registered. For the last part of the implantation, 
where the dose-rate relative to the urethra tolerance is more critical, we averaged 3 
measurements after the implantation of the last 3 strands and the needle retraction, to 
obtain more accurate results. The dose measurement was compared with the 
maximum tolerable dose-rate of the urethra. If the dose-rate was below the maximum 
dose-rate, and adding a new strand would not result in exceeding this maximum level, 
the next strand of seeds could be safely placed. If adding seeds would result in 
exceeding the maximum dose-rate, the needle placement could be reconsidered. 
Urethral dose values and prostate dose coverage are, however, closely linked 
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together, and the influence of omitting or repositioning a strand to prevent too high 
dose values in the urethra, should always be related to prostate coverage. After the 
placement of the last strand, the dose-rate of the MOSFET with the highest reading 
was expected to be above the minimal dose level and below the maximum dose level. 
After implanting all seeds, again 3 measurements were collected before removing the 
array from the catheter, to obtain the final dose-rate after the implantation. The extra 
time associated with this procedure was about 6 to 8 minutes.  
To determine the effect of geometric changes of the prostate, caused by the presence 
of the transrectal ultrasound probe and patient motion, additional measurements were 
performed in the recovery room directly after the implantation ( )recD& . recD& values were 
compared with the final dose-rate results obtained in the operation room ( )rtD& .   
6.3 RESULTS 
6.3.1 Phantom measurements 
6.3.1.1 Test to determine the dose-rate increase during the implantation 
The sequence simulation of needle placement demonstrated that all tested sequences 
resulted in a nearly linear dose-rate increase at the end of the implantation. The 
results, presented as the dose increase as a function of needle placement, are given in 
figure 2.  
 
Figure 2: Illustration of the dose-rate increase during the implantation of the strands in the 
phantom for 3 implantation sequences. The symbols on the curve present the dose 
measurements. The time between the placements of the needles was 60 sec, which is indicated 
by the tick marks on the x-axis. The results of MOSFET 3 are presented. 
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6.3.1.2 Simulation of the clinical procedure in a phantom 
The result of the overall in vivo simulation measurement is shown in figure 3. Point A is 
the moment where needle number 17 (2 needles left) was retracted. After this point the 
average dose-rate (3 measurements, integration time 1 minute) over interval [A,B] was 
(3.7 ± 0.2) cGy/h for MOSFET 3, the MOSFET in the highest dose region. The next 
needle (#18) was placed between time points B and C resulting in an average dose-
rate over interval [C,D] of (4.6 ± 0.2) cGy/h for MOSFET 3. The last needle (#19) was 
placed between time points D and E, resulting in an average dose-rate over interval [E, 
F] of (5.4 ± 0.4) cGy/h. The light grey line illustrates the minimum dose-rate that should 
be reached by the MOSFET in the high dose region, in this case by MOSFET 3 (3.6 
cGy/h). The dark grey line illustrates the highest expected dose-rate in the urethra, 
determined from the TPS and used as an indicator for the dose-rate limit, because the 
maximum tolerable dose level of the urethra was not relevant due to the limited number 
of seeds used for this measurement. Both MOSFET 3 and 4 were within the minimum 
and maximum dose-rate limits.  
 
6.3.2 Patient measurements 
The final in vivo dose-rates for the 5 patients as obtained during the implantation are 
illustrated in figure 4a.  A large standard deviation was observed due to the dose 
differences in the plans for the 5 patients and the differences in MOSFET position in 
Figure 3: In vivo simulation measurement in a phantom using 5 MOSFETs (M1-M5). Points A, C 
and E are the moments where the last 3 strands were placed. The in vivo dose-rates, between 
interval [A,B], [C,D] and [E,F], were averaged and displayed with standard deviations.  
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the prostate between the patients. For all patients the in vivo dose-rate was below the 
maximum tolerable dose-rate of 9.7 cGy/h.  
To evaluate the small dose values obtained by MOSFET 1 and MOSFET 5, the 
MOSFETs positioned at further distance from the prostate, we presented deviations 
between rtD& and recD& as a percentage of the maximum dose value. The deviations, 
calculated as: ( ) rtDrtDrecD &&& − , are presented in figure 4b. The results agree 
reasonably well and are within the standard deviation of the measurements.  
 
Figure 4: Patient measurements; a: final in vivo dose-rates for the 5 patients plotted against 
MOSFET position and connected by a line to illustrate the dose distribution over the urethra 
and b: deviations between rtD& and recD&  for the 5 patients plotted as a percentage of the 
maximum dose value for each MOSFET position. Mean results and standard deviations are 
given.  
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The minimum dose value that should be measured in the high dose area, determined 
from the pre-plan and corrected for the decay of the seeds, ranged between 113 Gy 
and 186 Gy for the 5 patients with a mean value of (159 ±29) Gy. For all patients, 
however, the dose to the MOSFET in the highest dose region did not reach this 
minimum dose level. When evaluating the post-plan, the treatment plan that illustrates 
the dose distribution based on the final seed distribution in the prostate, we observed a 
lower urethra dose compared to the pre-operative planned urethra dose. The minimum 
dose values determined using the post-plan ranged between 79 Gy and 155 Gy with a 
mean of (108 ±30) Gy, as indicated in figure 5.  
 
The in vivo measurements of two patients are shown in figure 6a and b. The dose-rate 
measured by MOSFET 3 over interval [A,B],  the moment when only 2 needles are left 
to insert, was (5.4 ± 0.1) cGy/h for plan 6a and (4.4 ± 0.1) cGy/h for plan 6b, obtained 
by averaging 3 measurements between interval A and B. Between interval B and C the 
next needle was inserted, which resulted in a mean dose-rate over interval [C, D]of (5.3 
± 0.4) cGy/h and (5.2 ±0.2) cGy/h for plan 6a and 6b, respectively. The last strand was 
implanted (interval [D, E]) and the final dose-rate after the implantation (interval [E, F]) 
was (6.6 ± 0.4) cGy/h for the first implant and (5.8 ± 0.3) cGy/h for the second implant. 
In figure 6a, both MOSFET 3 and MOSFET 4 are in the high dose-rate area, MOSFET 
3 exceeded the minimum dose-rate value. In figure 6b, MOSFET 3 is in the high dose-
rate area but the minimum dose-rate was not achieved.  
 
Figure 5: Minimum dose for the MOSFET in the high dose region, determined using the pre-
plan and the post-plan for 5 patients. The black symbols (■) are the minimum dose values 
determined using the pre-plan, while the grey symbols (♦) are the minimum dose values 
determined using the post-plan. 
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Figure 6: Results of in vivo dose-rate measurements of 2 patients (a and b). The light grey line 
is the minimum dose-rate value. The dark grey line is the maximum tolerable dose-rate limit for 
the urethra of 9.7 cGy/h, or an integral dose of 200 Gy. Point A describes the moment when only 
2 needles are left to insert. The time interval [B,C] and [C,D] comprises the last 2 strand 
implants. For interval [A,B], [C,D] and [E,F] an average dose-rate was determined.  
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6.4 DISCUSSION 
The method presented in this paper offers a clinical tool to relate actual delivered dose 
values to clinical side effects. During TIPPB, the final dose-rate is based on 
calculations performed by the TPS. Inhomogeneities in the prostate and surrounding 
tissues and inter-seed attenuation are not taken into account by our TPS. Uncertainties 
in the treatment procedure, such as seed position and seed activity can affect the 
urethral dose values. In vivo dosimetry is an appropriate tool to measure the dose-rate 
in the urethra during the implantation. It offers the opportunity to evaluate needle 
positioning during the procedure and to avoid unacceptable dose values in organs at 
risk.  
Besides 125I, other isotopes such as 103Pd and 131Cs are used for the treatment of 
prostate cancer. Given their somewhat different energy spectrum, combined with the 
energy dependence of the response of the detector in the low energy range4, slight 
differences in calibration factors may occur. For that reason it is important that 
calibration of the MOSFET detector in this low energy range is performed using 
isotopes identical to those used in clinical practice. The correction for catheter 
absorption should also be tested, because it depends on the photon energy of the 
seeds. The difference in dose-rate between the seeds does not influence the dose 
measurements, because the response of a MOSFET detector is dose rate 
independent7. In addition to the use of in vivo dosimetry during TIPPB, this approach 
can also be used for other brachytherapy techniques, such as HDR brachytherapy of 
prostate cancer or other cancer sites7.  
The linear-MOSFET-array is a suitable detector for in vivo measurements during 
TIPPB. The 5 MOSFETs on the array provide us with dose information over the region 
ranging from the perineum to the bladder base. One should, however, be aware that 
the inter-MOSFET spacing is 2 cm and that the method may be rather insensitive to 
small hot spots (e.g. single seed close to urethra) located between the detector points. 
A correction of the dose values for attenuation by the catheter was used for 
comparison of the in vivo and calculated dose values, because the TPS does not 
account for catheter attenuation3. Also a correction for temperature dependence of the 
linear-MOSFET-array response of 11% was used3. Needle attenuation was not taken 
into account. In the first part of the implantation, when the accuracy of the dose 
determination is not very high, this was not relevant. In the last part of the implantation, 
used to evaluate the dose-rate in relation to the maximum acceptable dose-rate of the 
urethra, we used the measurements after the retraction of the needle.  
During the first part of the implantation very low dose-readings are obtained. The 
accumulated dose in the prostate at the end of the implantation was about 2 cGy. 
Given the MOSFET sensitivity of 37.2 mV/cGy, this dose corresponds to a MOSFET-
reading of about 74 mV. The dose for MOSFETs at larger distance from the prostate 
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was even smaller, but at least 0.4 cGy, corresponding to a MOSFET reading of about 
15 mV. Because dose values are accumulated during the implantation, the dose 
readout in the last part of the implantation will be more accurate compared to the 
accuracy in the first part. Furthermore, the dose values measured by the MOSFETs in 
the high dose area, or close to the prostate, are more accurate compared to the dose 
values measured at further distances from the prostate.  
The dose-rate in the urethra, as calculated in the pre-plan, was higher compared to the 
dose-rate calculated in the post-plan, possibly due to seed placement inaccuracies and 
edema that occurs during the implantation. As a consequence, the in vivo 
measurements demonstrated dose-rates that were lower compared to the predicted 
dose-rates, calculated using the pre-plan. Dose coverage, however, was ensured, as 
demonstrated by the post-plan at the end of the implantation. The correlation between 
the lower urethral dose values and the seed distribution in the prostate is an object of 
further study. 
The dose-rate obtained in the operation room at the end of the implantation and in the 
recovery room agree reasonable well, illustrating that the US transducer in the rectum 
and patient positioning do not influence the dose in the urethra. Hence, in vivo doses 
obtained during the implantation are representative for the total accumulated dose in 
the urethra at these MOSFET positions.  
Clinical studies describing the use of a linear-MOSFET-array for measurements in the 
urethra are limited3, 8-10. The effect of displacement and deformation of the prostate on 
the planned dose in the urethra, caused by the presence of the transrectal ultrasound 
transducer and movement of the patient, has, to the best of our knowledge not been 
described. In this study we demonstrate that in vivo dose-rates in the urethra, obtained 
during the implantation, yield a good prediction of the total accumulated dose in the 
urethra. Two uncertainties still remain in the prediction of the accumulated dose from 
the in vivo dose-rate values obtained during implantation; the occurrence of edema 
during and after the implantation, and the migration of individual seeds. The influence 
of these phenomena on the total accumulated dose has been investigated by several 
other groups11-14. 
6.5 CONCLUSION 
In vivo dosimetry, using a MOSFET array, is a promising technique to evaluate the 
dose rate and the accumulated dose in the urethra during the implantation of 125I seeds 
for prostate brachytherapy. It offers a clinical tool to ensure maximum tolerable doses 
are not reached in this organ at risk by allowing on the fly adaptations to the treatment 
plan. In this study, for all patients the in vivo urethra dose-rate was below the maximum 
tolerable dose-rate.  
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7.1. IN VIVO DOSIMETRY IN RADIOTHERAPY 
In vivo dosimetry plays an important role in a quality assurance programme in 
radiotherapy because its main goal is to protect patients from errors in treatment 
delivery. It can serve as an overall check of the treatment procedure to ensure that the 
prescribed and delivered dose agree within acceptable limits. It can also serve for dose 
verification during the implementation of a new treatment technique or as an indicator 
to assess the dose to organs at risk. Since January 2001, MAASTRO CLINIC uses 
MOSFET dosimeters as part of a QA programme of treatment delivery. In our 
institution we developed an in vivo dosimetry protocol, using MOSFETs, for all 
treatments with curative and elective intent. At the start of this project, the commercially 
available TN-RD-50 system (Thomson and Nielsen, a division of Best Medical Ottawa, 
Canada) patient verification system was used. For phantom measurements, to validate 
the detector, the MOSFET AutoSense system (TN-RD-60), developed for on-line 
radiotherapy applications, was provided for a brief period of time by Thomson and 
Nielsen and Pi-Medical, their Dutch representative, because the TN-RD-50 patient 
verification system does not allow on-line dose reading. In 2004/ 2005, our TN-RD-50 
patient verification system was replaced by a mobile MOSFET system (TN-RD-70-W), 
a new wireless system that is entirely software driven. The mobile MOSFET system 
allows for remote control of one or more systems from a PC and dose readout without 
entering the room. At the moment this thesis was written, MAASTRO CLINIC has 7 
linear accelerators and on each linac a mobile MOSFET dose verification system 
including the remote software is available. For brachytherapy purposes an additional 
mobile MOSFET dose verification system with an additional bias box, allowing for the 
use of 2 linear arrays simultaneously, is available.  
In this thesis we demonstrated that an extensive validation procedure is essential to 
apply a specific type of detector and obtain accurate in vivo dose measurements. The 
calibration procedure and sensitivity variations of the detector system have to be 
determined for each measurement situation. In chapter 2, we investigated the 
accuracy of MOSFET detectors to measure dose to points in the region of a field 
junction in a split beam technique. The results demonstrated that in the junction region 
MOSFETs performed well but slightly overestimated the dose during measurements in 
the penumbra of the beam. A correction factor of 5% was used to correct the MOSFET 
results in this particular area. In chapters 3 and 4, the sensitivity variation of the 
detectors was determined in electron beams and in photon beams at extended 
distance, respectively. Instead of using correction factors for separate properties of the 
MOSFETs, an overall factor was used, converting the dose obtained under reference 
conditions to a dose value determined under clinical circumstances. Because these 
conversion factors were determined using an ionisation chamber as a reference 
instrument, sensitivity changes of each MOSFET are included in this factor. In chapter 
3, the MOSFET reading with the detector placed on the patient’s skin without additional 
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build-up, was converted to dose values at the depth of dose maximum. In chapter 4, 
entrance and exit in vivo readings obtained without build up material and using the 
calibration factor determined under reference conditions were converted to midline 
dose data under TBI circumstances. In chapters 5 and 6, we used a linear-5-MOSFET 
array to investigate the sensitivity of the detector for measurements in the urethra. In 
this study, we demonstrated that a correction for temperature of 11% from room 
temperature to body temperature is necessary, due to the design of the array. The 
angular dependence of the detector is within 3% and is of the same magnitude as 
observed by other groups1, 2 
In external beam radiotherapy the use of in vivo dosimetry is getting more and more 
accepted. After validating the detector for a specific measurement situation, useful 
dose information can be obtained. To evaluate the in vivo dose values, measurement 
uncertainties for each measurement situation should be quantified. In this thesis, the 
measurement uncertainty of the detector and the uncertainties in the treatment process 
involved, without the influence of patient related factors, were determined for different 
treatment geometries. The mean MOSFET reproducibility of the detector was 2.0% (1 
SD) for readings at 100 mV and 1.8 % (1 SD) for readings at 200 mV, which resulted 
from 10 successive measurements, using the standard sensitivity of the bias supply. 
This is of the same order of magnitude as observed by other groups3, 4. In electron 
beams we determined an overall uncertainty in dose determination of about 4% (1SD), 
while the overall uncertainty in the dose determination using MOSFETs in our TBI 
setting was about 3.5% (1 SD).  
In brachytherapy there has been a delay in the development of QA compared to 
external beam radiotherapy, where in vivo dosimetry is applied on a larger scale. 
Brachytherapy QA procedures are mainly focused on equipment or separate steps of 
the treatment process such as machine performance, accuracy of source positioning, 
implant reconstruction, radiation safety and consistency of the treatment planning 
procedure, mainly because accurate in vivo dosimetry is difficult to achieve. Compared 
to dose measurements in external beam radiotherapy, the dose uncertainty in 
brachytherapy is larger, due to the high dose gradients, the relatively low dose-rate and 
the complex photon energy spectrum of the sources. Our phantom measurements 
demonstrated an overall uncertainty of 8.0% (1SD) in this situation, which includes 
detector positioning and correction factor uncertainties. Cygler et al.1 used MOSFET 
detectors for in vivo dosimetry during permanent low dose-rate prostate implants and 
this group of investigators estimated the accuracy of the in vivo measurements in their 
study to be ±3% (1 SD) at each spatial position. This result, however, was based on 
their calibration measurement reproducibility, using a higher seed activity compared 
with the clinical situation.  
Before the implementation of in vivo dose measurements in routine daily practice, 
tolerance levels and action levels should be defined in order to evaluate the obtained 
dose value. A tolerance level, a variation from a standard or the permissible deviation 
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from a specified value of a structural dimension, should be defined for each single step 
in the treatment procedure, resulting in an uncertainty of the final dose delivery within a 
pre-defined level. Action levels are,  opposed to tolerance levels, decision tools applied 
by the radiation therapy technologists or other professionals who perform the in vivo 
dose measurements, and are linked to action. If the measurement result is within the 
action level, the measurement is accepted. If deviations exceed the action level, a 
specified action should be applied, because exceeding this threshold can be a result of 
inadvertent actions or accidental errors. Measurements that exceed the action level, in 
our institution, require a second measurement to exclude errors in the measurement 
procedure. In addition, depending on the amount of the deviation, all treatment data 
are checked and the medical physicist evaluates the measurement result. It is 
important that the action level is larger than the measurement uncertainty and the 
uncertainty in the final dose delivery, because too narrow action levels may result in 
unnecessary intervention, increased downtime of equipment and inefficient use of staff 
time. Optimal action levels, should be based on initial phantom and patient 
measurements. The action levels described in this thesis range from 7% in external 
beam in vivo dosimetry, up to 16% in brachytherapy dose verification. ESTRO-EQUAL 
recommends action levels of 5% for beam delivery in external beam radiotherapy using 
a mailed TLD system to check the dose delivered on axis in reference and non-
reference conditions for external beam radiotherapy5. This level is, however, based on 
phantom measurements and does not include patient related factors. A radiotherapy 
department should make a compromise between accuracy and workload of a QA 
programme, which will depend on the tumor site and OARs involved. In addition to 
action levels for individual patient verification, a periodically evaluation of verification 
results of groups of patients will give the ability to detect systematic deviations. Due to 
the dose gradients and very low dose-rates involved, the action levels applied in 
external beam radiotherapy are generally not achievable for in vivo dose 
measurements in brachytherapy. Consequently in vivo dosimetry during brachytherapy 
does not provide high accurate dose information, but is nevertheless a good approach 
to detect gross errors. 
MOSFET dosimeters are suitable detectors for a broad number of in vivo dosimetry 
applications such as dosimetry at extended distance, in the penumbra of a beam, for 
routine verification during photon and electron beam treatments and for measurements 
during brachytherapy in a catheter inside the patient. The detector mostly used in our 
study is a dual-bias dual-MOSFET detector. This detector consists of two identical 
MOSFETs, fabricated on the same silicon chip as presented in figure 1. In the linear 
array, the five MOSFET dosimeters share a distant common MOSFET, located at the 
array’s connector, in order to reduce the size of the cross section of the array and 
make it suitable for measurements in a catheter. The two identical MOSFETs in both 
the single and the array dosimeter, operate at two different gate biases (1 and 15 V). 
During irradiation each sensor will produce a threshold voltage shift, the gate voltage 
necessary to allow charge conduction through the MOSFET. The PC is on-line with the 
Thesis_Bloemen_v07.pdf   123 23-7-2009   16:23:07
Chapter 7 
 
124 
Reader Module and reading is obtained in real-time by passing current through the 
cable to the MOSFET chips. The difference between the two threshold voltage shifts is 
a linear function of absorbed dose6. 
 
In a dual-bias dual-MOSFET detector, both sensors follow similar temperature 
variations, leading to their differential response, which is almost independent of 
temperature6, 7. The MOSFET array, however, where five MOSFET dosimeters are 
shared with one distant common MOSFET, located at the array’s connector and 
therefore always at room temperature, has less compensation of the threshold voltage 
variations of the five MOSFETs when temperature increases. As a result, a 
temperature dependence of the MOSFET array response of approximately 11%, when 
raising the temperature from 20 to 37 °C, was observed in our study. 
MOSFET sensitivity increases as the incident energy decreases from 150 keV to 10 
keV, the energy range in brachytherapy purposes8. This energy dependence is typical 
for most dosimeters and the effect is due to dose enhancement and increasing 
dominance of photoelectric absorption, while between 60 keV and 90 keV both 
photoelectric and Compton scattering become important. For both mechanisms the 
energy deposited in the sensitive region of the MOSFET is delivered mostly by 
secondary electrons. The photoelectric cross-section depends strongly on the target 
material, with the result of interface dose enhancement because the photoelectric 
cross section is different in the silicon (Si) and the silicumoxide (SiO2) layer. More 
electrons will be produced in Si, the higher cross section material, so more electrons 
will cross from Si into SiO2 than will cross the interface in the other direction. In the 
Figure 1: The basic structure of a dual-bias dual-MOSFET, having a readout circuit for the 
threshold voltages VTH1 and VTH2 of each MOSFET in the sensor pair and a current between the 
source and the drain (Ids1 and Ids2) that is maintained during readout6. 
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external beam radiotherapy range, where high energy photon beams (1 to 20 MV) or 
electron beams (6 to 20 MeV) are used, the observed energy dependence does not 
exceed 5% for both electron and photon irradiations9, 10.  
Point detectors will always constitute an essential part of quality assurance in 
radiotherapy. Thermo-Luminescence Detectors (TLDs) and semiconductor detectors 
(silicon diodes) are the types of dosimeter most commonly employed for in vivo 
dosimetry purposes. Each of these detectors has their own advantages. MOSFETs 
and diodes provide dose information in real time. In case of discrepancy, this gives the 
ability to check each treatment parameter while the patient is still on the treatment 
couch. The advantage of both MOSFETs and TLDs is their small size, which allows for 
placement in a radiation beam without shadowing the dose in the patient or perturbing 
the beam characteristics and also allowing for placement in a catheter or a needle. The 
intrinsic precision of diodes is, however, superior to the MOSFET precision and 
tolerance levels for in vivo dosimetry using MOSFETs should be slightly widened with 
respect to measurements made with diodes3. For TLD dose measurements, an 
uncertainty of 2% (1SD) has been reported11, 12. These results are comparable to those 
of MOSFETs, but the use of TLD requires careful and time-consuming handling and 
annealing procedures to achieve these accurate results13, 14. The superior precision of 
diodes, on the other hand, is compromised by the dependence of the diode response 
on temperature, dose-rate and accumulated dose. In addition, the dose-rate and 
temperature dependence change as the diode accumulates dose15. Due to the 
presence of a metallic build-up cap on the diode, the detector is energy dependent, 
and the sensitivity of the diode changes as a result of changes in source-surface-
distance (SSD), collimator size, and the presence of a wedge or tray16. To obtain 
accurate correction factors, an extensive series of phantom measurements is 
necessary. In contrast to diodes, MOSFETs have no dependence on dose-rate6 and do 
not show a sensitivity variation with accumulated dose3. Thereby, the MOSFET 
response of the single MOSFET dosimeter shows less dependence on temperature 
than the diode3. For the Linear 5ive MOSFET array, however, a temperature 
dependence of 11% was demonstrated by our group when increasing the temperature 
from room temperature to body temperature, which is higher than for diodes. The life-
time of the MOSFET detector is limited, compared to the life-time of diodes and TLDs. 
The extent of the MOSFET life-time depends on the sensitivity of the detector and the 
bias voltage used. Using standard MOSFET sensitivity and bias voltage, the detector’s 
sensitivity is about 1mV/cGy in photon beams and the life-time is about 200 Gy. The 
use of high sensitivity MOSFETs in combination with high sensitivity bias, results in a 
sensitivity of 9 mV/cGy in photon beams, which reduces the life-time of the detector to 
about 70 Gy. These high sensitivity settings are however especially useful for 
measurements of small dose values (1-20 cGy) and for these dose values the number 
of measurements during the life time of the detector is quite reasonable. Thereby, the 
sensitivity differences for non-reference conditions between MOSFET detectors of a 
certain batch is within the intrinsic precision of the detector3. As a result the life-time of 
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a new MOSFET is only reduced by the calibration of the detector; no additional 
phantom measurements for correction factor determination are required. A schematic 
overview comparing advantages and disadvantages of (micro) MOSFET, diode and 
TLD is given in table 1.The choice of a radiotherapy department for a point dosimeter 
suitable for in vivo dose measurements depends on the goal of the in vivo dose 
measurement protocol. When strict tolerance levels are important, diodes are suitable, 
however require a larger workload at the initial phase of its use. When tolerance levels 
are less strict, e.g, when there is a lack of staff, MOSFET detectors will be superior, 
because of the simplicity of the system and the less extensive procedure to implement 
the detector in clinical practice.  
 Table 1: Schematic comparison of properties of (micro) MOSFET, diode and TLD.  
Dosimeter advantages disadvantages
small sensitive volume limited life-time
small physical size limited intrinsic presicion
real time dose information
simple dose read-out
neglectible beam pertubation
lack of correction factors
energy independent
Diode high intrinsic presicion energy dependent
high sensitivity temperature dependence
real time dose information dose-rate dependence
simple dose read-out dependence of response on 
accumulated dose
sensitivity changes as a result of 
changes in source-surface-distance 
(SSD), collimator size, and the presence 
of a wedge or tray
special care needed to ensure constancy 
of response
TLD desired shape and size no real time dose information
cheap time consuming procedure for dose read-
out
neglectible beam pertubation limited intrinsic presicion
shape and size is variable signal erased during readout
extended life-time easy to lose reading
many TLDs can be exposed in single 
exposure
accurate results require care
(micro) MOSFET
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Besides the use of point dosimeters, the interest in using Electronic Portal Imaging 
Devices (EPIDs) for in vivo dose measurements is increasing over the last years. 
EPIDs measure transit dose values, which can be correlated to the dose at a point in a 
patient. With such a system 2D and even 3D dose information can be obtained17. 
Because of this large amount of dose information, EPIDs have advantages compared 
to point dosimeters for use as in vivo dosimetry dosimeter in photon beams. For 
electron beam radiotherapy, brachytherapy or special photon beam treatment 
techniques, such as extended field radiotherapy (e.g. TBI) the use of EPIDs is limited. 
In techniques applying adjacent fields, EPID dosimetry can give a lot of dose 
information; however special software is necessary for adding the dose values of the 
separate beams accurately. Furthermore, the electronic system along the edges of the 
EPID is sensitive to radiation. Exposure of this frame to the direct radiation beam 
should therefore be avoided. This means that for beams having large field sizes, 
beams at extended distance or very asymmetric beams, EPID dosimetry is not 
possible. To our experience, about 13 % of the treatment fields cannot be imaged as a 
result of this aspect. MOSFET dosimeters have proven to be suitable detectors under 
these circumstances18-20. In the MAASTRO CLINIC, MOSFET entrance dosimetry is 
performed in the situations where EPI dosimetry is not possible. Finally, MOSFETs are 
used as a backup system, when an EPID does not function correctly. Our protocol 
prescribes that the initial in vivo dose measurement should be performed within 5 
treatment fractions after the start of the treatment, and this procedure is repeated for 
sequential treatment plans (boost plans or changes in the initial plan). In this thesis, the 
use of MOSFET dosimeters for routine in vivo dosimetry during photon beam 
treatments was not described, because in our institution EPIDs are used for routine in 
vivo dosimetry in these beams.  
7.1.1 In vivo dosimetry as part of a routine QA programme 
An important aspect of a quality assurance programme is a check of the actual dose 
delivered to the patient. In vivo dose measurements permit data to be collected of the 
dose actually delivered at points of interest. This requires a convenient dosimeter and 
a methodology to allow accurate determination of the dose. Entrance dose 
measurements present important information about the beam output, the number of 
monitor units, the presence and direction of a wedge and limited information about the 
patient set-up, e.g. SSD. Exit dose measurements, additionally, give supplementary 
information about the size and density of the irradiated part of the patient’s body. The 
importance of QA in radiotherapy is generally accepted, due to the complexity and 
many steps involved in the radiotherapeutic process. However, the workload involved 
in developing and assessing an in vivo dosimetry programme, is often a problem for a 
radiotherapy department. The literature available on in vivo dosimetry mostly concerns 
its use during routine treatments using photon beams21-28. Literature based on in vivo 
dosimetry in electron beams is scarce29, 30.  
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In our institution we developed an in vivo dosimetry protocol using MOSFETs for all 
curative and elective photon and electron beam treatments. Due to the intensive use of 
MOSFETs for in vivo dosimetry purposes in our institution, special attention is therefore 
paid to making it easy to use in daily practice with an acceptable accuracy. The 
radiation therapy technologists perform the measurements and a user interface was 
developed in which the radiation therapy technologists have to type in some specific 
treatment data. This program automatically determines the deviation of the 
measurement as a percentage of the prescribed dose. In chapter 3 we described our 
in vivo dosimetry protocol for use in electron beams. In this procedure, entrance dose 
measurements are obtained. The presence of a build-up cap during entrance dose 
measurements in electron beams is not desirable because it results in a dose reduction 
beneath the detector. The effect of the cylindrical aluminum build-up cap surrounding 
diode detectors is described by Yaparpalvi et al.30 and Frye and Rustgi29. The first 
group demonstrated that the aluminum build-up cap surrounding the diode sensitive 
volume of a commercial diode causes significant dose reduction, most noticeable with 
smaller fields and lower energy beams. The reduction in dose ranged from 16% (for a 
6 MeV beam and a 3 cm diameter circular field) to 4% (for a 12 MeV beam and a 10 x 
10 cm field). These authors inferred that frequent use of diodes is undesirable when 
treating a small field by low energy electrons, because it might result in appreciable 
reduction of dose to the target volume. Frye and Rustgi reported similar results. In their 
protocol electron beam in vivo dosimetry using diodes, is only applied for initial 
verification of multiple fraction (N>3) treatments on fields with 0–25% of open field area 
custom blocking for cones 10 x 10 cm2 or greater. In this way they reduce the dose 
perturbation due to the diode to 5% or less of the total prescribed dose. Finally, 
readings outside the acceptable range or anomalous readings (patient motion, diode 
falls off, etc.) are flagged for repeat measurements on phantom material only; no in 
vivo repeats are permitted. In chapter 3 we described a method to reduce the 
shadowing effect of the electron beam by the build-up covering the detector. We 
converted the reading of a MOSFET detector placed on the patient’s skin without 
additional build-up material to the dose at the depth of dose maximum using predefined 
factors and demonstrated that this technique is well suited for routine dose verification 
in electron beams.  
7.1.2 In vivo dosimetry as a tool to validate a treatment technique 
The validation of a new treatment technique should encompass both phantom 
measurements and patient measurements when appropriate. Regarding phantom 
measurements, the basic step would be to measure dose distributions using simple, 
multipurpose phantoms. The next step would be to check dose distributions in more 
clinical relevant phantoms, such as anthropomorphic phantoms. Such an approach, i.e. 
from simple phantom measurements to more complex phantom configurations, 
simulates the overall accuracy of the new treatment procedure. Nevertheless, these 
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phantom measurements do not reflect by definition the total accuracy of patient 
treatment delivery, since the patient him/herself is excluded from the process. In order 
to assess the overall accuracy of a new treatment procedure at the patient level, 
patient dose verification is an essential and complementary part of the validation 
procedure of a new treatment technique. In practice, however, the use of in vivo 
dosimetry to validate a treatment technique in clinical practice is uncommon in most 
radiotherapy centres.  
In chapter 2 the validation of a junction field technique in daily clinical practice is 
described after the initial validation of each separate treatment step and linear 
accelerator performance related factors. In theory, junction of fields using a half-beam 
method is ideal, because there is no divergence of the beam edge at the split line. In 
practice however, as demonstrated in this study, significant dose variation at the 
junction can occur due to small uncertainties in the positioning of the jaws at the 
position of the central beam axis. A 10% deviation of the dose value around the 50% 
point on a beam profile is related to a misalignment of 1 mm at a SSD of 100 cm for 
one block or 0.5 mm per jaw when the deviation for both jaws is in the opposite 
direction. Our linac QA programme is, with respect to the accuracy of the jaw position 
along the split line, performed using film dosimetry and more recently using EPID 
dosimetry. A deviation less than 10% at the junction line is accepted. This linear 
accelerator related tolerance combined with patient movements during the treatment, 
sometimes resulted in large dose discrepancies along the split line. The in vivo 
measurements also demonstrated that the under- and overdosage that arises in the 
split line area, average out during a series of fractionated treatments. Attention has to 
be paid when only a small number of treatment fractions are prescribed, because dose 
deviations along the split line may then not average out. To be aware of these 
uncertainties, in vivo dosimetry is indispensable.  
In vivo dose information gives the opportunity to improve a specific treatment 
technique. Thanks to our in vivo dosimetry results and the detected dose deviations, 
we optimized our dose calculation procedure for TBI treatments from a point dose 
calculation without using a TPS, to a 3D dose calculation using our commercial TPS, 
as described in chapter 4. The use of a 3D planning system provides us with dose 
information over all regions of interest thus allowing a reduction of the dose in the 
extremities by using a simple MLC technique, or by using compensators specific for an 
individual patient. The use of a multileaf collimator is a good tool to improve dose 
homogeneity in the patient’s body, as demonstrated in this thesis. It has, however, not 
yet been implemented in clinical practice due to the lack of a digital transfer system 
converting TPS parameters to treatment parameters of the accelerator. Such a digital 
transfer system is important because in the TPS, the SSD can virtually be extended to 
400 cm while the patient is at the centre of the 2 opposed beams. In clinical practice, 
the extended source midline distance of 400 cm is achieved by positioning the gantry 
at a fixed location at 274°, and positioning the couch alongside the treatment room 
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wall. Parallel opposed beams are achieved by switching the patient’s position between 
the two fields. As a result, gantry angles and collimator angles are converted from TPS 
parameters to treatment parameters. In case of a segmented technique using the MLC 
as a compensator, converting the gantry and collimator angles of both segmented and 
open fields from treatment planning parameters to the treatment parameters, is error 
prone. Using a digital transfer system will prevent possible misinterpretation of these 
data. Patient treatments calculated using this 3D planning technique were evaluated in 
clinical practice using in vivo dosimetry. 
7.1.3 In vivo dosimetry to check the dose in organs at risk 
In addition to disease free survival, quality of life is an important outcome of a 
radiotherapy treatment in patients having cancer. Quality of life is related to the dose in 
normal tissues and particularly in OARs. The aim of the treatment planning process is 
to restrict the dose in these organs. In practice, however, there are several factors that 
effect the planned dose in the OAR. Deviations between plannend and actual dose 
values may originate from uncertainties in the delineation of the OAR on the CT 
images, in the dose calculation, in accelerator performance related factors, and in 
patient positioning. Verification of both the geometry and dose distribution is needed to 
prevent the patient from errors that may result in exceeding the tolerance dose of the 
OAR.  
In chapters 5 and 6 we demonstrated the suitability of a technique to validate the dose 
in the urethra, the organ at risk during brachytherapy of permanent prostate implants, 
using 125I seeds. In practice, however, in vivo dosimetry in brachytherapy is not easy to 
perform, due to the high dose gradients involved and the necessity of performing 
measurements inside a patient. We described a method for dose verification in a 
catheter, correcting the in vivo dose values for catheter absorption and temperature 
dependence. In vivo dose measurements performed directly after the implantation give 
the ability to check the treatment procedure and trace systematic errors in the 
treatment chain including the dose calculation performed by the TPS. This information 
can be used to improve the treatment technique and treatment procedure. The in vivo 
results can not be used for adaptation of the treatment plan of a particular patient, 
because the measurements are performed after the implantation of the seeds. 
Constant monitoring the dose-rate during the implantation, however, gives the 
opportunity to adapt the treatment plan when the dose in the urethra will be too high 
and prevents the patient from having urinary side effects caused by too high absorbed 
doses in this organ at risk. By continuing the measurements for a short period directly 
after the implantation of the last seeds, the final dose rate after the implantation is also 
obtained and these in vivo dose values can next be used for evaluation of systematic 
results. This means that constant dose monitoring during and directly after the 
implantation gives the ability to evaluate and adapt the treatment plan for a particular 
patient, and additionally can be used to check and improve the treatment technique 
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and procedure. In addition to the use of in vivo dosimetry after TIPPB, this approach 
can also be used for other brachytherapy techniques, such as HDR brachytherapy of 
prostate cancer or other cancer sites.  
7.2. FUTURE PERSPECTIVES  
Data obtained using in vivo dosimetry are evaluated by comparing measured dose 
values to data calculated by the TPS. For an accurate comparison, it is important that 
the location of the in vivo dose measurement point is in agreement with its location in 
the TPS. In practice however, this is not always easy to achieve. In case of 
conventional external beams, the detector will generally be placed on the central axis 
of the beam. In the TPS this point is also easy to find. In case of half beams or fields 
where one or more collimator shields the central beam axis, this is more difficult. 
Deviations in the location of the point where the dose is calculated and measured may 
result in false-positive errors. This will be the case when fields having large dose 
gradients are applied, for instance when wedged fields, oblique incident beams, 
irregular surfaces or brachytherapy treatments are used. To reduce these false-positive 
errors in TBI treatments, our protocol describes that the locations of these points for in 
vivo dose measurements are carefully chosen in the treatment preparation phase. 
During the virtual simulation CT-procedure, marks are placed in pre-defined areas on 
the patient’s skin. These marks are visible both during treatment planning and during 
the actual treatment. In conventional external beam radiotherapy, however, field 
positions, sizes and gantry angles are determined during treatment planning and 
information about the measurement location is not provided during the CT-based 
virtual simulation procedure. In these situations additional information about the 
location where the in vivo dose measurement is performed is important. For external 
beams, this can be achieved by using additional images obtained during the actual 
treatment fraction, to visualize the detector in the beam. Loading these images into the 
TPS will allow determining the dose at the exact detector location. In this way a 
separation between errors due to detector positioning inaccuracies and actual dose 
errors can be separated and the number of false-positive errors can be reduced. An 
example of this method is using a cone-beam CT scan made just before the actual 
treatment fraction with the detector positioned at the measuring position. Such a cone-
beam CT scan can be used for patient setup verification, but also provides, when 
loaded into the TPS, useful information about the dosimeter position in the actual 
treatment plan and the calculated dose at this position. To visualize a MOSFET 
detector on the images, an additional marker will be necessary for electron beams. In 
photon beams our MOSFET detectors are visible, due to the build-up cap on the 
detector. Besides the use of cone-beam CT for patient and dosimeter position 
verification, it can be used for dose calculation. The cone-beam information, loaded 
into the treatment planning system, gives the ability to calculate the actual absorbed 
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dose in a treatment fraction with the patient in treatment position. Repeating this 
procedure for each treatment fraction gives information about the actual dose 
accumulated over the entire treatment provided the TPS has the ability to add dose 
distributions of single treatment fractions. However, one should be aware of the extra 
dose given with cone beam CT. A careful balance should be made between the 
additional dose given by one or a series of cone-beam CT scans and the additional 
information, according to the ALARA principle.    
Additional imaging to visualize the detector will also be important for in vivo dose 
measurements during brachytherapy treatments, where the detector is placed in a 
catheter or needle in a patient. Due to the large dose gradients involved, knowledge of 
the exact position of the detector in the catheter or needle is important to allow a 
meaningful comparison to the dose calculation performed by the TPS. MOSFET 
detectors are however not visible on CT- and ultrasound images. In the studies 
described in this thesis we therefore used a dummy array, having markers close to 
each MOSFET, to visualize the MOSFET position during imaging. For the in vivo dose 
measurements these markers would affect the dose distribution. Therefore during the 
in vivo measurements the linear array was used having the disadvantage of introducing 
differences in the actual position of the linear array compared to the position of the 
dummy array in the catheter. A position tracking device might be useful for linking 
dosimeter position and dose values. This year (2009), Best Medical (Ottawa, Canada) 
will introduce the RADPOS system. This system will make it possible to link the 
position of the MOSFET detector in or on the patient to measured in vivo dose values. 
The dosimetry system is connected with a position-tracking device, having the 
possibility of accurately and real-time deriving the sensor position and orientation. The 
advantage of this system compared to imaging is the lack of administering additional 
dose to the patient’s body. Especially when repeated measurements are performed 
this will be an important issue. Movements of the patient during the treatment, which 
affect the dose measurement, will be visible using this system. This is not the case 
when using imaging to locate the detector position before the actual treatment, 
because changes in position that may occur after the imaging process will not be 
visualized. On the other hand, a patient tracking system should be compatible with the 
TPS in order to link dose values and dosimeter position in the treatment room to 
coordinates in the TPS. A high geometric accuracy of such a system is therefore a 
prerequisite for its clinical use.   
In this study in vivo dosimetry was used to check the entrance dose in vivo in seperate 
radiation beams. It would, however, also be of interest to check the dose in the target 
area itself. If entrance dose measurements alone are applied, this means that the 
entrance dose has to be converted to the corresponding target dose, using patient and 
treatment set-up information. A combination of entrance and exit dose measurements 
is a more accurate way of obtaining the target dose. Various methods are available to 
obtain the midline dose from entrance and exit dose values. These methods give 
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generally good results when the patient is considered to be homogeneous, but in the 
presence of tissue inhomogeneities considerable deviations may occur. Positional 
shifts of these inhomogeneous tissue areas, located between the entrance point of the 
beam and the target area, will influence the dose in the target. Entrance in vivo 
dosimetry alone is not able to detect these errors. To determine the dose in the target 
area, exit dose information is needed in addition to the entrance dose data. This exit 
dose information can be obtained using a second point dosimeter; however, also a 
combination of entrance point dosimetry and transit EPID dosimetry is a method 
potentially suitable for this purpose. For an accurate dose determination in the target 
area, tissue density data of the patient during the actual treatment fraction is essential. 
This data can be obtained by using the EPID information or by performing an additional 
cone-beam CT scan just before the fraction in which the dose measurement is 
performed.   
In this study in vivo dose values were compared to calculated dose values thus yielding 
an opportunity to prevent errors in the treatment process. In vivo dosimetry, however, 
is also useful to link dose values to clinical outcome. Collecting systematic dose data 
provides us with a large amount of dose information for the different treatment sites. 
The follow-up procedure of the patients after the actual treatment allows us to establish 
clinical outcome, side effects and quality of life, which gives us the ability to link 
absorbed dose data to clinical outcome for each treatment site and treatment 
technique. This information is essential to improve current radiotherapy treatments and 
for future developments in radiotherapy. 
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IN VIVO DOSIMETRY IN RADIOTHERAPY  
In this thesis, an overview is provided of MOSFET applications in various fields of 
radiotherapy. The pilot studies described in this thesis resulted in the implementation of 
in vivo dosimetry in routine clinical practice. The various steps in this process starting 
with the calibration of the detector, the phantom measurements to test the procedure 
and finally the patient measurements were described for a wide range of applications in 
both internal and external beam radiotherapy.  
In vivo dosimetry as part of a routine quality assurance PROGRAMME 
In chapter 3 we describe the use of MOSFET dosimeters for entrance in vivo dose 
verification in electron beams. The goal of this study was to design a method for 
routine entrance in vivo dose verification, without build-up material on the detector, to 
prevent the target volume from shadowing effects of the build-up material. In this 
procedure, we convert surface readings of the detector to absolute dose values at 
depth of dose maximum, using conversion factors obtained by a comprehensive set of 
phantom measurements. In this procedure the MOSFET reading, converted to dose at 
depth of dose maximum, was compared to the dose prescribed at this depth. An 
additional correction for the distance between the surface and the applicator, a 
correction for fields having sides smaller than 6 cm and for irregular field shape is 
recommended in this procedure for accurate dose determination. The procedure was 
tested in clinical practice for 40 patients, mostly treated for breast tumours. The results 
demonstrated deviations from the prescribed dose with a mean difference of -0.7% and 
a standard deviation of 2.9%. From this study it can be concluded that performing dose 
measurements with MOSFET detectors placed on the patient’s skin without additional 
build-up is a well suited technique for routine dose verification in electron beams if 
appropriate conversion and correction factors are applied. 
 In vivo dosimetry as a tool to validate a new treatment technique 
In chapters 2 and 4 results are presented of studies of in vivo dose measurements to 
validate a new treatment technique in clinical practice.  
The first goal of the study described in chapter 2 was to determine the accuracy of 
MOSFET measurements for dose determinations in a junction field technique using 
half beams. The second goal was to evaluate the dose distribution across the split line 
using MOSFET dosimeters. The results obtained from a comprehensive set of 
phantom measurements using MOSFET detectors, were compared to the results of 
ionisation chamber and photographic film measurements. Next, the influence of factors 
related to the mechanical properties and QA procedures of the linear accelerator were 
discussed. These results were used to evaluate patient measurements, where the 
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accuracy of the junction was determined on 5 patients receiving loco-regional 
treatment of breast cancer during 10 treatment fractions. From this study we 
concluded:  
(1) significant dose deviations in the junction area average out over repeated 
treatments;  
(2) a single measurement in the junction area should not lead to any action;  
(3) the linac QA procedure to check the dose at the junction line should simulate the 
clinical situation as much as possible;  
(4) MOSFET dosimeters overestimate dose values in the penumbra region. 
In the study described in chapter 4, in vivo dosimetry was used to verify a new 3-
dimensional (3D)-dose calculation procedure of our Total Body Irradiation (TBI) 
technique. To obtain relevant dose calculation information, a total body CT scan was 
performed and loaded into our commercial Treatment Planning System (TPS). A 3D-
dose distribution was generated, after the initial validation of this TPS for extended 
distance radiotherapy. To verify the new procedure in the clinic, in vivo dosimetry was 
performed for 5 patients, at five locations on the patient’s body. Entrance and exit dose 
values were converted to midline doses, using conversion factors previously 
determined with phantom measurements. These measurements demonstrated that 
MOSFET and TLD dose values agreed within 3.0%, and MOSFET and TPS data even 
within 0.5%. The convolution algorithm of the TPS, which is routinely applied in the 
clinic, overestimated the dose in the lung region. Using a superposition algorithm 
reduced the calculated lung dose with approximately 3%. The dose inhomogeneity 
predicted by the TPS can be reduced by using a simple IMRT technique. From this 
chapter, we conclude that:  
(1) using a TPS for dose calculation of TBI gives good insight in over- and under-
dosage in the patient and the influence of patient positioning on dose 
homogeneity;  
(2) MOSFETs are suitable dosimeters for in vivo dosimetry purposes during TBI if 
appropriate conversion factors are applied.  
 In vivo dosimetry to check the dose in organs at risk 
In chapters 5 and 6 the application of MOSFET dosimeters for dose verification in 
organs at risk during brachytherapy is described. 
In chapter 5 results are presented of a study of a new linear 5-MOSFET-array 
dosimeter for in vivo dose verification of permanent prostate implants using 125I. 
Phantom measurements were carried out to validate the measurement technique, to 
determine the measurement accuracy and to define action levels for clinical 
measurements. Patient measurements were performed directly after the implantation 
procedure. A MOSFET-array was placed in the urinary catheter, in order to provide 
useful information about the actual dose in the urethra, to evaluate the implantation 
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technique, to evaluate the accuracy of the TPS and to link dose distributions in OARs 
to clinical side effects. A CT-scan was made and dose values, calculated by the 
treatment planning system, were compared to in vivo dose values measured with 
MOSFET-dosimeters. The in vivo results were corrected for temperature dependence 
of the MOSFET-array response and photon attenuation in the catheter. In vivo dose 
values were obtained for 17 patients. In the high dose region (>100 Gy) calculated and 
measured dose values agreed within 1.7 % ±10.7 % (1SD). In the low dose region 
outside the prostate (<100 Gy) larger deviations occurred. From this study, we 
concluded that MOSFET-detectors are suitable for in vivo dosimetry during 
brachytherapy of prostate cancer using 125I. An action level of ±16 % (2 SD) for 
detection of errors in the implantation procedure is achievable after validation of the 
detector system and measurement conditions. 
The goal of the study described in chapter 6 was to investigate the feasibility of a 
linear-MOSFET-array for real-time dosimetry during permanent prostate 
brachytherapy, to check the complete treatment chain and to prevent patients from 
getting urinary complications as a consequence of too high doses in this organ at risk. 
The results of phantom measurements, described in chapter 5, were used for this 
study. Additional phantom measurements were performed to determine the optimal 
conditions for clinical measurements. An overall validation of the measurement method 
was performed with a simulation of clinical practice in a phantom. Real-time 
measurements were performed for 5 patients during the implant. To evaluate if the 
real-time urethra dose with the ultrasound transducer in the rectum and the patient in 
treatment position is a reference for the total accumulated dose, additional 
measurements were performed in the recovery. Real-time measurements and 
measurements performed in the recovery agreed very well, illustrating that the 
ultrasound transducer in the rectum and patient positioning do not influence the dose in 
the urethra. Real-time in vivo dose values obtained during the implantation are 
therefore representative for the total accumulated dose in the urethra at these 
positions. For the 5 patients the dose-rates during and after the implantation were 
below the maximum tolerable dose-rate of the urethra and adaptation of the planned 
seed distribution was therefore not necessary. The conclusion of the study presented 
in this chapter is that real-time dosimetry using a MOSFET–array is a promising 
technique to evaluate the dose in the urethra during the implantation of using 125I seeds 
for prostate irradiation.   
Finally, chapter 7 gives general conclusions that can be derived from this thesis and a 
broad discussion of the results from our studies with regard to the use of in vivo 
dosimetry in radiotherapy. Furthermore future perspectives are provided.  
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IN VIVO DOSIMETRIE BIJ RADIOTHERAPIE  
In dit proefschrift wordt een overzicht gegeven van de mogelijkheden van in vivo 
dosisverificatie met MOSFET dosimeters op het brede toepassingsgebied van de 
radiotherapie. Verschillende pilot-studies, beschreven in dit proefschrift, hebben 
geresulteerd in routinematige uitvoering van in vivo dosimetrie in de klinische praktijk. 
De verschillende stappen in het acceptatie- en implementatieproces van een nieuwe 
dosimeter, met als doel geprotocolleerde in vivo dosimetrie in de dagelijkse praktijk, 
worden in dit proefschrift beschreven voor een breed scala aan toepassingen voor 
zowel inwendige als uitwendige radiotherapie. Kort samengevat bestaat dit proces uit 
het kalibreren van de detector, het verrichten van fantoommetingen voor het testen van 
het meetinstrument, het vaststellen van de procedure voor het verrichten van 
patiëntmetingen en het testen van deze procedure bij een geselecteerde 
patiëntengroep.  
 In vivo dosimetrie als onderdeel van een kwaliteitsborgingprogramma 
In hoofdstuk 3 beschrijven we het gebruik van MOSFET stralingsmeters voor intrede 
in vivo dosisverificatie bij elektronenbundels. Het doel van deze studie was het 
ontwerpen van een methode voor routinematige in vivo dosisverificatie bij 
elektronenbundels, zonder gebruik te maken van opbouwmateriaal op de detector. Dit 
om dosisreductie achter het opbouwmateriaal te voorkomen. In de procedure, 
beschreven in dit hoofdstuk, werden dosismetingen aan het oppervlak met behulp van 
omrekeningsfactoren omgezet naar absolute dosiswaarden op de diepte van het 
dosismaximum. Deze omrekeningsfactoren werden verkregen door een uitgebreide 
reeks van fantoommetingen. De MOSFET-waarneming, omgerekend naar dosis op 
diepte van het dosismaximum, werd vervolgens vergeleken met de voorgeschreven 
dosis op deze diepte. Een correctie voor de afstand tussen het oppervlak en de 
applicator, een correctie voor kleine velden met zijden kleiner dan 6 cm en een 
correctie voor onregelmatige veldvorm, worden aanbevolen in deze procedure voor 
een nauwkeurige dosisbepaling. De procedure werd getest in de klinische praktijk voor 
40 patiënten, voornamelijk patiënten die werden behandeld voor borstkanker. De 
resultaten toonden een gemiddeld verschil van -0,7% en een standaarddeviatie van 
2,9% ten opzichte van de voorgeschreven dosis. Uit deze studie kan worden 
geconcludeerd dat het uitvoeren van dosismetingen met MOSFET-detectoren, 
geplaatst op de huid van de patiënt zonder extra opbouwmateriaal op de detector, een 
geschikte techniek is voor routine dosisverificatie bij elektronenbundels, mits 
nauwkeurige conversie en correctiefactoren worden toegepast.  
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In vivo dosimetrie als instrument voor het valideren van een nieuwe 
behandelingstechniek 
In de hoofdstukken 2 en 4 worden de resultaten van studies gepresenteerd waarbij in 
vivo dosimetrie wordt toegepast voor het valideren van een nieuwe 
behandelingstechniek.  
Het primaire doel van de studie beschreven in hoofdstuk 2 was het vaststellen van de 
nauwkeurigheid van MOSFET-metingen voor dosisverificatie in de regio waar twee 
halve bundels op elkaar aangesloten worden. Het uiteindelijke doel was om de 
dosisverdeling over het aansluitgebied te verifiëren met behulp MOSFET-
stralingsmeters. De MOSFET-resultaten bij een uitgebreide reeks van 
fantoommetingen, werden vergeleken met de resultaten van ionisatiekamerdetectoren 
en fotografische filmmetingen. In dit hoofdstuk wordt tevens de invloed van factoren in 
verband met de mechanische eigenschappen en QA-procedures van de lineaire 
versneller besproken. Deze informatie werd gebruikt voor het evalueren van de 
meetresultaten bij een groep van 5 patiënten. Deze patiënten ondergingen een loco-
regionale radiotherapie behandeling, waarbij met behulp van een halve bundeltechniek 
zowel het borstweefsel als de axillaire/supraclaviculaire klieren bestraald werden. 
Gedurende 10 behandelfracties werden MOSFET metingen verricht om de 
nauwkeurigheid van de dosis in het aansluitgebied van de bundels te bepalen. De 
conclusies van deze studie luiden:  
(1) significante dosisafwijkingen in het aansluitgebied middelen zich uit over 
herhaalde behandelingsfracties  
(2) een enkele meting in het aansluitgebied mag nooit leiden tot een actie  
(3) de linac QA procedure om de nauwkeurigheid van de aansluiting te bepalen moet 
de klinische situatie zoveel mogelijk benaderen  
(4) MOSFET stralingsmeters overschatten de dosiswaarden in het halfschaduw 
gebied.  
In hoofdstuk 4 wordt in vivo dosimetrie toegepast om een nieuwe driedimensionale 
(3D)-dosisberekeningstechniek voor een totale lichaamsbestralingtechniek (TBI), te 
verifiëren en te controleren. Voor het verkrijgen van relevante 
dosisberekeningsinformatie, werd bij de patiënten in deze studie een totale lichaam 
CT-scan gemaakt. De beeldinformatie werd geladen in een commerciëel Treatment 
Planning System (TPS), nadat dit systeem eerst gevalideerd was voor lange afstand 
radiotherapie. Een 3D-dosisverdeling werd daarbij gegenereerd. In vivo dosimetrie 
werd verricht bij 5 patiënten, op vijf locaties op het lichaam van de patiënt met zowel 
MOSFET als TL-detectoren. Intrede- en uittrede dosiswaarden werden omgerekend 
naar dosiswaarden midden in de patiënt, waarbij gebruik werd gemaakt van 
omrekeningsfactoren. Deze omrekeningsfactoren werden vastgesteld door middel van 
een uitgebreide set fantoommetingen. MOSFET en TLD dosiswaarden komen binnen 
3,0% overeen. MOSFET en TPS dosiswaarden komen binnen 0,5% overeen. Het 
convolutie-algoritme van het TPS, dat routinematig wordt toegepast in de kliniek, 
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overschat de dosis in de longregio. Met behulp van een superpositie algoritme wordt 
de longdosis nauwkeuriger benaderd. De dosisinhomogeniteiten in het lichaam van de 
patiënt, zoals berekent met behulp van het TPS, kunnen worden verminderd door 
gebruik te maken van een eenvoudige IMRT-techniek. Uit dit hoofdstuk concluderen 
we dat:  
(1) het gebruik van een TPS voor dosisberekening bij TBI een goed inzicht geeft in de 
over- en onderdoseringen in de patiënt en inzicht geeft in de invloed van 
patiëntpositionering op dosishomogeniteit  
(2) MOSFET stralingsmeters zijn geschikt voor in vivo dosimetrie doeleinden tijdens 
TBI. 
In vivo dosimetrie als instrument om de dosis in risico organen te bepalen 
In de hoofdstukken 5 en 6, wordt de toepassing van MOSFET stralingsmeters voor 
dosisverificatie in risico organen beschreven.  
In hoofdstuk 5 worden de resultaten van een studie gepresenteerd waarbij een 
nieuwe lineaire 5-MOSFET array-dosimeter toegepast wordt voor in vivo 
dosisverificatie bij permanente prostaatimplantaten met jodium-125 zaadjes. 
Fantoommetingen werden verricht voor het valideren van de meettechniek, voor het 
bepalen van de meetnauwkeurigheid en voor het testen van de detector voor de 
klinische metingen. Patiëntmetingen werden verricht bij 17 patiënten in de recovery, 
direct na de implantatieprocedure. Een MOSFET-array werd in de urinekatheter 
geplaatst, met als doel het verifiëren van de actuele dosis in de urineleider. Deze 
informatie werd gebruikt voor het evalueren van de implantatietechniek en het 
beoordelen van het TPS. Informatie over de ureterdosis geeft bovendien de 
mogelijkheid om actuele dosisinformatie te koppelen aan klinische bijwerkingen. Na de 
in vivo metingen werd een CT-scan gemaakt. Dosiswaarden berekend door het TPS 
op basis van de post-implant CT-scan, werden vergeleken met de in vivo 
dosiswaarden gemeten met de MOSFET-stralingsmeters, na correctie van de in vivo 
resultaten voor de temperatuursafhankelijkheid van de MOSFET-array respons en voor 
absorptie van de katheterwand. In het hoge dosisgebied (> 100 Gy) komen berekende 
en gemeten dosis binnen 1,7% ± 10,7% (1SD) overeen. In het lage dosisgebied (<100 
Gy), de regio buiten de prostaat, werden grotere afwijkingen gemeten. Uit deze studie 
hebben we geconcludeerd dat MOSFET-detectoren geschikt zijn voor in vivo 
dosimetrie na brachytherapie met jodium-125 bij prostaatkanker. Een actielevel van ± 
16% (2 SD) voor het opsporen van fouten in de implantatieprocedure is haalbaar na 
validatie van de detector en meetomstandigheden. In het hoge dosisgebied zijn 
kleinere actielevels haalbaar. 
In hoofdstuk 6 word het gebruik van een lineair-MOSFET-array getest voor real-time 
dosimetrie tijdens brachytherapie van de prostaat. Het primaire doel van de real-time 
metingen gedurende de implantatie van de jodium-125 zaadjes, is het verifiëren van de 
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dosis in de urineleider. Dit geeft de mogelijkheid de verdeling van de zaadjes aan te 
passen op basis van de in vivo meetresultaten met als doel te hoge stralingsdoses en 
urinaire complicaties te voorkomen. Het secundaire doel is het controleren van de 
behandelketen en de implantatietechniek. De resultaten van fantoommetingen, 
beschreven in hoofdstuk 5, werden gebruikt voor deze studie. Aanvullende 
fantoommetingen werden verricht om de optimale omstandigheden voor de klinische 
metingen vast te stellen. Tevens werd een simulatiemeting verricht om de klinische 
praktijk na te bootsen. Real-time metingen werden verricht bij 5 patiënten in de 
operatiekamer tijdens de implantatie van de zaadjes. Om te beoordelen of de real-time 
dosis in de urineleider, met de echografie-transducer in de endeldarm en de patiënt in 
behandelpositie, een referentie is voor de totale cumulatieve dosis in de urineleider, 
werden aanvullende metingen verricht in de recovery. Real-time metingen en metingen 
verricht in de recovery kwamen goed overeen, hetgeen illustreert dat de echografie-
transducer in het rectum en positionering van de patiënt geen aantoonbare invloed 
hebben op de dosis in de urineleider. Real-time in vivo dosiswaarden verkregen tijdens 
de implantatie, zijn dus representatief voor de totale cumulatieve dosis in de urineleider 
op deze posities. Voor alle 5 patiënten bleken de dosis-waarden tijdens en na de 
implantatie lager dan de maximaal toelaatbare dosiswaarde van de urineleider. 
Aanpassing van de geplande zaadverdeling in de prostaat was derhalve niet nodig. De 
conclusie van deze studie is dat real-time dosimetrie met behulp van een MOSFET-
array een veelbelovende techniek is voor de evaluatie van de dosis in de urineleider 
tijdens de implantatie van jodium-125 zaadjes bij prostaat bestraling.  
Tenslotte geeft hoofdstuk 7 de algemene conclusies weer die kunnen worden afgeleid 
uit dit proefschrift. Er wordt een uitgebreid overzicht gegeven van de resultaten van de 
studies beschreven in dit proefschrift en het gebruik van in vivo dosimetrie in de 
radiotherapie. Bovendien worden mogelijke toekomstperspectieven beschreven, 
waardoor in vivo dosisverificatie in de toekomst verbeterd kan worden. 
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DANKWOORD 
 
Het gevoel dat ik nu heb, bij het afronden van mijn proefschrift en het schrijven van dit 
dankwoord, is te vergelijken met gevoel van een bergbeklimmer die zojuist de top heeft 
bereikt. Bij het bereiken van deze top heb ik niet de meest voor de hand liggende route 
genomen. Nee, het was een route met verschillende omzwervingen via landweggetjes 
(opleidingen) en langs dorpjes (diverse functies). Echter, deze omzwervingen vormden 
geen verspilde tijd en moeite. Integendeel, ze resulteerden in een brede ervaring en 
een ruim blikveld. Deze ervaring heb ik goed kunnen gebruiken bij het beklimmen van 
de berg en het tot stand brengen van mijn uiteindelijke doel, het bereiken van de top 
ofwel het afronden van mijn proefschrift. Bovendien heeft het de reis een stuk 
aangenamer gemaakt. Op de top van de berg, sta ik nu na te genieten van alle 
ervaringen die ik de afgelopen jaren heb mogen opdoen, het geweldige uitzicht, maar 
vooral het triomfantelijke gevoel dat ik er, al is het dan via een alternatieve weg, 
gekomen ben. Nu ik echter boven aan de berg sta zie ik dat ik eigenlijk weer aan de 
voet van een volgende berg sta, een veel hogere berg. Het gevoel van triomf verdwijnt 
langzaam naar de achtergrond. Al snel maakt het gevoel van triomf echter plaats voor 
wilskracht. Wilskracht om mijn bergschoenen weer op te poetsen en verder te gaan, 
een nieuwe weg in te slaan in een poging ook deze tweede berg te bedwingen. Te 
kijken of ik ooit ook deze top zal bereiken of dat ik wellicht onderweg een aangename 
plek tegenkom waar ik een tijd blijf hangen…. 
Bij het beklimmen van deze berg heb ik vele mensen ontmoet die ik wil bedanken voor 
de mogelijkheden die ze me gegeven hebben de top te bereiken. Omdat het 
onmogelijk is om iedereen persoonlijk te vernoemen, wil ik starten om alle mensen te 
bedanken die direct maar ook indirect met mijn promotie te maken hebben gehad en 
die ik hieronder niet noem.  
Promotor, prof. Philippe Lambin en copromotoren dr. Ben Mijnheer en dr. ir. André 
Dekker wil ik bedanken voor hun bijdrage en ondersteuning bij mijn promotie. Beste 
Philippe, jij bent naast opdrachtgever tevens inspirator geweest voor het verrichten van 
in vivo dosimetrie in MAASTRO CLINIC. Dankzij jou kreeg ik de mogelijk me te gaan 
richten op onderzoek en iets te gaan doen met de opleiding waar ik op dat moment 
mee bezig was. Je enthousiasme was aanstekelijk en maakte dat ik net een stapje 
harder liep. Jij was ook degene die me stimuleerde uiteindelijk te gaan promoveren. Ik 
kan me nog precies herinneren wat je hierover zei: ” Het stelt niet zo veel voor, je 
publiceert 3 artikelen en schrijft een inleiding en samenvatting en klaar ben je….”. De 
berg bleek uiteindelijk iets hoger dan je in eerste instantie suggereerde, maar spijt van 
mijn keuze heb ik nooit gehad. Bedankt hiervoor.  
Beste Ben Mijnheer, waar jij ook was (en dat was regelmatig in het buitenland), je was 
altijd bereikbaar voor vragen en het lezen van een manuscript. Van de verschillende 
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coauteurs, betrokken bij de diverse publicaties, was jij steeds degene die het eerste 
reageerde op een manuscriptopzet. Je was altijd op een positieve manier kritisch. 
Maandelijks kwam je naar Maastricht voor overleg en evaluatie van mijn 
onderzoeksresultaten. Omdat ik je voor je bezoek de meest recente data wilde sturen, 
kreeg jij dus vaak pas de avond voordat je naar Maastricht af zou reizen een e-mail 
met de daarbij horende documenten. Je hebt je dus nooit hoeven vervelen in de trein 
op weg naar Maastricht ….  
André Dekker, gedurende mijn promotie ben jij als copromotor bij mijn onderzoek 
betrokken en heb je een deel van de begeleiding op je genomen. Tijdens de wekelijkse 
vergadering van de “Dose Guided Radiotherapy-groep” (DGRT-groep) waarin de 
onderzoeksresultaten van de verschillende onderzoekers besproken werden was je 
altijd goed in het stellen van kritische vragen en het meedenken naar oplossingen en 
resultaten. Bedankt voor deze kritische blik. De overige leden van de DGRT-groep, 
Wouter, Bas en Steven, ook jullie wil ik bedanken voor het meedenken in de 
verschillende fasen van het onderzoek en het brainstormen over de behaalde 
resultaten. 
Huub Backes, als hoofd para- en peri-medische groep en later innovatiemanager was 
jij er mede verantwoordelijk voor dat ik de mogelijkheid kreeg een Master opleiding te 
volgen naast mijn gewone werkzaamheden als radiotherapeutisch laborant. Deze 
studiejaren waren niet eenvoudig doordat ik tegelijkertijd naast een fulltime baan, 20 
uur in de week zelfstudie moest verrichten en ook nog eens samen met mijn partner 
het oude huis dat we gekocht hadden volledig moesten verbouwen. Maar Huub, jij hebt 
altijd het volste vertrouwen in me gehad dat ik deze studie binnen de geplande tijd en 
met voldoende resultaat zou afronden. Mijn dank hiervoor!  
Bij het afstuderen aan de Master opleiding bleek een van mijn begeleiders een 
bekende te zijn, Ria Korthoeve, Radiotherapeut Oncoloog en docent MBRT. Ria, jij 
noemde mij in je praatje tijdens de diploma uitreiking “een voorddaverende trein die 
direct door gaat naar het eindstation, zonder te stoppen voor de tussenliggende 
stations” en jij was degene die tijdens het begeleiden van mijn afstuderen begon over 
promoveren. Je vond dat wel iets voor mij. Dit was echter iets waar ik op dat moment 
zelf nog niet over nagedacht had. Maar wat wel in mijn hoofd bleef nasluimeren. De 
eerste belangstelling was gewekt. Ik slaagde binnen de benodigde tijd met een “Cum 
Laude” eindresultaat. Beste Ria, bedankt voor de prettige begeleiding tijdens mijn 
afstuderen, maar vooral voor het vertrouwen dat je me gaf ten aanzien van de 
toekomst. 
Wim DuBois was als Radiotherapeut Oncoloog bij MAASTRO CLINIC betrokken bij de 
opstartfase van het dosimetry project. Wim, samen met jou ben ik in andere instituten 
gaan kijken als oriëntatie op het project. Je had in je werkzaamheden zo je eigen 
werkwijze, maar je was wel degene die vaak bij me binnenliep om te vragen hoe de 
stand van zaken was en om me te ondersteunen. Tevens heb jij een belangrijke 
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bijdrage geleverd aan mijn eerste publicatie. Bedankt voor dit alles. Helaas, na relatief 
korte tijd verliet je MAASTRO CLINIC om elders aan de slag te gaan. Ik moest vanaf 
die tijd zonder jou verder. 
Ook Iaïn Bruinvis wil ik in deze niet vergeten. Iaïn, jij was destijds hoofd van de klinisch 
fysica groep, en hebt er aan bijgedragen dat ik van de “paramedische groep” 
(laborantengroep) naar de klinisch fysica groep ben “verhuist”, waardoor ik meer 
mogelijkheden had mezelf te ontwikkelen en mijn onderzoek verder uit te breiden. 
Tevens heb je een belangrijke bijdrage gehad aan mijn eerste publicatie. Echter, ook jij 
verliet na relatief korte tijd MAASTRO CLINIC. Je opvolger was André Minken, een 
klinisch fysicus die al in MAASTRO CLINIC werkte. André, jij en ik werkten al voor je 
aanstelling als hoofd Klinisch Fysica Groep regelmatig samen. Ik wil je bedanken voor 
je adviezen met betrekking tot het verrichten van de vele metingen die er gedaan 
moesten worden en je bijdrage aan één van de artikelen.  
Peter Visser, klinisch fysicus in MAASTRO CLINIC, bedankt voor je hulp bij het 
opzetten van “MosDos”, een database voor het verwerken en registreren van de in vivo 
meetresultaten. Lars Murrer, eveneens klinisch fysicus in MAASTRO CLINIC, jou wil ik 
bedanken voor je adviezen betreffende de metingen bij brachytherapy en je bijdrage 
aan mijn laatste publicaties. En natuurlijk ook voor het feit dat je mijn paranimf wil zijn! 
De klinisch fysisch medewerkers van MAASTRO CLINIC wil ik bedanken voor hun 
bijdrage bij het verrichten van de vele fantoommetingen voor het valideren van de 
MOSFET dosimeter. In het bijzonder wil ik Sem Krasuski bedanken. Sem, bedankt 
voor de fijne samenwerking rondom het onderzoek bij TBI en de vele kalibraties die je 
verricht hebt. Uiteraard wil ik ook de rest van de KFG-groep bedanken voor de fijne 
samenwerking en de gezellige uitstapjes. 
Tevens wil ik een aantal radiotherapeut-oncologen van MAASTRO CLINIC bedanken 
voor hun bijdrage aan dit proefschrift. Tom Verschueren, bedankt voor de 
samenwerking tijdens het TBI project. Je had het volste vertrouwen in de dosimetrie 
resultaten, die uiteindelijk hebben geleid tot de nieuwe berekeningsmethode. Francis 
van Gils en Ludy Lutgens, bedankt voor jullie medewerking tijdens de dosismetingen 
op de uitslaapafdeling en in de operatiekamer tijdens het inbrengen van de radio-
actieve zaadjes. Francis, jou in het bijzonder wil ik nog bedanken voor je bijdrage aan 
de laatste 2 artikelen. En niet te vergeten Jos Jager. Jos, als ik je tegen kwam in de 
gang maakte je altijd de grap dat je wel mijn paranimf wilde worden…. Nu is het dan 
bijna zover, ik kon het niet laten je echt te vragen.  
Ook de laboranten werkzaam bij MAASTRO CLINIC: bedankt voor het verrichten van 
de vele in vivo patiëntmetingen op de verschillende lineaire versnellers.  
Verder wil ik de studenten van de opleiding Biometrie die hebben meegeholpen aan 
mijn onderzoek bedanken voor hun bijdrage bij het verrichten van de metingen voor 
het onderzoek MOSFET dosimetrie bij brachy. Gerben Kaas, Raoul Daemen, Joost 
van Elk en Björk Haanstra, bedankt voor jullie goede inzet.  
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Cary Dehing-Oberye, statistisch analist in MAASTRO CLINIC, bedankt voor je 
adviezen in de beginfase van mijn onderzoek op het gebied van de statistische analyse 
van de resultaten.  
Het afronden van een proefschrift kost enorm veel tijd. Secretariële ondersteuning is 
hierbij onmisbaar. Rian, Simone en Sonia, mijn dank voor jullie bijdrage.  
De leden van de beoordelingscommissie, prof. Wildberger, prof. Heijmen, prof. 
Verhaegen en dr. Venselaar wil ik bedanken voor alle tijd die ze hebben gespendeerd 
aan het bestuderen en beoordelen van dit proefschrift.  
Abdelbasset Hallil, klinisch fysicus en “Director of Research & Development“ bij Best 
Medical, (Ottawa, Canada) het bedrijf waarvan Thomson and Nielsen, de fabrikant en 
ontwikkelaar van de in deze thesis toegepaste MOSFET systemen, een onderdeel is. 
Beste “Basset”, bedankt voor het verlenen van de dosimetertechnische informatie 
rondom de MOSFET dosimeters. Door deze informatie kon ik mijn 
onderzoeksresultaten voldoende onderbouwen.  
Tenslotte wil ik mijn ouders bedanken voor de goede steun gedurende mijn studie- en 
promotieperiode. Pap, mam, zonder jullie was ik nooit zo ver gekomen. Tevens wil ik 
mijn ouders en schoonouders bedanken voor de goede en liefdevolle opvang van mijn 
kinderen op dagen dat ik naar een cursus of congres moest of gewoon tijdens 
werkdagen. Met een geruster hart kon ik de kinderen niet achterlaten. 
Als laatste, lieve Eric, bedankt voor je steun en begrip tijdens mijn studie en 
promotieperiode. Je hebt nooit geklaagd als je er alleen voor stond met de kinderen of 
als ik naar een cursus of congres was. Lucas en Elise, jullie aanwezigheid maakte dat 
ik in drukke tijden het werk kon relativeren. Bedankt voor jullie steun.  
En tot slot, op de ruggen van Lady en Joy kon ik heerlijk ontspannen en al het werk 
van me laten afglijden…  
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CURRICULUM VITAE 
Esther Bloemen-van Gurp werd geboren op 30 maart 1970 te Deventer. Na anderhalf 
jaar verhuisde het gezin naar het Brabantse Oisterwijk, waar Esther het grootste deel 
van haar jeugd doorbracht. In 1989 voltooide zij haar HAVO diploma aan het 
Durendael College te Oisterwijk. Aansluitend startte zij het Hogere Laboratorium 
Onderwijs (HLO) aan de Hogeschool te Eindhoven. Na 1 jaar wisselde zij, op eigen 
initiatief, het Hogere Laboratorium Onderwijs in voor de nieuwe HBO opleiding 
“Medisch Beeldvormende en Radiotherapeutische Technieken” (MBRT), tevens aan de 
Hogeschool te Eindhoven. In 1994 behaalde ze haar Bachelorgraad. In oktober 1994 
kon ze beginnen bij het voormalig Radiotherapeutisch Instituut Limburg te Heerlen 
(tegenwoordig MAASTRO CLINIC te Maastricht), als radiotherapeutisch laborante. Het 
Brabantse landschap werd ingeruild voor de Limburgse heuvels. In 1999 startte ze 
naast haar werkzaamheden als radiotherapeutisch laborante, met de 2-jarige opleiding 
“Master of Arts in Health” aan de Hogeschool te Eindhoven. In 2001 werd de 
Mastergraad behaald met een cum laude resultaat. Mede dankzij deze studie kreeg 
Esther de mogelijkheid om zich binnen MAASTRO CLINIC verder te ontwikkelen op 
het gebied van onderzoek, met als aandachtsgebied in vivo dosimetrie met MOSFET 
dosimeters. Ze volgde de cursus ”Physics for clinical radiotherapy” te Leuven, de 
statistiekcursussen “Statistics part 1: introduction in clinical statistical methods” en 
“Statistics part 2: regression and variance analysis”, te Maastricht en de NVVO 
oncologie cursus ”Introduction to the clinical and fundamental Oncology”. Daarnaast 
behartigde Esther de belangen van de medewerkers van MAASTRO CLINIC, als 
voorzitter van de ondernemingsraad. In 2006 kwam aan deze nevenfunctie een einde, 
toen de onderzoeksfunctie omgezet werd naar een promotieplaats, met Prof. Philippe 
Lambin als promotor en Dr. Ben Mijnheer en Dr. Andre Dekker als co-promotor. In 
2008 werd haar inzet op het gebied van in vivo dosimetrie bij brachytherapy beloond 
met het behalen van een internationale award, de Jack Fowler award, uitgereikt tijdens 
de 27th Annual ESTRO meeting in Göteborg (Zweden). Op 1 april 2009, na het 
afronden van haar promotieonderzoek, is Esther gestart als post-doctoraal 
onderzoeker bij MAASTRO CLINIC met als onderwerp 3D ultrasound voor 
dosisgestuurde radiotherapie. Esther Bloemen-van Gurp is getrouwd met Eric Bloemen 
en heeft twee kinderen, Lucas en Elise. 
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PUBLICATIONS 
1. Bloemen-van Gurp E.J., du Bois W.F.J., Visser P.A., Bruinvis I., Jalink D., 
Hermans J. and Lambin P. Clinical dosimetry with MOSFET dosimeters to 
determine the dose along the field junction in a split beam technique. 
Radiotherapy and Oncology 67 (2003) 351–357. 
2. Bloemen-van Gurp E.J., Minken A.W.H., Mijnheer B.J., Dehing- Oberye C.J.G. 
and Lambin P. Clinical implementation of MOSFET detectors for dosimetry in 
electron beams. Radiotherapy and Oncology 80 (2006) 288–295. 
3. Bloemen-van Gurp E.J., Mijnheer B.J., Verschueren T.A.M.  and Lambin P. Total 
body irradiation, towards optimal individual delivery: dose evaluation with 
MOSFETs, TLDs and a treatment planning system. Int. J. Radiation Oncology 
Biol. Phys., Vol. 69, No. 4, pp. 1297–1304, 2007. 
4. Bloemen-van Gurp E.J., Murrer L.H.P., Haanstra B.K.C., van Gils F.C.J.M., 
Dekker A.L.A.J., Mijnheer B.J. and Lambin P. In vivo dosimetry using a linear 
MOSFET-array dosimeter to determine the urethra dose in 125I permanent prostate 
implants. Int. J. Radiation Oncology Biol. Phys., Vol. 73, No. 1, pp. 314–321, 2009. 
5. Bloemen-van Gurp E.J., Haanstra B.K.C., Murrer L.H.P, van Gils F.C.J.M., 
Dekker A.L..A.J., Mijnheer B.J. and Lambin P. Real-time dosimetry with a linear 
MOSFET array to evaluate the urethra dose during permanent implant 
brachytherapy using Iodine-125. Int. J. Radiation Oncology Biol. Phys (in press). 
PUBLISHED ABSTRACTS 
1. Bloemen-van Gurp E.J., Minken A.W.H., Visser P.A., du Bois W.F.J., Lambin P. 
Implementation of MOSFET dosimetry in daily practice. 21st Annual ESTRO 
Meeting, Praha, Czech Republic, 2002. 
2. Du Bois W.F.J., Bloemen-van Gurp E.J., Visser P.A., Bruinvis I., Jalink D., 
Hermans J., Lambin P., Minken A.W.H. Commissioning of a MOSFET-TNRD-50 
dosimetry system for routine measurements of 6 MV and 10 MV external beam 
photon radiation treatments. 21st Annual ESTRO Meeting, Praha, Czech Republic, 
2002.  
3. Bloemen-van Gurp E.J., Wulms C., Lambin P., Mijnheer B.J, Minken A.W.H. 
Correction factors for accurate use of MOSFETs for entrance in-vivo dosimetry in 
photon beams. 23rd ESTRO Meeting, Amsterdam, The Netherlands, 2004. 
Thesis_Bloemen_v07.pdf   161 23-7-2009   16:23:10
 
 
162 
4. Bloemen van Gurp E.J., Minken A.W.H., Dehing-Oberije C.J.G, Lambin P., 
Mijnheer B.J. The implementation of MOSFET detectors for clinical dosimetry in 
electron beams. 23rd ESTRO Meeting, Amsterdam, The Netherlands, 2004. 
5. Bloemen- van Gurp E.J., Mijnheer B.J., Minken A.W.H., Verschueren T.A.M, 
Murrer L.H.P., Lambin P. Total body irradiation, towards optimal individual 
delivery: dose evaluation with MOSFETs, TLDs and A Treatment planning system. 
25th ESTRO Meeting, Leipzig, Germany, 2006. 
6. Bloemen-van Gurp E.J., Murrer L.H.P., van Elk J., Mijnheer B.J., van Gils 
F.C.J.M, Lambin P. Accuracy of in vivo dose verfification in brachy therapy using 
microMOSFET dosimeters. 26th ESTRO Meeting, Barcelona, Spain, 2007.   
7. Haanstra B.K.C., Bloemen- van Gurp E.J., Murrer L.H.P., van Gils F.C.J.M., Pijls 
R.J.M.W., Dekker A.L.A.J., Mijnheer B.J.  and Lambin P. In-vivo dosimetry at 
interstitial prostate irradiation. 23rd Annual Symposium of the Belgian Hospital 
Physicists Association, Leuven, Belgium, 2008. 
8. Bloemen- van Gurp E.J., Haanstra B.K.C., Murrer L.H.P., van Gils F.C.J.M., Pijls 
R.J.M.W., Dekker A.L.A.J., Mijnheer B.J.  and Lambin P. In-vivo dosimetry in the 
urethra after interstitial prostate irradiation. 27th ESTRO Meeting, Göteborg, 
Sweden, 2008. 
9. Bloemen-van Gurp E.J., Lutgens L., Murrer L.H.P., Verhaegen F.J.W., Dekker 
A.L.A.J., Mijnheer B.J. and Lambin P. In vivo dosimetry in HDR brachytherapy for 
cervix cancer. 10th Bienial ESTRO meeting on physics and radiation technology for 
clinical radiotherapy, Maastricht, The Netherlands. 
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ACHIEVEMENTS AND IMPLEMENTATIONS 
The research work performed by Esther Bloemen-van Gurp resulted in a broad 
application of MOSFET in vivo dosimetry in MAASTRO CLINIC.  
In vivo dosimetry in MAASTRO CLINIC is applied to all patients treated with a curative 
intent, using photon or electron beams. In standard photon beam treatments, portal 
dose images are the primary tool for dose verification. For special treatment 
techniques, such as TBI, large fields, very asymmetric fields and larger distance 
treatments, portal dosimetry is not possible, due to the radio-sensitive electronics in the 
edge of the EPID device. In these situations, MOSFETs are used for dose verification. 
Furthermore, MOSFET dosimeters are used for dose verification in electron beams, 
because of the lack of signal for EPID dosimetry.  
MOSFET in vivo dose measurements are performed for approximately 1500 treatment 
fields each year. Our clinical database contains the measurement data of more than 
9000 photon and electron beams.  
In vivo dosimetry in photon beams 
In 2002, routine in vivo dosimetry was implemented in daily practice in MAASTRO 
CLINIC for photon beam radiotherapy treatments having curative treatment intent. For 
each photon beam an in vivo measurement is performed by the radiation technologists, 
as a quality check of the treatment procedure. The measurements, performed under 
full build-up to achieve equilibrium conditions, are compared to the calculated dose 
data, calculated using the TPS. To convert the in vivo dose data and compare the 
corrected dose values to the calculated dose values, Esther and her group developed 
a home-made software program “MOSDOS”, to process the data and to calculate the 
deviation between calculated and in vivo dose data. In addition, she developed a 
decision tool for the radiation technologists and the physicians to standardize the 
actions when the deviation between the in vivo dose value and the calculated dose 
value exceeds the tolerance level (figure 1). Furthermore, action levels were defined, 
based on their clinical experience. These action levels ranged from 7% in standard 
beam configurations up to 10% for breast treatments and very asymmetric radiation 
fields.  
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Figure 1: Decision tool for the radiation technologists and the physicians to standardize the 
workflow of the in vivo dose measurements. 
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In vivo dosimetry in electron beams 
After the implementation of photon beam in vivo dosimetry in the clinic, Esther 
continued her work for electron beam configurations. This work focused on the 
response of MOSFET detectors in electron beams and the feasibility of measuring 
without build-up on the detector. The optimal conditions for the clinical measurements 
and conversion factors to convert in vivo surface dose to dose at depth of Dmax, were 
established. The clinical introduction of routine electron beam in vivo dosimetry started 
in 2003. MOSDOS was further developed to convert the in vivo surface dose to dose 
values at depth of dose maximum, and to calculate dose deviations between in vivo 
and calculated dose data.  
In vivo dosimetry in total body irradiations 
In 2003, in addition to the work in electron beams, the use of MOSFET dosimeters 
under TBI circumstances was investigated. This work resulted in 2004 in the routine 
application of MOSFETS for in vivo dosimetry in TBI treatments. Entrance and exit 
dose measurements were converted to midline dose values using predefined factors, 
and the in vivo results were compared with the prescribed dose. As a result of the in 
vivo dose data and the simple dose calculation protocol used routinely in our clinic, 
Esther investigated the probability to use the clinical TPS for 3D-dose calculation at 
extended distance, in order to obtain more accurate dose calculations. In 2006 this 
study resulted in a new, fully digitalized, protocol for TBI in MAASTRO CLINIC (figure 
2) using a 3D-dose calculation method and the opportunity of using the MLC as a 
compensator.  
 
 
Figure 2: Design of the lung blocks for the treatment of TBI patients.  
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In vivo dosimetry in brachytherapy 
In 2006 Esther extended her work in the area of brachytherapy. The sensitivity of 
MOSFET detectors for 125I was investigated for both reference and non-reference 
conditions. The results were used for in vivo dose measurements in the patient, during 
and after permanent implant brachytherapy using 125I. This study demonstrated that in 
vivo dosimetry using MOSFET dosimeters is a very useful tool for image guided 
brachytherapy.   
In 2008, this study was awarded with the Jack Fowler Award, an award that recognizes 
an outstanding junior investigator for exceptional work in radiation oncology, medical 
physics and/ or radiobiology, and was presented during the 27th Annual ESTRO 
meeting in Göteborg, Sweden.  
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